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Abstract 
 Malaria vaccine research has been battling with persistent challenges, including 
polymorphisms of vaccine antigens, difficulties with production processes, and limited 
immune protection against the disease. Intrinsically unstructured proteins (IUPs) are a fairly 
newly classified group of proteins that have no stable 3D structure and are generally heat-
resistant. They usually contain low complexity regions and repetitive sequences, both of 
which are distinct characteristics of the malaria proteome. Surprisingly, some of the vaccine 
candidates that have been extensively studied were later reported to have unstructured 
regions, some of which serve as targets of protective immunity. In keeping with their 
interesting immunological profiles and their unique properties, which are exceptionally 
beneficial for vaccine production, malarial IUP antigens may be good vaccine candidates. 
 
 This PhD project has the following aims:-   
1) to develop a synthetic  unstructured protein antigen based on the Block 2 region of  
       MSP-1, named the MSP-1 hybrid 
2) to characterize a novel vaccine antigen derived from the MSP-3.3 protein, namely an 
IUP region of PF10_0347 gene product, for its potential as a vaccine candidate 
3) to develop a second-generation vaccine by combining the MSP-1 hybrid, with two allelic 
variants of MSP-2, to overcome antigenic polymorphism and strain-specific immune 
responses 
4) to validate protocols for IUP identification from proteins extracted from the malaria 
parasite.  
This study showed that 1) MSP-1 hybrid production was scalable, yielding high protein 
yields with comparable immunological properties to small-scale production. MSP-1 hybrid 
was shown to be compatible with different adjuvants, and elicited specific antibodies 
covering the whole range of Block 2 allelic diversities. 2) A novel antigen, MSP-3.3C, an 
IUP based on the 3’ region of the PF10_0347 gene, was cloned, expressed and purified. 
Anti-MSP3.3C antibodies showed very strong parasite growth inhibitory effects in vitro. 3) 
The MSP-multihybrid antigen was expressed using simple techniques, but only at low levels. 
It contains epitopes from all three parasite antigen components, and is recognized by specific 
naturally acquired antibodies. 4) an unconventional 2D gel technique was tested as a method 
of malaria parasite IUP identification. Plans for further validation of this technique were 
discussed.  
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Chapter 1: Introduction 
1. Malaria and human immunity to malaria  
1.1 Malaria 
 The malaria parasite has long been known to infect humans. Despite efforts to 
control this disease, it still remains a public health problem and has been named among the 
top most life-threatening communicable diseases (Sachs & Malaney 2002). It affects the 
lives of people in 100 different countries and is responsible for approximately one million 
deaths per year, mostly amongst young children under the age of five and pregnant women 
in sub-Saharan Africa (World Health Organization 2010a). Malaria is endemic in tropical 
and subtropical areas, including Sub-Saharan Africa, Asia and South America, occupying a 
broad banded area around the equator (Figure 1.1). The geographical patterns of malaria 
endemicity presented by Gething et. al. in 2011 showed that the risk of P. falciparum is 
varied, but the highest level of parasite incidence was seen in Africa (Gething et al. 2011). 
Although malaria has been endemic mainly in African countries, outbreaks have been 
reported in areas outside the tropics, such as in North America and Korea. This suggests that 
the parasites can also reach well into temperate climates (Doolan & Dobano 2009). 
1.2 Challenges to the control and eradication 
 Although, many efforts to control and eradicate malaria have been tried by many 
organisations worldwide, around 48% of the global population still remain at risk (Hay et al. 
2004). The World Health Organisation’s Global Malaria Eradication Program (GMEP) has 
successfully eliminated malaria from many parts of the world, but the disease persists in 
some economically poor countries (Sachs & Malaney 2002al). Malaria has not totally been 
removed from these regions due to difficulties of access to endemic areas, socio-political 
issues, the costs of effective anti-malaria drugs, and the lack of an effective vaccine.  
 One of the important reasons for persistence of malaria in Africa is the presence of 
mosquito vectors of the Anopheles genus. Insecticides and insecticide-treated bednet 
programmes were introduced into Africa in order to cope with this problem. DDT spraying, 
in parallel with the environment improvement strategies (for example, removing mosquito 
breeding areas) and drug treatment had been used successfully, resulting in reduction of the 
vector populations and decrease in malaria distribution in many areas. These interventions 
face new problems, including the development of insecticide resistance (Tanner & de 
Savigny 2008; Guerin et al. 2002). Bednet use is associated with reduced mortality and 
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incidence of mild malaria episodes. However, the emergence of mosquito resistance to 
insecticides in Africa has now diluted the efficiency of this method (Lengeler 1996).  
 Increasing frequency of drug-resistant parasites also causes complications in malaria 
control, resulting in re-emergence of malaria and increased death rates (Sachs 2002). The 
dynamics of resistance may be mediated by factors such as the level of drug use in the 
population (Hastings & Watkins 2005). Chloroquine resistance, for example, is widespread 
in African counties where chloroquine is continuously used. The efficacy of sulphadoxine-
pyrimethamine, which is commonly used in some countries as an alternative to chloroquine, 
has also declined rapidly (Frosch et al. 2011). In SouthEast Asia, P. falciparum is resistant to 
most of the available antimalarial drugs. Chloroquine and sulfadoxine-pyrimethamine 
resistance was reported in the Thai-Cambodian border as early as 1950 (Wernsdorfer & 
Payne 1991) and then again in the mid-1960s (Björkman & Phillips-Howard 1990). 
Recently, a decline in efficacy of Artemisinin was reported (Dondorp et al. 2009; Phyo et al. 
2012). Since artemisinin is recommended by the WHO as a first-line treatment of 
uncomplicated malaria in endemic areas, the emergence of resistance adds more 
complications to global malaria control (World Health Organization 2010b).  
 With the completed genome sequences of several P. falciparum parasite isolates 
(Gardner et al. 2002; Jeffares et al. 2007), advances in biomedical research and financial 
support from charitable foundations, the possibility of malaria eradication has been recently 
reconsidered (Tanner & de Savigny 2008). Although research on drug target identification 
and new drug discovery are important, these efforts must be complemented by malaria 
vaccine development, which will hopefully provide effective protection in the long-term 
against clinical disease and support the goal of malaria control and eradication globally 
(Holder & Holder 2009; Genton 2008; Moorthy & Hill 2002).  
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Figure 1.1: The world map shows the extent and intensity of Plasmodium falciparum 
malaria endemicity in 2010. The P. falciparum parasite rate surveys used to produce 
this map are age-standardized to the 2 to 10 year age-range (PfPR2-10). The 
continuum of blue to red represent PfPR2-10 from 1%-100%. The areas which were 
defined as stable risk (P. falciparum annual parasite incidence (PfAPI) ≥0.1), 
unstable (PfAPI < 0.1) and no risk (PfAPI =0) are represented by dark grey, light 
grey and white area respectively (Gething et al. 2011). 
 
1.3 Parasite life cycle  
 There are five primate malaria parasites that are regularly transmitted to humans, 
including Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium 
ovale, and Plasmodium knowlesi. Among the 5 species of human malaria, P. falciparum is 
the most virulent, often resulting in severe symptoms and causing 90% of the mortality from 
the disease. Malaria parasites have complex life cycles involving female mosquitoes of the 
Anopheles genus, the primary host where parasites reproduce sexually, and in the 
intermediate mammalian host (Figure 1.2). 
 Once parasites enter the host by injection from the salivary glands of the Anopheles 
mosquito, malaria parasites in sporozoite form travel via the bloodstream to the liver where 
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they replicate asexually and asymptomatically to yield thousands of merozoites, which then 
burst from infected hepatocytes and are re-introduced into the bloodstream, marking the 
initiation of the asexual blood-stage of the parasite lifecycle. Merozoites invade erythrocytes, 
replicate and develop through a series of life cycle stages known as rings, trophozoites and 
then schizonts. Approximately 16-32 new merozoites within a schizont are released during 
the subsequent erythrocyte rupture resulting in rising densities of parasitaemia. As a 
consequence, this process causes a rapid loss of red blood cells and leads to a spectrum of 
mild to severe symptoms (Bledsoe 2005). Released merozoites in the blood stream continue 
the blood-stage cycle by re-infecting new red blood cells. Erythrocyte invasion by the 
parasite is a complicated process, which involves many surface proteins as well as secreted 
proteins from the apical end of the parasite (Rodriguez et al. 2008; Farrow et al. 2011; 
Cowman & Crabb 2006). Soon after bursting from mature schizonts, merozoites firstly form 
low affinity interactions with uninfected red blood cells, a step which is suggested to be 
reversible (Blackman 2000). Reorientation of the parasite then follows, resulting in 
interaction between the apical end of the parasite and the red blood cell (Bannister & 
Dluzewski 1990). Stronger binding between the parasite and the red blood cell takes place 
when a tight junction is formed and moves along the surface of the merozoite from the apex 
(Blackman 2000; Farrow et al. 2011). Upon the entrance of the merozoite, the majority of 
the protein complexes which form the surface coat of the merozoite are discarded by the 
activities of proteases (Harris et al. 2005). Although the protease-mediated processing is 
known to be critical for parasite survival (Blackman 1994; Blackman 2000), there still no 
clear explanation why parasites invest a considerable amount of their time and energy in 
creating surface molecules that are removed later in the asexual life cycle (Kauth et al. 2003; 
Holder & Blackman 1994).  
 During this stage, by mechanisms that are still unclear, some parasites develop into 
sexual stages called male and female gametocytes, which circulate freely in the blood 
stream. These forms are taken up by mosquitoes during a blood meal. The two types of 
gametocytes then fuse, producing a zygote, beginning the infection in the mosquito. This 
diploid form undergoes meiosis and differentiates to form ookinetes. This form of the 
parasite can penetrate the mosquito gut, and differentiate into oocysts, which contain 
thousands of haploid sporozoites. These sporozoites are then released from the bursting 
oocyst, migrating to the mosquito salivary glands, ready to be released into host skin during 
the salivation which occurs during mosquito blood meal feeding. 
 




















Figure 1. 2: The malaria parasite life cycle.represents (A) Exo-erythrocytic cycle, (B) 
Erythrocytic cycle and (C) Sporogenic cycle. Following the bite of a Plasmodium-
infected mosquito, sporozoites migrate to hepatocytes, where multiple rounds of cell 
division occur. Many thousands of merozoites then released. and invade 
erythrocytes, Some invading merozoites, develop into male or female gametocytes, 
are taken up by the mosquito during a blood meal. In the mosquito gut, these sexual 
forms of the parasite develop into gametes, fuse to form zygotes and then develop 
into an oocyst, from which sporozoites are released. These sporozoites travel to the 
insect salivary glands and are re-introduced into a human host during the 
mosquito’s next blood meal. Diagram from Centers for Disease Control and 




  6 
1.4 Antigenic polymorphism and antigenic variation  
 The effectiveness of protective immunity can be diluted by the parasite’s 
polymorphisms in the surface proteins encoded from single copy genes, such as merozoite 
surface protein 1 (MSP-1) (Bledsoe 2005; Galamo et al. 2009; Lyon et al., 2008) and 
merozoite surface protein 2 (MSP-2) (Genton et al. 2002; McCarthy et al. 2011) and due to 
antigenic variation in the gene products of multicopy gene families, notably the var (Kyes, 
Kraemer, et al. 2007b), stevor (subtelomeric variable open reading frame) (Blythe et al. 
2004; Niang et al. 2009), and rifin (repetitive interspersed family) (Kyes et al. 1999). 
Immunity to heterologous parasite strains is not as effective as with previously encountered 
homologous strains (Pombo et al. 2002; Lyon et al., 2008) and cross-reactions between 
antibodies to different serotypes of some antigens are rare (Felger et al. 2003). If high titre 
strain- or variant- specific antibodies are required to provide efficient protection, multiple 
exposures to a mix of malaria strains may be required to induce acquired immune responses 
to the wide repertoire of antigenic variations prevalent in parasite populations. Thus, this 
may partly explain why protective immunity develops slowly (Malaguarnera & Musumeci 
2002).  
1.4.1 Antigenic polymorphism  
 Antigenic polymorphism or allelic diversity in the malaria parasite can be found in 
many of its antigens, especially the surface antigens. Accordingly it is widely assumed that 
antigenic polymorphism is associated with immune interference and immune evasion. 
Diversity of surface proteins may arise from point mutations, complementary-strand slippage 
(Brown et al. 2002; Tanabe et al. 1987), intragenic recombination, or miss-alignment (Brown 
et al. 2002; Rich et al. 1997). Genes that encode surface proteins of P.falciparum, such as 
msp-1 and circumsporozoite protein (csp), are thought to be very old evolutionarily (Rich et 
al. 1998; Rich et al. 1997). Many of these genes contain repeating nucleotide sequences that 
code for repetitive amino acid sequences which are highly mutable (Mwingira et al. 2011). 
The variations in these genes are mostly in the form of duplication and/or deletion of the 
repeated segments, caused by intragenic recombination (IGR). The repetitive DNA 
sequences within these genes are subject to higher rates of mutation than non-repeated 
sequences (Rich et al. 2000). Unlike the repetitive central region sequences of csp, which is 
very conserved and has been maintained within each allele, the msp-2 of P.falciparum shows 
much greater diversity in length, number of repeats and amino acid content, which is thought 
to result from proliferation of repeats within the msp-2 gene (Rich et al. 2000). For msp-1, 
polymorphisms are rare in most regions, except notably the Block 2 region, which contains a 
set of repetitive tripeptides in two of three allelic types (Miller et al. 1993).  
  7 
1.4.2 Antigenic variation  
 Infectious organisms such as parasitic protozoa (Kyes, Kraemer, et al. 2007b; 
Stijlemans et al. 2007), bacteria (Barbour et al. 2006), as well as viruses (Lindesmith et al. 
2012) have a mechanism called antigenic variation, which allows them to switch their 
surface proteins and to evade host immune recognition and allow reinfection of host cells. In 
P.falciparum malaria, this mechanism is used in gene transcription of the var genes, the 
diverse family of genes encoding for PfEMP1. Var gene switching was shown to happen 
early after parasites invade the erythrocyte (Scherf et al. 1998; Kyes, Christodoulou, et al. 
2007a) and during subsequent invasion cycles this results  in a non-homogenous parasite 
population. Similar to var genes, the rif (repetitive interspersed family) and stevor are the 
known gene families, which encode for two further families of variant surface antigens 
(Khattab et al. 2008; Dzikowski et al. 2006). 
2. Naturally acquired immunity to malaria parasites 
 In response to malaria infection host immune responses, which are regulated by both 
innate and adaptive immune system, are triggered. Passive maternal immunity was reported 
to provide protection against disease to babies (Doolan & Dobano 2009). Malaria symptoms 
are always detected in naïve individuals, while in high transmission areas, “anti-disease 
immunity” can be established in young children. This protection is acquired rapidly, 
resulting in reduction of severe clinical symptoms and children in endemic areas quickly 
develop immunity to death. However, this kind of immunity was reported to be short-lived in 
the absence of continual exposure (Doolan & Dobano 2009). The “anti-parasite immunity” 
which allows individuals to be protected against high-density parasitaemia is only developed 
slowly, whilst “sterilizing immunity” against infection is hardly ever fully achieved, as 
observed in asymptomatic adults, who carry gametocytes and therefore serve as reservoir for 
continued transmission (Good & Doolan 1999; Marsh & Snow 1997)  and usually dies out 
quickly in the absence of parasitaemia (Crompton et al. 2010; Doolan & Dobano 2009). 
Immunity to malaria can be unstable due to other factors such as host genetics and 
polymorphism of parasites, and sterile immunity may not be achieved (Richie & Saul 2002; 
Langhorne et al. 2008).  
 Life-threatening forms of disease from malaria infection are normally found in 
children and become less frequent in adults (Carvalho et al. 2002; Marsh & Snow 1997). The 
most deadly form of severe disease is cerebral malaria, of which the clinical symptoms are 
such as sequestration of infected red blood cells in cerebral microvascular and presence of 
coma (Marsh & Snow 1997). Cytoadherence phenotype of parasites such as binding to 
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ICAM1 (Craig & Scherf 2001; Ochola et al. 2011; Cserti-Gazdewich et al. 2010), and 
rosetting (Hill 2011; Doumbo et al. 2009; Rowe et al. 1995) are showed to be correlated with 
this pathology.  
 Mathematical models using data from north-eastern Tanzania and Gambia classify 
clinical immunity that develops with age and exposure as relatively short lived, while 
immunity that reduces parasitaemia and is acquired later in life is considered to be long lived 
immunity, with a half-life of more than 20 years (Filipe et al. 2007). In young children and in 
adults in areas of low endemicity, immunity against malaria develops quite slowly, and 
rarely, if ever, becomes sterile immunity and usually dies out quickly in the absence of 
parasitaemia (Kinyanjui et al. 2007; Cavanagh et al. 1998). This suggests that routine 
exposure to the malaria parasite is necessary for both production and persistence of memory 
and effector cells. Some of the antibody responses to defined antigens are often very short-
lived (Kinyanjui et al. 2007; Früh et al. 1991; Cavanagh et al. 1998) and may be unable to be 
boosted on re-exposure (McCallum et al. 2008). In contrast, adults may attain very long-
lived immunity. This was illustrated by the re-emergence of malaria in Madagascar which 
showed that adults had maintained immunity to malaria disease at least for 30 years, after 
they had first experienced a number of infections before the eradication of malaria in that 
area (Migot et al. 1995).  
2.1 Factors influencing development of immunity against malaria 
 The immune response of each individual to malaria parasites is shaped by 
cumulative host factors. Development of immunity does not therefore correlate with any 
single factor but is affected by multiple factors (R. Wang et al. 2009; Doolan & Dobano 
2009).  
2.1.1 Age 
 It is generally accepted that immunity to malaria is age-dependent. Children under 6 
months of age are resistant to severe disease and high parasitaemia (Doolan & Dobano 
2009). This protection is probably provided by passively acquired maternal IgG (McConkey 
et al. 2003; Amaratunga et al. 2011). These antibodies continue to decline during the first 
year of life. Secretory IgA in breast milk may also supply alternative protection for infants 
(World Health Organization 2010a; Kassim 2000). In areas of high endemicity, the risk of 
severe forms of malaria, such as cerebral malaria and death tends to increase with age from 
birth and it is not until children reach the age of five that the frequency of disease and 
mortality start to decrease. Severe cases are rare from adolescence onwards. (Richie et al. 
2007; Doolan & Dobano 2009). This may suggest that the immune system of young children 
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is not fully developed, and without passive immunity, they are susceptible to clinical malaria 
before acquisition of adaptive immunity. It has been reported that acquisition of specific 
antibody isotypes begins with IgM, followed by IgG1 and IgA respectively. Tongren et al., 
2006 suggested that the default pathway of IgG subclass switching in children is towards a 
mixed IgG1 and IgG3 response (Tongren et al. 2006). Some antigens, such as AMA-1, 
induce high IgG1 responses in all age groups (Saul & Fay 2007; Tongren et al. 2006), while 
acquisition of IgG1 and IgG3 against MSP-119 increases with age (Shi et al. 1996) and the 
change in proportion between IgG1 and IgG3 antibodies specific to MSP-2 is age-dependent 
(Pye et al. 1997; Taylor et al. 1998; Duah et al. 2010). As subclass switching from IgG1 to 
IgG3 is not possible in the same B cell clone, but requires formation of a new B cell clone 
that switches from IgM to IgG3, this change in subclass specificity of IgG responses is not 
caused by any age-related delay in the class-switching mechanism. This delay in IgG3 
response is more likely to be the result of an the alteration in immune response preference, 
which is dependent on the maturation stage of the immune system (World Health 
Organization 2010c; Achtman et al. 2005; Duah et al. 2010).  
2.1.2 Exposure 
 Malaria infections in naïve individuals of any age are generally symptomatic even if 
they have low parasitaemia levels (Carvalho et al. 2002; Doolan & Dobano 2009). In 
endemic areas, the cumulative exposure to malaria is influenced by both the intensity of 
malaria transmission and the duration of exposure (which is related to the age of the 
individual) (World Health Organization 2010c; Tongren et al. 2006).  
 Transmission rate has, of course, been shown to have a clear effect on the 
development of immunity against malaria (McCallum et al. 2008). In highly endemic 
malaria regions immune responses against severe disease mature after only few infections; 
however, this is not the case for children who have been living in areas of low transmission, 
where individuals remain susceptible into teenage and even adult years (S. Gupta et al. 
1999).In the areas where the risk of infection is high, older children and adults rarely suffer 
severe forms of malaria and high-density parasitaemia, while those who develop severe 
disease are usually young children, infants, malaria-naive visitors and pregnant women 
(Richie & Saul 2002; Doolan & Dobano 2009).  
 Transmission intensity is also linked to forms of severe malaria. In young children, 
cerebral malaria is more frequent in areas of low transmission intensity while malarial 
anemia is more prevalent in higher transmission areas (Marsh & Snow 1999). Acquisition of 
IgG1 antibodies against MSP-119 and AMA-1 are dependent on cumulative antigen exposure 
(Tongren et al. 2006), and the levels of growth-inhibitory antibodies is influenced by malaria 
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transmission intensity (McCallum et al. 2008). Repeated malaria exposure, especially at 
high-transmission rates, may also increase the chances of contact with a wider range of 
antigenic variation in the parasite population thus providing protective immunity to a broader 
spectrum of parasite strains (Aravind et al. 2003; Rich et al. 2000; Takala & Plowe 2009). 
2.1.3 Pregnancy  
 Women who are pregnant become susceptible to severe malaria despite the fact that 
they have previously developed protective immunity. This may be caused by physiological 
immunosupression, which may alter concentration of cytokines and hormones, but is also the 
result of the presence of a placenta which forms a new niche where P. falciparum parasites 
can accumulate in the placenta by adhering to chondroitin sulfate A (CSA) (Beeson et al. 
1999).  
2.2 Naturally acquired immune responses against malaria  
2.2.1 Innate immunity 
 Although innate immune responses has not yet been extensively studied for malaria 
infection, it has been postulated to be important for host defense as well playing a role in 
priming adaptive immunity (Perlmann & Troye-Blomberg 2002). It was suggested that 
innate immunity is initiated when parasite density reach threshold (Daubersies et al. 2008), 
which results in partial clearance of infected cells. Activation of dendritic cells (DCs) and 
macrophages may be one of the earliest events in the innate response to malaria (Beck et al. 
1997; Stevenson & Riley 2004). Mechanisms such as activation of Toll-like receptors, which 
subsequently induce the phagocytic activities of macrophages (Capone et al. 2010; Gowda et 
al. 2011), may be important in parasitaemia control and lead to protection. Apart from 
function in opsonisation, macrophages may also be involved in antibody-dependent cellular 
inhibition, production of nitric oxide, and TNF (Good & Doolan 1999; Hensmann & 
Kwiatkowski 2001). And It was reported that merozoite, but not infected erythrocytes, can 
trigger a phagocyte oxidative metabolism activation in polymorphonuclear cell and 
mononuclear cell (Lunel et al. 1990). DCs are responsible for the production of cytokines 
that are important for protection (Pouniotis et al. 2004). NK-cell which is activated by 
parasitic red blood cells and cytokines was reported to produce IFN- which is involved in 
parasite killing (Artavanis-Tsakonas & Riley 2002). In addition, the unconventional 
population of T cells known as T cells, was reported to be activated by the infected 
erythrocytes during the acute disease (Hviid et al. 2001). They can recognize schizont 
antigens (Pichyangkul et al. 1997), produce large amounts of IFN (Hviid et al. 2001; 
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Hensmann & Kwiatkowski 2001) and shown to have an anti-parasite function (Elloso et al. 
1994).  
2.2.2 Adaptive immunity 
 It has been postulated that the immune responses are evoked as early as the injection 
of sporozoites through skin. Processed sporozoite antigens can be presented on MHC class I 
by DCs or by infected liver cells to CD8+ T cells. Cytotoxic T cells (CTLs) detected in 
humans protected by immunisaion with irradiated P. falciparum sporozoites showed the 
potential to lyse infected liver-cells in vitro, expectedly by IFN-induced nitric oxide (NO) 
(Doolan & Hoffman 2000). The study on RTS,S vaccine showed that CD8+ T cells are able 
to produce IFN that is associated with the protection from sporozoite challenge (Sun et al. 
2003). In addition, CTLs may also release perforin and granzyme or bind to apoptosis-
inducing receptors on the infected hepatocyte, which sequentially leads to cytolysis of 
infected cells (Kwiatkowski 1995). The pre-erythrocytic stage is relatively short compared 
with other stages of the parasite life-cycle, therefore memory cells of CD4+and CD8+ T 
cells must be maintained as effector cells at quite high frequencies, otherwise they must have 
ability to rapidly differentiate into effector-killer cells (Langhorne et al. 2008). 
 The erythrocytic stage of the parasite lifecycle is the major cause of malaria disease 
symptoms. Therefore, it is expected to be a key target for protective immune responses 
(Marsh & Kinyanjui 2006). Cell-mediated immune responses are proposed to be important 
for induction of protection against both pre-erythrocytic and erythrocytic malaria parasite 
stages. T cells may be involved in protection mechanisms, both as helper cells in antibody 
responses and as effector cells (Good & Doolan 1999). In protected individuals who had 
been exposed to low-dose infection, proliferative CD4+ and CD8+ T cell responses, 
cytokine responses including IFN-, and high nitric oxide synthase activity in peripheral 
blood mononuclear cells were observed. The immune mechanisms of these responses are 
unclear, but it was postulated that they are induced by parasite toxins such as GPI anchors 
via TLR2 (Pombo et al. 2002). It has been suggested that CD4+ T cells are important for 
production and maintenance of protective antibody responses to the parasite, but the 
prevalence of naturally exposed people who contain measurable levels of malaria-specific 
CD4+ T cells is usually low. Either these CD4+ T cells have only a minor role in immune 
protection or only few T cells are required (Good & Doolan 1999). Data on longevity of T 
cell in malaria infection is not conclusive, however, it seems to depend on age, persistence of 
antigens and exposure level (Achtman et al. 2005; Deloron & Chougnet 1992).  
 Humoral immune responses are thought to be important against blood-stage 
parasites (Langhorne et al. 2008). Naturally transfer of antibodies from mother to foetus via 
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the placenta showed a protective effect against clinical disease and parasite density in 
children younger than 6 months (Branch et al. 1998). The passive transfer of IgG from 
immune donors has also shown dramatic reductions in parasitaemia and clinical symptoms in 
malaria infected adults (Sabchareon et al. 1991) as well as in children (Cohen et al. 1961).  
2.3 Antibodies response to malaria  
 Since erythrocytes have no MHC, it is unlikely that cytotoxic T cells can efficiently 
kill malaria parasites in their intra-erythrocytic form; although one study has proposed a 
possible T cell induction mechanism via TLR (Pombo et al. 2002). Accordingly, antibodies 
are thought to be the major effector mechanism in immunity against P. falciparum 
merozoites (Marsh & Kinyanjui 2006). Specific anti-parasite antibodies are generally a 
marker of recent or current infection, and because P.falciparum infection is chronic and 
immunity almost never sterile, it can be postulated that antibodies are continuously 
produced.  
 Primary malaria infections elicit a variety of antibody isotypes and IgG subclasses, 
which are though to provide early protection against disease (al-Yaman et al. 1997). By 
contrast, subsequent re-infections induce only some IgG subclasses and this leads to 
improved protective efficacy of the antibodies (Garraud et al. 2003).  
2.4 Ig isotypes  
 The effect of antigen, age and, exposure have been shown to be associated with 
differences in human IgG subclass responses to malaria parasites. One study by our lab 
observed differential IgG subclass responses to regions of the same antigen, MSP-1 
(Cavanagh et al. 2001). In this paper it was proposed that soluble, processed, and 
intrinsically unstructured antigens such as MSP-1 Block 2 and MSP-2 elicit IgG3 due to 
their likely uptake as immune complexes via follicular dendritic cells or DCs, influencing the 
subsequent Ig class switch, whereas insoluble, polymeric membrane bound antigens on the 
surface of the merozoite (e.g. MSP-119, AMA-1) may be taken up by different APCs and 
elicit a more IgG1 biased response. Others have reported that antigens such as MSP-2 
(Tongren et al. 2006; Metzger et al. 2003; Taylor et al. 1998), MSP-3 (Cavanagh et al. 2001; 
Oeuvray et al. 1994), MSP-7 (Wang et al. 2003), which contain polymorphic or repetitive 
sequences, and the polymorphic region of MSP-1 Block 2 (Cavanagh et al. 2001), seem to 
mainly induce IgG3, while conserved antigens such as AMA-1 (Tongren et al. 2006), MSP-
119, (Egan et al. 1995; Tongren et al. 2006), RAP-1 (Stowers et al. 1997), MSP-5 and MSP-6 
(Wang et al. 2003), which do not have polymorphic repeats, induce IgG1.  
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 The protective antibodies to malaria are restricted to a subset of IgG subclasses. 
IgG1 and IgG3 are most frequently reported to be associated with protection, whereas IgG4 
is indicated as non-protective (Bouharoun-Tayoun & Druilhe 1992; Rzepczyk et al., 1997; 
Taylor et al. 1998; Oeuvray et al. 1994; Cavanagh et al. 2004; Conway et al. 2000; Polley et 
al. 2006; Polley et al. 2003; Metzger et al. 2003; Sarthou et al. 1997). IgG2 was reported to 
interfere with protective antibody responses (Bouharoun-Tayoun & Druilhe 1992), although 
the study by Aucan et al., 2000 showed that it is associated with protection in some 
individuals who carry the H131 allele of the gene encoding FcRIIA, which has IgG2 
binding ability (Aucan et al. 2000). There was a report on the ability of the R131 allelic form 
of FcRIIA in IgG2 binding (Norris et al. 1998), however the population studied by Aucan 
et. al mostly have H131 allele (Aucan et al. 2000). According to this, more study on different 
populations should provide more inclusive information on the relationship between 
protective IgG2 and the Fc receptors. Fewer studies have investigated protective IgM 
responses in malaria. It was not associated with protection in one seroepidemiological study 
(Branch et al. 1998). Parasite specific IgE was postulated to be able to cross-link CD23 on 
monocytes and endothelial cells, resulting in overproduction of TNF and nitric oxide 
(Perlmann et al. 1997). Significantly higher concentrations of IgE were also observed in 
patients with cerebral malaria compared to non-malaria control sera (Perlmann et al. 1997; 
Perlmann et al. 2000). 
 IgG3 have been demonstrated for their correlation with the protection against 
clinical malaria (Roussilhon et al. 2007; Soe et al. 2004) and some showed inhibitory effect 
in in vitro antibody-dependent monocyte mediated growth inhibition assays (Tebo et al. 
2001). This is supported by the fact that most protective IgG to MSP-2 and MSP-3 antigens 
are IgG3 (Aucan et al. 2000; Metzger et al. 2003; Rzepczyk et al., 1997; Taylor et al. 1998; 
Oeuvray et al. 1994; Polley et al. 2006). The mechanism of antibody-associated clearance of 
parasites is not totally understood. Both IgG1 and IgG3 have high affinity to FC receptors. 
They are able to fix complements and can be induced in Th1-type responses (Norris et al. 
1998; Garraud et al. 2003). These two cytophilic isotypes, especially IgG3, can mediate FC 
receptor cross-linking, involved in opsonisation (Aucan et al. 2000; Bredius et al. 1994), and 
act synergistically with human monocytes in parasite killing in vitro through binding to Fc 
receptor (Branch et al. 1998; Oeuvray et al. 1994). This functional activity of antibody, 
observed in the in vitro assay is called antibody-dependent cellular inhibition (ADCI) 
(Bouharoun-Tayoun et al. 1995; Groux et al. 1990; Theisen et al. 1998; Tebo et al. 2001). 
The IgG3 is suggested to be short-lived with a catabolic half-life of approximately 7 days 
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(Morell et al. 1970). According to this, re-infection may require triggering of the 
proliferation of memory B cells and therefore production of specific IgG3 
 In malaria, it is not known which cytokines induce these subclass switching 
mechanisms and from which cells they are produced. However, in the light of this 
knowledge, an ideal malaria vaccine should be able to trigger IgG1 and IgG3 responses and 
stimulate cytokines associated with antibody of the IgG1 and IgG3 subclasses (Garraud et al. 
2003).  
2.5 Functional roles of antibodies  
 A number of functional roles have been suggested for antibodies in protection 
against clinical symptoms of malaria as well as reduction in parasitaemia (Marsh & 
Kinyanjui 2006; Garraud et al. 2003)  
2.5.1 Adhesion blocking 
 During the asexual blood stage, many erythrocyte-associated malarial antigens are 
produced and function as a hook to endothelial cells. Antibodies against these antigens, 
therefore, are expected to prevent sequestration in small vessels, enhance clearance of 
infected erythrocytes from the circulation and allow infected cells to be eliminated by the 
spleen (Doolan & Dobano 2009). Naturally acquired IgG antibodies to VAR2CSA (Beeson 
et al. 2006; Dahlbäck et al. 2006) and their correlation with protection from clinical malaria 
were reported (Taylor et al. 2004; Duffy & Fried 2003). These antibodies were proposed to 
provide protection against placental malaria by interfering with the binding of infected red 
blood cells to CSA (Dodoo et al. 2001; Duffy & Fried 2003).  
2.5.2 Opsonising 
 Macrophages and monocytes can perform their function in phagocytosis more 
efficiently when infected erythrocytes are opsonised by antibodies. In malaria, studies also 
showed that high level of antibodies promoting merozoite phagocytosis is associated with 
low risk of clinical symptoms (Druilhe & Khusmith 1987). Normal monocytes that were 
incubated with IgG from immune subjects enhanced uptake of the merozoite, but not the 
schizont of P. falciparum (Khusmith & Druilhe 1983). Neutrophil was also reported to be 
able to opsonise merozoite in the presence of malaria-immune sera, of which the rate of its 
effect can be enhanced by cytokines such as IFN, TNF, and IL-1 (Kumaratilake & 
Ferrante 2000).  
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2.5.3 Inhibiting merozoite invasion or parasite growth  
 Some antibodies to parasite surface protein antigens are reported for parasite 
inhibitory effect. For example, monoclonal IgM to pseudopeptide antigen based on N-
terminal of MSP-2 (Lozano et al. 2007), antibodies to PfMSPDBL1 (Sakamoto et al. 2012) 
and antibodies to conserved regions of MSP-11 (Obando-Martinez et al. 2010) demonstrated 
neutralizing properties inhibiting parasite invasion in vitro. Surface proteins that have been 
extensively investigated as targets of parasite inhibitory antibodies are MSP-1 and AMA-1. 
Naturally acquired antibodies that interfere with the processing of the MSP-1 such as, 
antibodies against MSP-119 (Florens et al. 2002; Blackman et al. 1990; Nwuba et al. 2002; 
Branch et al. 2000; O'Donnell et al. 2001; Uthaipibull et al. 2001; Dekker et al. 2004) can 
inhibit erythrocyte invasion and are associated with protection from clinical malaria in field 
studies (Branch et al. 1998; Conway et al. 2000). However, one study suggested that 
correlation between the level of anti-MSP-119 inhibitory effect and protection from infection 
can be varied according to the measurement methods (John et al. 2004). Antibodies that 
raised against MSP-142 were reported to show an inhibitory effect on parasite growth (Angov 
et al. 2003; Singh et al. 2006b; Woehlbier et al. 2006) and studies in Aotus monkeys, showed 
protective effect against challenge of blood-stage parasite (Singh et al. 2006b). Interestingly, 
these antibodies were shown to penetrate through infected erythrocyte and bind to 
intracellular parasites, suggesting that they have an inhibitory effect on development of 
schizont, or releasing process of merozoites (Singh et al. 2006b). The antibodies raised in 
rabbits or mice that can block formation of AMA-1 complex (Collins et al. 2009)  or 
modification of AMA-1 can prevent parasite invasion in in vitro assay (Dutta et al. 2005; 
Dutta 2003). Purified IgG from malaria naïve volunteers who were immunized with AMA-1 
(FVO) vaccine was reported for the parasite growth inhibition effect in vitro (Remarque et 
al. 2012).  
 However, parasite inhibition of specific antibodies or immune sera in vitro does not 
necessarily correlate with clinical protection. For example, the immunization of the mixture 
of both allelic types of AMA-1 (3D7 and FVO) in rabbits yielded the antibodies that showed 
the growth inhibition effect in vitro (Kennedy et al. 2002) and shown to be immunogenic in 
Phase I study in Malian children (Dicko et al. 2008). But, the Phase II trial showed that the 
group which received AMA-1 vaccine and the control group which received vaccine against 
Haemophilus influenzae type b have similar time to first parasite density >3000/µL/day, 
which was set as the endpoint of this trial. Therefore, the effect of vaccine is not significant 
(Sagara et al. 2009). This observation has lead to the hypothesis that these antibodies may 
have parasite killing effect in monocyte-dependent manner (Druilhe & Pérignon 1997). 
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2.5.4 Antibody-dependent cellular inhibition  
 Antibody-dependent cellular inhibition (ADCI) has been proposed as an important 
mechanism in controlling malaria parasitaemia and clinical symptoms (Bouharoun-Tayoun 
et al. 1990). The ADCI effect is initiated when a specific merozoite surface component and 
cytophilic antibodies bound to monocyte, which releases a soluble mediator and, 
sequentially blocks the division of parasites. By microscopic investigation, ADCI does not 
equally affect all stages of parasites. The maturation of rings and trophozoites was not a 
main target point of this effect, but the late trophozoite and schizont stage where an 
uninucleated or picnotic form of parasite have been observed (Bouharoun-Tayoun et al. 
1995).  
 It was reported that only a single antigen is required to initiate this mechanism and 
the effect is of the same magnitude as using the combination of antigens. However, on these 
target antigens, at least two epitopes for cytophilic IgG are required (Jafarshad et al. 2007). 
Surface antigen are thought to be critical in triggering the ADCI effect (Bouharoun-Tayoun 
et al. 1995). Antigens reported as triggering ADCI reactivity include MSP-1 Block 2 
(Galamo et al. 2009), MSP-3 (Pleass & Holder 2005; Oeuvray et al. 1994), and GLURP 
(Wykes et al. 2007; Soe et al. 2004; Theisen et al. 1998).  
 In vitro studies showed that only monocyte, but not other macrophages derived from 
monocyte, polymorphonuclear, lymphocytes or platelets could mediate this effect 
(Bouharoun-Tayoun et al. 1990; Lunel & Druilhe 1989). Antibodies are reported to trigger 
monocyte activation via both FcRIIa and FcRIIIa, of which their roles in ADCI is not 
really understood in detail. Other immune cells such as NK cells and polymorphonuclear 
cells are able to express these receptors. Nevertheless, there was no ADCI activity reported 
for these cells and this is may due to their structural differences (Edberg et al. 1989). The 
antibodies that have this feature are only reported for cytophilic IgG subclasses, where IgG3 
was more active than IgG1. This agrees with the immunoepidemological finding that IgG3 is 
linked to protection (Druilhe & Pérignon 1994). It has been postulated that this is may due to 
the fact that the IgG3 has a more flexible hinge region which may allow it to link antigen and 
the Fc receptor more efficiently (Redpath et al. 1998; Jafarshad et al. 2007). This mechanism 
only requires a small amount of antibody compared to those that have a neutralizing property 
(Jafarshad et al. 2007). Cytokines were reported to play their role in this mechanism. 
Treatment of IL-4 resulted in a decrease in ADCI effect, while contrasting ADCI effect can 
be yielded when monocytes were treated with IFN. TNF was shown to be an essential 
mediator (Bouharoun-Tayoun et al. 1995). The oxidative stress may be created by means of 
ADCI, and lead to parasite killing. Even though, according to one study, there was no 
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supporting evidence for the possible role of NO radicals (Bouharoun-Tayoun et al. 1995), it 
may still be too soon to make a conclusion, for under the condition of the ADCI, source is 
limited and all the mediators that essential for this mechanism are yet to be discovered. 
2.5.5 Involve in complement partway 
 Oxygen radicals can be created both by parasite and the host immune system. The 
antibodies can be induced by the oxidative stress in parasitised red blood cell, which is the 
result of haemoglobin degradation (Becker et al. 2004). The observation showed that 
infected red blood cell contains more than normal amounts of haemichromes, which 
generated by oxidative stress, that cause the aggregation of band3 (Giribaldi et al. 2001). 
This abnormal formation of band3 allows significant binding of anti-band3 IgG. This can 
lead to the establishment of the alternative complement pathway, resulting in production of 
C3b. This fragment of complement has ability to bind to complement receptor type1 (CR1), 
anti-band 3 cluster, normal band3 ligand, and aminophospholipids. These alterations of 
infected erythrocyte surface allow them to be recognised by CR1 of macrophage via C3b or 
by FC receptor via bound anti-band3 IgG (Morell et al. 1970; Becker et al. 2004). (Figure 
1.3) 
 
     
Figure 1.3: Diagram illustrates role of antibodies and oxidative residues in 
phagocytosis. In infected erythrocytes, oxidative stress can lead to aggregation of 
band3 which can be recognised by antibodies, and generation of complement factor 
C3b, which can bind to surface of infected erythrocyte, CR1 receptor of erythrocyte, 
or mostly to anti-band 3 cluster. Phagocytosis by macrophage can be initiated when 
it is stimulated via Fc receptor, or via CR1 (Becker et al. 2004).  
Band3 cluster                 C3b 
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3. Malaria vaccines 
 Despite many available approaches for malaria protection and cure, an effective 
vaccine is also required and is considered an important tool for the global fight against 
malaria. Since natural acquired protective immunity can be slow in maturing and short lived 
if boosting is discontinued, malaria vaccines have to do more than natural infection by 
providing lasing long sterile protection (Carvalho et al. 2002) and hastening the development 
of the immunity to limit mortality and morbidity rate (Richie & Saul 2002).  
3.1 The development of malaria vaccine and strategies 
3.1.1 Obstacles 
 There are many factors suggested to be the obstacles in malarial vaccine 
development. First of all, Plasmodium falciparum has extremely complicated biology. 
Throughout its life cycle, the parasite produces different stage specific antigens which 
establish sophisticated interactions between the parasite the and host immune system (Good 
& Doolan 1999). Limited knowledge of the relationship between the immune system and 
malaria the parasite antigens also present a challenge in malaria vaccine research (Crompton 
et al. 2010). Immuno-epidemiological studies have provided useful data, but so far we are 
still unable to identify a stable correlation between immune responses and protection. 
Conventionally, vaccine antigens are identified by immunological techniques. The major 
limitation of this method is the chance of missing out the less abundant, poorly immunogenic 
antigens that trigger short-lived immunity, which actually may relate to the protection 
(Richie & Saul 2002). Thus, some considered that selecting malarial vaccine candidates 
according to this basis is non-systematic and alternative methods are urgently needed 
(Carvalho et al. 2002).  
 Using vaccines that represent only one form of the antigen could provide protection 
against only some strains of parasite because protein antigens of malaria parasite have 
extensive antigenic polymorphisms. In addition, this may select nonvaccine serotypes and 
allow new recombination forms of parasites to be emerge (Takala & Plowe 2009). Antigenic 
variation also enables the parasite to dodge host immune recognition (Craig & Scherf 2001).  
 Malaria vaccines are facing challenges in the manufacturing process. For the whole 
parasite vaccine, there has been a lot of effort trying to produce irradiated sporozoites on a 
large-scale, while the expressing of conformationally correct sub-unit protein antigens was 
problematic (Hill 2011).  
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 Each of the established in vitro assays using in malaria vaccine research has 
limitations and has to be standardized in order to compare the results (Holder & Holder 
2009). Nevertheless, they can only supply limited predictive value and cannot guarantee 
effects of the vaccines in vivo (Carvalho et al. 2002). More over, the comparative 
immunology between human host and animal models of malaria, is not very well understood 
and can caused difficulty in the interpretation of the experimental data (Carvalho et al. 2002; 
Richie & Saul 2002).  
3.1.2 Approaches for malaria vaccine development 
 Approaches for malaria vaccine development have been developed based on 
different principals. Injection of irradiated sporozoite, was shown to induce sterile protection 
against malaria in humans (Hoffman et al. 2002). Although, the production of sufficient 
sporozoites to supply a large number of vaccinations is unrealistic (Carvalho et al. 2002), it 
was believed to be a very effective vaccine. Aseptic products under good manufacturing 
practices (GMPs) have been developed (Luke & Hoffman 2003). The trial was performed in 
malaria-naïve adults and it was reported that the irradiated sporozoite was safe, but the 
immunogenicity and protective efficacy of the vaccine were considered as suboptimal 
(Epstein et al. 2011). Subunit vaccines have gained more popularity for they allow more 
flexible design and are easily mass produced, (Wang et al. 2009). The DNA vaccine is based 
on the knowledge that the foreign proteins, encoded from introduced DNA, can be produced 
in the host and trigger immune responses (Carvalho et al. 2002). Heterologous prime-boost 
vaccination regime was later developed, and showed to enhance the immunogenicity of the 
DNA vaccine (McConkey et al. 2003).  
3.1.3 Development of subunit vaccines 
 The development of subunit vaccine can be divided into three steps; research and 
development (R&D), pre-clinical testing and clinical trials (World Health Organization 
2010a).  
 For the design of subunit vaccines, ideally, the antigens that have been identified for 
their important roles in parasite survival and the epitopes that are able to trigger protective 
immune responses are chosen and included in the construct This rationale is not only allows 
well-identified antigens and/or epitopes to be included in the vaccine, but also minimizes the 
chance that interfering antibodies may be produced and benefits the production step by 
limiting the size of the protein antigen (Richie et al. 2007). It has been suggested that multi-
immune responses to a range of antigens may provide better protection. Thus, the idea of 
multistage and multi-antigen vaccine has been proposed as the rationale for modern vaccine 
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design. The synthetic multi-component protein antigens generally include epitopes of B-cell 
and/or T-cell which are known to be associated with protection. (Jones & Hoffman 1994). 
Although they do not increase the overall efficiency of the vaccine, according to the 
prediction from mathematical models, the multi-component vaccines were suggested to be 
useful in reducing the proportion of poor responders. And as long as it is targeting a single 
organism, the immune interference is unlikely to be a problem (Saul & Fay 2007).  
 Even more challenging is the need to increase the efficiency of the vaccine. 
Compared to irradiated sporozoite, many of the peptide antigens are poorly immunogenic 
and can only be effective when used with Freund’s adjuvant, which cannot be used in 
humans (Carvalho et al. 2002). To overcome this negative point, many adjuvants have been 
developed. These are expected to enhance immunogenicity of the antigen and raise higher 
antibody titres. Various adjuvants licensed for human use, which have been formulated with 
different malarial vaccine candidates and tested in different species of animals, have given 
promising results (Pye et al. 1997).  
 Antigens that have been selected are produced and validated for their production 
protocols as well as the formulations, safety, and immunogenicity in animal models. Once 
they have been approved in small animals such as rodents and then in non-human primates, 
they are progressed to human clinical trials. In this stage, the procedures must meet a higher 
standard called as Good Manufacturing Practice (GMP). Clinical trials can be further divided 
into four phases. In the Phase I trial, vaccines are tested for safety and immunogenicity, as 
well as investigated for immune responses in non-immune volunteers or small group of 
people in an endemic area. Phase II can be divided further into sub-phases. In Phase IIa, non-
immune volunteers who had received vaccine were challenged with the sporozoites via 
mosquito bites. Subjects are monitored until the blood-stage form of parasite is detected, 
which is when the procedure is terminated and the individuals are treated with drug (World 
Health Organization 2010c). Although the test is intended to evaluate the ability of vaccine 
to delay infection, it was commented that low parasitaemia may be needed to boost essential 
immune responses against blood-stage parasites. Therefore, the early elimination of the 
parasite from bloodstream can lead to the underestimation of the blood-stage vaccine 
performance (Carvalho et al. 2002). Instead of testing in naïve individuals, subjects from 
endemic areas were tested in Phase IIb trial. Time intervals between infections of the 
immunized group are compared with the control group and the protective property of the 
vaccine is assessed. More subject groups from different endemic areas are tested in the Phase 
III trial. The candidates that are satisfied by these three stages of testing are further tested in 
the final stage. The Phase IV requires larger populations, in which the vaccine is tested for 
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its long-term efficacy and may also be investigated for non-inferiority of immune responses 
when tested in areas that other vaccines have already been deployed (World Health 
Organization 2010c). So far, SPf66 (Valero et al. 1996)  and RTS,S (Bejon et al. 2008) have 
progressed into Phase III trial.  
3.2 Targets of malaria vaccine  
 The malaria vaccines targeting antigens of pre-erythrocytic, asexual erythrocytic and 
sexual stages are expected to raise different immune responses and provide different values 
of protection.  
3.2.1 Pre-erythrocytic stage vaccines 
 By targeting sporozoite or infected hepatocyte, pre-erythrocytic stage vaccine is 
expected to prevent the infection. Evidence from irradiated sporozoite immunization 
suggested that T-cell responses are important if directed against parasite and lead to strong 
protection (Richie & Saul 2002). However, protection from pre-erythrocytic vaccine will not 
be successful, if any of the invading sporozoites evade the immune system and progress to 
the erythrocytic stage, especially in naïve individuals. 
 The most developed pre-blood stage vaccine is RTS,S. This vaccine is made up of 
recombinant protein antigen which is based on a combination of tandem repeat tetra-peptide 
and C-terminal T-cell epitopes regions of CS antigen (circumsporozoite protein), which is 
the most abundant antigen of sporozoite, and hepatitis B surface antigen S, as well as an un-
fused S antigen. Formulated with AS02 adjuvant, which is an oil-in-water emulsion that 
contains immune-stimulants, it was shown to provide protection against natural infection in 
semi-immune adults in Gambia (Bojang et al. 2001). In Phase IIb trials, which were 
conducted in children in African countries, it was also confirmed that the vaccine is safe, 
able to induce high antibody response, which was associated with the reduction of time to 
new infection (Alonso et al. 2005; Aponte et al. 2007; Bejon et al. 2008). And recently, first 
results of Phase III trial showed that RTS,S/AS01 was able to reduce both clinical and severe 
malaria by half in young children during the 12 months after vaccination (Agnandji et al. 
2011). With this reported efficiency and acceptable safety, it is expected that the RTS,S will 
become the world’s first licensed malaria vaccine. 
 Apart from the CSP based antigen, other liver-stage antigens such as LSA1, LSA3, 
SPf66, TRAP, SALSA and STARP are identified and studied for their potential as vaccines. 
Liver-stage antigen 1 (LSA1), has consistently been shown by studies of malaria-exposed 
humans to be a target of specific immune responses that is linked to the protection against 
P.falciparum infection (Kurtis et al. 2001). However, a recombinant LSA1 protein based 
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vaccine, Ad35-LSA1 vaccine, failed to protect individuals from parasite-infected mosquito 
bites in a challenge trial (Cummings et al. 2010). LSA3 has been developed into different 
form of vaccines. The recombinant LSA3 protein antigens showed the promising ability to 
protect Aotus monkeys from P. falciparum sporozoite challenge (Perlaza et al. 2008), while 
in a different study the immunization of DNA vaccine encoding LSA3 was reported to 
protect chimpanzees against sporozoite infection (Daubersies et al. 2008). The chemically 
synthetic SPf66, the merozoite-sporozoite-based antigen is another pre-erythrocytic stage 
vaccine tested in Phase III trials. Its potential to activate protective responses was reported in 
some area (Beck et al. 1997). Thrombospondin-related adhesion protein (TRAP) is known to 
contain CD8+ T-Cell epitopes. A prime-boost regime of simian adenovirus (AdCh63) which 
is encoded for ME-TRAP and boosted with modified Vaccinia virus Ankara (MVA) which 
is encoded for the same antigen, showed strong CD8+ T cell responses (Capone et al. 2010).  
3.2.2 Erythrocytic stage vaccine 
 The asexual blood stage vaccines have been researched intensively. This type of 
vaccine aims to reduce symptoms of malaria, decrease parasitaemia and eventually eliminate 
parasites (Richie & Saul 2002). Blood-stage vaccine is mainly focused on antibody 
production and generates antibody-relate responses, based on the evidence that transfer of 
antibodies from naturally acquired immunity can protect malaria naïve from clinical 
symptoms (Richie & Saul 2002).  
 Vaccines against blood-stage parasite can be divided into two main categories 
include (1) invasion-blocking, and (2) anti-disease vaccine. Invasion-blocking vaccines aim 
to disrupt parasite invasion, focusing on parasite surface proteins or erythrocyte surface 
proteins. Among popular candidate antigens are MSP-1 and AMA-1, which are believed to 
have roles in initial attachment (Goel 2003)  and parasite entry (Mitchell et al. 2004)  
respectively. PfEMP1 is the focus of anti-disease vaccine research for it allows the parasite 
to sustain chronic infection by accumulate in the brain or placenta causing severe forms of 
malaria.  
 The big challenge in erythrocytic stage vaccine development is the polymorphism of 
the antigens. Also, it was commented that current blood stage vaccines are focused on only a 
small number of candidate antigens. Thus, the better target antigens need to be identified and 
included in the vaccine (Hill 2011). More information about candidate antigens will be 
further discussed. 
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3.2.3 Transmission-blocking vaccine 
 In contrast to other types of malaria vaccine, transmission-blocking vaccine targets 
diminishing the rate of infection, prevent the development of gametocytes in the mosquito 
and therefore lead to overall reduction of malaria transmission. Antigens such as Pfs25, the 
ookinete antigen, have undergone Phase I clinical trials (Malkin et al. 2005; Collins et al. 
2006). Even though it could induce transmission-blocking activity, systemic adverse events 
such as erythema nudosum which is associated with the formulation of Pfs25/ISA51 was 
reported (Wu et al. 2008).  
3.2.4 Multi-stage vaccine 
 The vaccines containing antigens from many stages of parasite are expected to 
provide more hitting target for immunity, which then elicit more types of protective immune 
responses and therefore, provide better protection (Hill 2011; Carvalho et al. 2002). 
FALVAC-1, for example, is made up of a long series of antigen domains including CSP, 
LSA1, MSP-1, SSP2, AMA-1, RAP1, EBA175 and Pfg27. Immunisation of this vaccine was 
reported to produce immunity to different stage of the parasite. The synthetic polymer, 
SPf66, which consists of blood-stage antigens and the peptide derived from CSP was tested 
in Africa. The results suggested that it has low protection efficiency against P. falciparum 
(Graves & Gelband 2009). The multi-stage vaccine, NIIMALVAC-1, which contains B-cell 
and T-cell epitopes from different antigens can be produced in insect cells and was reported 
for its immunogenicity in mice (Shi et al. 2000). NYVAC-Pf7 is a highly attenuated vaccinia 
virus containing seven different genes (including CSP, TRAP, LSA1, MSP-1, SERP,… 
AMA-1 and Pfs25) from all stages of P. falciparum into the virus genome. The Phase I/IIa 
trial of this vaccine reported that only one volunteer was protected against challenged with 
bite of P. falciparum-infected mosquitoes.(Ockenhouse et al. 1998).  
3.3 Surface antigens of erythrocytic stage parasite  
 Many blood-stage antigens have been identified, some of which have been further 
developed into vaccines, but not many of them have been characterized for their functions. 
The antigens of blood-stage can be categorised into (1) erythorcytic antigens, which 
presented on the surface of infected erythrocyte; (2) merozoite surface antigens, which 
present on surface of merozoite; and (3) apical proteins, which present only at the apical end 
of the merozoite.  
3.3.1 Erythrocytic antigens 
 Erythrocytic antigens are the antigens, which are expressed by the malaria parasite 
and then presented on an infected erythrocyte membrane. The molecular mechanism of 
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protein extra-parasitic trafficking network is not totally understood, but it is likely to involve 
the Maurer’s clefs (MC) (Taraschi 1999; Wickham et al. 2001). It was reported that the 
motif called Plasmodium export element (PEXEL) is required for transportation (Marti 
2004). Using this gene sequence, protein products of stevor, rifin, and Pfmc-3TM gene 
families were predicted to be transported to the erythrocyte membrane (Lavazec et al. 2006).  
 The antibodies against these antigens may prevent infected erythrocyte binding to 
host cells, mediate antibody-dependent cellular cytotoxicity (ADCC), play a role in 
opsonisation, or complement-mediated lysis (Carvalho et al. 2002). The immunogenic 
antigens of this stage have been identified and have been developed as anti-disease vaccines, 
which aim to prevent development of severe morbidity.  
3.3.2 Erythrocyte membrane protein 1 (PfEMP1) 
 Erythrocyte membrane protein 1 (PfEMP1) is coded by the multigene family called 
var genes. Var genes are located mostly at the telomeric regions of he parasite's 
chromosomes (Gardner et al. 2002). In P. falciparum, PfEMP1 is synthesised early and 
slowly transported to the surface of infected erythrocyte (Kriek et al. 2003). Regulation of 
var gene transcription and switching is not only dependent on negative feed back from var 
gene product (Kyes, Kraemer, et al. 2007b) but also on non-coding sequences histone 
hypoacetylation (Freitas-Junior et al. 2005), nuclear repositioning, and there may be other 
mechanisms which are yet to be discovered (Kyes, Kraemer, et al. 2007b). PfEMP1 is 
encoded in two exons; the first one produces the variable extracellular binding region and a 
transmembrane domain, while the second produces a conserved cytoplasmic tail (Su et al. 
1995). Important domains of this protein include the KAHRP, PEXEL sequence, which is 
responsible for transportation of this protein out from the parasitophorous vacuole (Marti 
2004). Other extracellular regions such as Duffy binding like (DBL) and cysteine-rich 
interdomain region (CIDR), are used to categorize structures of PfEMP1 (Kyes, Kraemer, et 
al. 2007b). Different groups of PfEMP1 can have various functions due to these domains. 
For example, the PfEMP1 containing CIDR1 was showed to interact with host receptor 
CD36 (Baruch et al. 1997), while the PfEMP1 that lacks CIDR1 domain, encoded by 
var2CSA, was reported to bind to the placenta (Salanti 2004). 
 The VAR2CSA, which is a type of PfEMP1 binds to low-sulfated chondroitin 
sulfate A (CSA) in the placenta (Salanti et al. 2003; Duffy et al. 2005; Gamain et al. 2005). 
This large (around 350 kDa) and conformational protein is technically difficult to produce. 
Thus, individual domains are developed as vaccines (Oleinikov et al. 2008; Dahlbäck et al. 
2006). It was reported to be recognized by natural acquired antibodies which are associated 
with a low risk of low weight of newborn babies (Harnyuttanakorn et al. 1992; Salanti 
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2004). Further studies on the IgG against this protein showed that they are mainly targeting 
polymorphic regions (Beeson et al. 2006; Dahlbäck et al. 2006). And the polymorphic 
conformational targets that are associated with the protection were also reported (Barfod et 
al. 2006). Polymorphisms could be an obstacle to this vaccine’s development (Hviid 2011). 
However, the study in rats showed that the adhesion-inhibitory antibodies raised by 
immunization of one of the most conserved domains of the VAR2CSA can be achieved 
(Nielsen et al. 2009). According to these data, further studies on the PfEMP1 domains and 
their relatedness to protection will be help in selecting the potential domains to be produced 
as vaccines.  
3.4 Merozoite surface proteins  
 The merozoite antigens are considered as a viable targets for antibodies and have 
been developed as vaccine candidates. Vaccines based on these antigens are expected to 
raise the titer of antibody, which have ability to kill or inhibit merozoite invasion.  
3.4.1 Merozoite surface protein 1 (MSP-1) 
 MSP-1 is the most abundant surface protein, covering around 40% the parasite’s 
surface. MSP-1 contains repetitive amino acid sequences (Cavanagh et al. 2001; Ferreira et 
al. 2003). These sequences are different in length and genetic content between allelic groups, 
but showed low inter-population variance and allelic types are well maintained within and 
between parasite populations, suggesting strong balancing selection on this region of the 
msp-1 gene (Conway et al. 2000).The MSP-1 can be divided into 17 blocks by the degree of 
nucleotide homology between strains as conserved, divergent and highly divergent regions. 
The dimorphic sequence rule can be used to categorize variation into two allelic types, which 
















Figure 1.4: Schematic diagram of the P. falciparum MSP-1 represents the location 
of 17 blocks as described by Tanabe et al., 1987 (Tanabe et al. 1987). They can be 
divided according to the degree of polymorphism as conserved (open boxes), 
dimorphic (full), semi-conserved (hatched boxes), and polymorphic (speckled box). 
Processed products of MSP-1 precursor at sizes of 83, 28, 38 and 42 kDA are 
shown. Block 2 of MSP-1 can be further categorised into three types named as K1 
type and MAD20 type, each of which contains iconic-type-specific flanking regions 
and type-specific repetitive region, and RO33 type which does not contain repetitive 
sequences. Examples of Block 2 variants belonging to each Block 2 types are given. 
(Figure from (Cavanagh et al. 1998)) 
 
 The MSP-1 precursor, a 190-195 kDa GPI-linked protein, is produced during the 
schizogony stage, transported to the surface of the erythrocytic merozoite, where the signal 
sequence at N-terminus is cleaved off (Polley et al. 2003; Blackman et al. 1990; Cavanagh et 
al. 2001). At the late schizont stage, the precursor undergoes proteolytic processes by a 
parasite-derived protease, giving four protein fragments known as p83, p28, P30, p38 and 
p42 (Figure 1.5). These units and other two surface proteins, MSP-6 and MSP-7, bind 
together non-covalently as a complex on the surface of the merozoite (Jiang et al. 2000; 
Kauth et al. 2006). Just before the invasion, another proteolytical event is taking place. The 
C-terminal of p42 is cleaved into p33 and p19 (Figure 1.5). Finally, most of the complex is 
removed, except for the MSP-119, which is left to be the only part carried in to the new 
erythrocyte (Holder et al. 1999; Holder & Blackman 1994). The cleavage and shedding of 
this protein have been shown to be critical steps for the invasion of the parasite (Blackman et 
al. 1990).  




Figure 1.5: Schematic diagram of the precursor of MSP-1 P. falciparum 3D7 shows 
signal sequence (SS), GPI moiety (GA), products after cleavages (p83, p30, p38, 
p33, and p19) (Figure from (Woehlbier et al. 2006)). 
 
 MSP-1 was proposed to be involved in invasion of host cells or cell-to-cell adhesion 
as determined by bioinformatics analysis of the P. falciparum genome database (Florens et 
al. 2002; Gardner et al. 2002). Based on studies of the MSP-1 ternary complex, the stability 
and efficiency of MSP-1 in anchoring the parasite to erythrocytes could be beneficial to the 
merozoite (Kariuki et al. 2005). The important of MSP-1 for the parasite’s survival is also 
supported by experiments attempting to modify this molecule (Cowman et al., 2002; 
Blackman et al. 1990). MSP-1 may interact with neighbor proteins to perform their 
functions. A complex of MSP-142 and another merozoite protein, MSP-9, may function in 
Band 3 binding (Oh & Chishti 2005). The specific interaction between two domains of MSP-
9, MSP-119 and Band3 was proposed. It was suggested that the two MSPs are able to bind 
different receptor domains of a Band3 homodimer during the equilibrium stage (Kariuki et 
al. 2005). The structure of the complex between MSP-1 components and other gene 
products, such as MSP-636 and MSP-7 has also been reported (Kauth et al. 2006).  
 Antibodies to MSP-1 are present in naturally malaria-exposed individuals and some 
studies show correlation with protection from malaria symptoms. It was shown that this 
protection is in an allele-specific manner (Galamo et al. 2009; Lyon et al.,  2008). And the 
epitopes for protective B-cells and T-cells in MSP-1 were reported (Diggs et al. 1993; 
Woehlbier et al. 2006). The antibodies of MSP-1 fall rapidly to the detection limit soon after 
antimalarial treatment, suggesting that humoral immunity response against malaria is short-
lived (Cavanagh et al. 2001). This may be due to the short half-life of IgG3. Also, it was 
predicted that the memory B cells and long lived plasma cell do not survive as long as those 
in other infections, or they are fewer in number (Achtman et al. 2005).  
 A number of studies have supported MSP-1 as potential vaccine candidate. The 
antibodies raised by this vaccine are expected to prevent the progression of parasites into the 
intraerythrocytric state and may also inhibit the maturity of the liver stage parasites, which 
then diminish the number of parasites released into the circulation. Naturally acquired 
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cytophilic antibodies can be activated by all blocks of the MSP-1 (Gardner et al. 2002), but 
for malaria vaccine development, only the protective epitopes should be included in the 
vaccine construct rather than use length of MSP-1 (Diggs et al. 1993). The most developed 
MSP-1 vaccine is based on C-terminal of the MSP-142 fragment. However, the N-terminal 
region of the MSP-1 has also been proposed as immune targets (This will be review in 
chapter 3) (Tetteh et al. 2005; Cavanagh et al. 2004; Conway 1997; Locher et al. 1996). The 
antibodies to the MSP-142 component showed that they can inhibit P. falciparum in strain-
specific manner (Lyon et al., 2008). The Phase I trial of this vaccine presented hopeful 
results, reporting that it was immunogenic and safe. However, it conferred no protection in a 
Phase IIb trial, which is may be due to allelic polymorphism (Ogutu et al. 2009). The MSP-
119 was also defined as the main target of immunity. Immunization of the recombinant C-
terminal region of MSP-119 formulated with Freund’s adjuvant was reported to provide 
protection against P. falciparum in the Aotus monkey (Kumar et al. 2000). Multi-
compartment vaccines based on MSP-1 based antigens such as AdCh63/MVA MSP-1 have 
been studied. This vaccine contains dimorphic forms (3D7 and FVO) of C-terminal, N-
terminal and the MSP-119. It was reported that this protein showed high CD4/CD8 T cell 
induction and some IgG induction in a Phase I trial study (Sheehy et al. 2011).  
3.4.2 Merozoite surface protein 2 (MSP-2) 
 MSP-2 is an 44-55 kDa protein presented through blood stage of parasite from ring 
stage to mature schizonts and merozoites (Smythe et al. 1988; Ramasamy 1987). It contains 
glucophosphatidylinositol domain (GPI anchor), which is the domain that attached to 
merozoite’s surface. Like MSP-1, the MSP-2 is shed from the surface of merozoite upon 
invasion (Smythe et al. 1988). 
 To date, at least 170 allelic sequences have been published for MSP-2, suggesting 
that it is the most polymorphic gene of the P. falciparum parasite. The central region of 
MSP-2 is very polymorphic (Heidari et al. 2007) and varies in length, number and content 
between isolates (Smythe et al. 1990). It is flanked by N- and C- terminal regions, both of 
which are more conserved. The central polymorphic region contains allelic tandem repeated 
motifs flanked by non-repetitive sequences. According to the non-repetitive variable 
sequence, MSP-2 can be distinguished into two allelelic families (Fenton et al. 1991; Smythe 
et al. 1991; Smythe et al. 1990). These are serogroup A (IC-1/3D7-type) of which 
CH150/9(5/6) is a member, and serogroup B (FC27-type), in which the Dd2 strain of P. 
falciparum is a member (Smythe et al. 1990). The idiosyncratic of dimorphism of these two 
P.falciparum MSP-2 alleles is suggested as a result of a proliferation of repeats in two 
different regions of the molecule which leads to loss of other regions (Rich et al. 2000).  
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 The MSP-2 was reported as to be largely unstructured (Yang et al. 2007; Adda et al. 
2009) and form amyloid-like fibrils via the conserved N-terminal region (Low et al. 2007). 
Like MSP-1, function of MSP-2 is suggested to be involved in erythrocyte invasion by 
studies of invasion-inhibition antibodies (Epping et al. 1988; Miettinen-Baumann et al. 1988; 
Clark et al. 1989). MSP-2 is immunogenic (Taylor et al. 1995; Aubouy et al. 2003)  and 
interestingly, statistical analysis showed that MSP-2 is under natural positive selection 
(Conway 1997). 
 The allelic family specific antibodies were detected in naturally immune infections 
(Felger et al. 2003; Tami et al. 2002)  and shown by two different studies that they lack 
ability to cross-react between the two allelic forms of MSP-2 families (Taylor et al. 1995; 
Franks et al. 2003). The hot spot of anti-MSP-2 targets is located within the polymorphic 
centre part of the antigen (Taylor et al. 1998; Metzger et al. 2003), where the antibodies to 
constant N and C terminal regions are produced as a minority (Zhang et al. 2008). Anti-
MSP-2 subclasses are generally IgG1, especially in young children, and IgG3, where its 
higher prevalence is correlated with increasing age of host (Polley et al. 2006; Taylor et al. 
1998; Tongren et al. 2005).  
 Anti-MSP-2 antibodies were shown by different studies that they were associated 
with protection (al-Yaman et al. 1995) and low risk of clinical malaria (Polley et al. 2006). 
In vitro studies for the activities of the MSP-2 antibodies showed different results. The 
merozoite invasion inhibiting property of the mouse monoclonal anti-MSP-2 antibodies was 
reported (Clark et al. 1989). The purified human IgG to this antigen   showed growth 
inhibitory effect in a dose-dependant manner (Courtin et al. 2009). However, it was reported 
by another study that the human anti-MSP-2 has no growth inhibiting property in vitro, and 
only showed parasite killing effect in the presence of monocytes (ADCI) (Flueck et al. 
2009). The trial of the vaccine based on one form (3D7) of MSP-2 in Papua New Guinea 
showed that it can reduce parasite densities in children and lower prevalence of parasites. 
However, another allelic form (FC27) was suggested to be selected by this immune pressure 
(Genton et al. 2002). Later, the Phase I trial of MSP-2-C1, which contains both allelic forms, 
in malaria naïve volunteers showed that the immunisation could raise the specific IgG to 
both forms of MSP-2, which showed the ADCI activity but not the GIA activity (McCarthy 
et al. 2011).  
3.4.3 Merozoite surface protein 3 (MSP-3)-superfamily 
 MSP-3 superfamily protein members on chromosome 10 of P. falciparum, including 
MSP-3 (MSP-3.1), MSP-6 (MSP-3.2), PF10_0347 (H101 or MSP-3.3), PF10_0348 (MSP-
3.4), PF10_0352 (H103 or MSP-3.7) and PF10_0355 (MSP-3.8) were identified based on 
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their common small stretch of amino acid (NLRNA/G) near the N-terminal, called 
“signature sequence”. Unlike other protein families such as var, genes of MSP-3 family 
members are single exon, located on the same chromosome (Singh et al. 2009).  
 Strikingly, C-terminal conserved sequences of MSP-3, MSP-6 and other paralogs are 
similar, very conserved among parasite isolates and reported to be cross-recognised by 
antibodies raised by each of six members of the MSP-3 family. It was commented that this is 
very unusual for malaria parasite genes encoding for surface protein antigens, suggesting 
that these domains should be very important for the parasite. Alternatively, these epitopes 
may be selected by immune pressure through evolution and play a role in the homeostasis 
between host and parasite, allowing the host to survive the infection so the parasites can be 
further transmitted (Singh et al. 2009). Parasite knockout lines of some MSP-3-family 
member are established and showed that gene disruptions did not cause significant effect on 
parasite survival (Cowman et al., 2002; Pearce et al. 2005). to this, it was commented that 
members of the MSP-3 family may compensate for the loss of the others. However, each of 
these antigens has unique domains, such as the MSP-3.4 and MSP-3.8 which contain a DBL-
like cyctein-rich domain, similar to those of the var gene products. So before their functions 
will be further investigate, the fact that these proteins may provide diverse functions cannot 
be excluded (Singh et al. 2009). 
 Hyper-immune sera of individuals in malaria endemic area showed different patterns 
of antibody subclass responses to member of the MSP-3-family proteins. The IgG1 and IgG3 
were shown to have strong reactivity compared to other subclasses (Singh et al. 2009). The 
C-terminal domain contains the antigenic domains, which are targets of natural acquired 
immunity associated with parasite killing (Singh et al. 2005). Antibodies to the antigens 
based on the C-terminal region of the MSP-3 family members were also reported for their 
efficiency in ADCI (Singh et al. 2009).  
3.4.3.1 MSP-3 
 MSP-3 is a 48 kDa protein which associates with other surface proteins on 
merozoite surface (LaCount et al. 2005; Oeuvray et al. 1994) MSP-3 is a polymorphic 
antigen, which can be categorised into two major allelic types (3D7-like and K1-like) (Huber 
et al. 1997). It comprises heptad repeats, a hydrophilic region and a putative leucine zipper 
sequence at the C-terminal (McColl et al. 1994). The study of MSP-3-truncated parasite 
showed that this mutant parasite had lower invasion efficiency. Thus, the role of MSP-3 in 
red blood cell invasion was proposed (Mills et al. 2002).  
 The IgG3 was reported to be the major subclass IgG to the MSP-3, followed by 
IgG1 (Osier et al. 2007). Cohort study in Ghana reported that the level of IgG3 to MSP-3 
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increase with age until the children reach 7 years old (Dodoo et al. 2008). It was showed that 
the IgG3 to the MSP-3 is significantly associated with a reduced risk of clinical malaria 
(Dodoo et al. 2008; Osier et al. 2007; Soe et al. 2004; Roussilhon et al. 2007).  
 The immunization of MSP-3 recombinant protein was reported to provide immune 
protection against the parasite challenging in non-human primate (Hisaeda et al. 2002). The 
IgGs to MSP-3 showed the parasite killing property in the ADCI assay (Jafarshad et al. 
2007; Oeuvray et al. 1994). And two studies reported that the targets for the antibodies with 
ADCI activities are within the conserved region of the MSP-3 (Soe et al. 2004; S. Singh et 
al. 2004; Druilhe et al. 2005). MSP-3 vaccine trials showed promising results. Clinical trial 
phase I reported that the antibodies raised by MSP-3 antibodies were able to kill P. 
falciparum, both in vitro and in vivo (Druilhe et al. 2005). Safety and immunogenicity of the 
formulation were further confirmed in Phase Ib studies in African population, which showed 
that MSP-3 vaccine was able to boost strong IgG1 and IgG3 in vaccinated children (Lusingu 
et al. 2006; Sirima et al. 2009).  
 
Figure 1.6: This schematic diagram compare genes of major P. falciparum 
merozoite surface antigens. MSP-1 can be divided into 17 blocks where Block 2 has 
exceptional polymorphism and generally contains a repetitive sequence (stripe). 
MSP-2 contains a polymorphic repetitive sequence at the central region, flanked by 
variable regions (black) and conserved regions (white). MSP-3 as well as MSP-6 
contain conserved regions at both the 5’ and 3’ of the genes. While they both 
contain non-repetitive variable regions, repetitive sequence is reported only in MSP-
3. In the other hand, the indel region (dark speckled) or region which is reported for 
insertion and deletion, is reported only in MSP-6 (Roy et al. 2006). 
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3.4.3.2 MSP-6 
 The overall sequence organization of MSP-6 is related to MSP-3 (Pearce, Triglia, et 
al. 2004b; Trucco et al. 2001). Both of them contains N-terminal signal sequence (Singh et 
al. 2009). Unlike the C-terminal which is hightly conserved, the N-terminal part of MSP-6 is 
polymorphic. It is likely to be less antigenic than the C-terminal part and may be cleaved by 
proteolytic process (Pearce, et al. 2004b). 
 MSP-6 was expected to be a target of protective antibodies and can be developed 
into a vaccine candidate (Singh et al. 2005). Analysis for the specific antibodies to each 
region of MSP-6 showed that overall, IgG1 and IgG3 are dominant subclass species, while 
IgG2 antibodies was also detected against some region of MSP-6 (Singh et al. 2005). 
 Similarly to MSP-3, The C-terminal part of the MSP-6 was identified as a target of 
the antibodies with ADCI activity (Singh et al. 2009; Singh et al. 2004; Oeuvray et al. 1994). 
Apart from the epitopes that are cross-reactive by the antibodies that recognise MSP-3, 
MSP-6 also provides extra epitopes for the naturally induced antibodies which showed the 
ability to inhibit malaria parasite growth in the ADCI manner (Singh et al. 2005).  
 Another recently identified MSP-3-superfamily member is PF10_0347 (referred as 
H101 or MSP-3.3 in some studies). Based on amino acid content, this protein is more similar 
to the MSP-3 than the MSP-6 and it may have redundant functions as other MSP-3-protein-
family members (Singh et al. 2009). More detail about this protein will be discussed chapter 
3.  
3.5 Apical organellar proteins 
 The apical end of malaria merozoite has a high protein content, showing as electron 
dense matrix on electromicroscopy. The proteins reported to be associated with invasion of 
merozoite are such as merozoite apical membrane antigen 1 (AMA-1), rhoptry associated 
proteins (RAP), reticulocyte-binding proteins (Rh), and erythrocyte-binding antigen (EBA). 
3.5.1 Apical membrane antigen 1 (AMA-1) 
 AMA-1 is extensively studied in malaria research. It is a low abundance protein that 
firstly is expressed at late schizont stage as a 83 kDa precursor protein. Just before invasion, 
the precursor protein undergoes several proteolytic processes into the final 66 kDa product, 
which is then translocated within micronemal organelle (Bannister et al. 2000; Howell et al. 
2001; Narum & Thomas 1994; Healer et al. 2002). It was presented in sporozoite of P. 
falciparum (Florens et al. 2002) and showed to have a function in hepatocyte invasion 
(Silvie 2004). AMA-1 is highly polymorphic (Chesne-Seck et al. 2005) and it is under 
positive balancing selection (Cortés et al. 2003; Garg et al. 2007; Polley & Conway 2001). 
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AMA-1 was proposed to be necessary for parasite survival. This idea was supported by the 
reports on the function of AMA-1, which is experimentally proved to be associated with 
invasion of erythrocytes (Healer et al. 2004; Healer et al. 2005; Triglia et al. 2000; Treeck et 
al. 2009), the mode of actions of anti-AMA-1 antibodies (Dutta 2003; Dutta et al. 2005), and 
the fact that the knockout parasite line has never been successfully established (Triglia et al. 
2000).  
 AMA-1 is very immunogenic in natural infections (Polley et al. 2004; Thomas et al. 
1994; Cortes et al. 2004). Isotypes of anti-AMA-1 antibodies are biassed for IgG1 and IgG3, 
whereas IgG2 and IgG4 are also detected (Riley et al. 2000; Polley et al. 2004; Metenou et 
al. 2007; Stanisic et al. 2009). It has been shown by different studies that both conserved and 
allele-specific epitopes regions are the targets of antibodies (Hodder et al. 2001; Polley et al. 
2004; Cortes et al. 2004). The association between naturally induced anti-AMA-1 antibodies 
and protection was reported (Courtin et al. 2009). The In vitro assay showed that the anti-
AMA-1 antibodies have strongly inhibitory effect against invasion of homologous strain of 
parasite, but have less effective against heterologous strain, suggesting that the inhibitory 
effect is mainly strain-specific (Hodder et al. 2001; Kocken et al. 2002).  
 Vaccines based on AMA-1 antigen in combination with aluminum hydroxide, 
Montanide ISA720, and AS02, were tested in Phase Ia/Ib clinical trials. It was proven to be 
safe. The antibodies produced by the immunisation showed high GIA activity in one study 
(Roestenberg et al. 2008) but failed in another one (Geels et al. 2011). According to these 
results, it was suggested that antibodies to a broad spectrum of AMA-1 form is necessary for 
the efficiency of the vaccine. Therefore, for the vaccine design, polymorphism of the AMA-
1 should be taken into account. AMA-1-DiCo which is a construct containing AMA-1 
sequences both from the 3D7 and FVO strains has been developed. This antigen when 
formulated with CoVaccine HT or Montanide ISA51 was shown to be safe and 
immunogenic in rhesus macaques (Kusi, Remarque, Riasat, Walraven, Thomas, Faber & 
Kocken 2011b). 
3.5.2 Rhoptry-associated protein 
 Rhoptry-associated protein 1 (RAP1) and RAP2 have their location at apical 
organelles. Rhoptry is involved in erythrocyte invasion. RAP1 is produced as 86 kDa protein 
(Howard & Schmidt 1995) and then cleaved to yield an 82 kDa fragment called p82. Later in 
schizogony stage, the p82 is further processed at the N-terminal to generate 67 kDa protein 
(p67) (Bushell et al. 1988). The p82 and p67 fragments are dominant in mature schizont and 
were reported to form a heterooligomeric complex with RAP2 and RAP3 (Howard, Narum, 
et al. 1998b). Although processing of p82 and p67 is barely understood, it was proposed to 
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play a crucial function during merozoite invasion (Howard, Jacobson, et al. 1998a)  and the 
antibodies to the N-terminal of p67, which are supposed to interfere with their processing, 
were shown to inhibit parasite growth (Harnyuttanakorn et al. 1992). According to this, 
RAP1 and RAP2 are interesting as vaccine candidates. Unlike many other antigens, the 
polymorphism of RAP1 is quite limited (Howard 1996).  
 The study in Tanzanian children age younger than five showed that the IgM 
antibodies, but not the IgG, to the recombinant RAP1 increased with age. Also, it showed 
that IgG to the antigen RAP1 is negatively correlated with parasite density, suggesting that 
anti-RAP1 IgG has a role in parasitaemia control and resistance to infection (Jakobsen et al. 
1996). Different longitudinal study of human antibody responses in adult Gambians reported 
that the IgG to RAP1 was very short-lived. However, a stronger RAP1 antibody response in 
subsequent infection was observed. This suggested that presence of parasites is necessary to 
initiate and then to maintain the specific antibodies (Fonjungo et al. 1999).  
 The RAP1 and RAP2 have been showed to have elicited protection responses 
against P. falciparum infection in Saimiri monkey (Ridley et al. 1990). The in vitro assay 
also suggested that the antibodies to RAP1 may be able to inhibit replication of parasites 
(Harnyuttanakorn et al. 1992; Howard, Jacobson, et al. 1998a). Nevertheless, some anti-
RAP1 antibodies were reported as growth-promotion antibodies, which may enhance 
binding of merozoite to red blood cells (Howard, Jacobson, et al. 1998a).  
3.5.3 Reticulocyte-binding homolog protein (Rh) family 
 The Rh proteins were postulated to have a function in erythrocyte invasion and play 
a role in host selection (DeSimone et al. 2009; Duraisingh, Triglia, et al. 2003b; Gao et al. 
2008; Gaur et al. 2007; Triglia et al. 2001b; Tham et al. 2010; Rayner et al. 2001). They are 
located in the apical organelles of merozoite and released to the surface membrane during 
invasion (Duraisingh, Triglia, et al. 2003b). So far, the identified PfRh family proteins are 
PfRh1 (Rayner et al. 2001), PfRh2a, PfRh2b, (Rayner et al. 2000) PfRh4 (Kaneko et al. 
2000), PfRh5 (Hayton et al. 2008) and PfRh3, which was commented to be a pseudogene 
(Taylor et al. 2001). These PfRh proteins can be characterized by their ability to mediate 
merozoite invasion via the sialic acid-dependent pathway (PfRh1 (Rayner et al. 2001)) or 
sialic acid-independent pathway PfRh2a (DeSimone et al. 2009), PfRh2b (Duraisingh, 
Maier, et al. 2003a) and PfRh4 (Gaur et al. 2007)). PfRh1 was also reported to involved in a 
trypsin independent pathway of merozoite invasion (Rayner et al. 2001). According to the 
study of Rh2a and Rh2b, they were reported to be produced during late schizont stage and 
transferred to the apical end of the merozoite (Triglia et al. 2001b). The change in expression 
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of these proteins suggested that they may be involved in the immunnity evasion mechanism 
(Gao et al. 2008; Persson et al. 2008).  
 The complement receptor 1 (CR1) was reported as a receptor for Rh4 (Tham et al. 
2010), while receptors for other Rh proteins family, (such as Rh1 binding ligand, receptor Y 
(Rayner et al. 2001) or Rh2 candidate receptor Z (DeSimone et al. 2009; Duraisingh, Triglia, 
et al. 2003b).) are yet to be characterized. Sizes of the Rh proteins are big and vary from 
around 200 kDa to more than 350 kDa (Duraisingh, Triglia, et al. 2003b; Triglia et al. 2001a; 
Rayner et al. 2001). The Rh2a and Rh2b are similar and slightly different only in the C-
terminal region (Rayner et al. 2000; Triglia et al. 2001a). The knockout line of these two 
genes can be achieved, and there was no effect on the survival of the mutant P. falciparum 
lines (Duraisingh, Triglia, et al. 2003b) 
 Rh proteins were reported targets for antibodies. The polymorphism region in the C-
terminal of PfRh2b was showed to be a target of humoral immunity (Ahouidi et al. 2010). 
The antibody raised to the Rh1 binding region was reported to inhibit merozoite invasion 
(Gaur et al. 2007). The anti-Rh4 antibody was reported to disrupt function of this ligand in 
invasion (Tham et al. 2009), however another report showed that the antibodies to Rh4 failed 
to block parasite invasion (Gaur et al. 2007). 
3.5.4 Erythrocyte-binding antigen (EBA) family 
 Like reticulocyte-binding protein, the erythrocye-binding antigens (EBA) have been 
showed to play an important role in the invasion of P. falciparum parasite (Lopaticki et al. 
2011). The EBA proteins can bind to sialic acid, but also can mediate erythrocyte invasion 
via alternative receptors (Duraisingh, Maier, et al. 2003a; Stubbs 2005). The genes encoding 
for EBA175, EBA181, EBL1 and EBA140 were identified. EBL1 is not presented in all 
parasite lines, which may be due to the missense mutations in the coding region(Mayer et al. 
2009). EBA165, which also has missense mutation, it was suggested as a pseudogene and its 
protein product has not yet been detected (Triglia et al. 2001b). EBA175 and EBA140 were 
reported to be found only in merozoite and trophozoite (Florens et al. 2002).  
 Some of the EBA-binding ligands on erythrocytes were identified. EBL1 was 
reported to bind glycophorin B (Mayer et al. 2009), while EBA175, and EBA140 can bind to 
erythrocyte receptors glycophorin A and C respectively (Orlandi et al. 1992; Lobo 2003).  
 The EBL and Rh proteins are functionally interact and cooperative. The function of 
these two proteins family overlaps, for the loss of function of some ebl genes leads to 
increased transcription of the Rh family gene (Lopaticki et al. 2011). Under certain 
condition, a selected gene can be activated, resulting in phenotypic variation. Since EBA and 
Rh may perform the same function, it is possible that these two protein families bind to red 
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blood cells via a specific receptor, verify the target cell for invasion and then activate the 
signals including rhoptry release. All these properties of the EBA and Rh proteins allow 
parasites to have alternative invasion pathways (Duraisingh, Maier, et al. 2003a), adapt to 
host polymorphic (Duraisingh, Triglia, et al. 2003b) ,and also escape immune responses 
(Persson et al. 2008).  
 It has been shown that the EBA proteins are targets of human invasion-inhibitory 
antibodies. Although EBA175 gene disruption does not effect parasite survival (Duraisingh, 
Maier, et al. 2003a; Kaneko et al. 2000), the anti-EBA175 was reported to inhibit merozoite 
invasion in vitro (Orlandi et al. 1992).  
3.6 Adjuvants and immunization regimes  
 One of the challenges in malaria vaccine development is to achieve last-long 
memory and protective immunity that can persist without natural boosting. An adjuvant is an 
immunoenhancer, expected to assist in enhancing specific immune responses. They may 
increase the ability of antigen uptake by antigen-presenting cells (APCs), allow slow-release 
of the antigen, and improve the stability of the antigen, thus, enabling better antigen 
presentation to the immune system (Leroux-Roels 2010). Adjuvants can be divided into two 
main groups; (1) immunostimulants that enhance immune response (such as TLR ligand, 
cytokines, exotoxin, etc.) and (2) vehicles that present vaccine antigens (such as mineral 
salts, emulsion, virosome, etc.) (Coler et al. 2009).  
 In nature, molecules such as lipoproteins, proteins, LPS or DNA, unmethylated 
deoxycytidy-deoxyguanosines (CpGs) are called pathogen-associated molecular pattern 
(PAMPs), which are recognised by pattern-recognition receptors (PRRs) such as TLRs. This 
knowledge has been used as a basic of adjuvant development (Coler et al. 2009). The 
efficiency of adjuvants can be varied from one antigen to another. The formulation of the 
adjuvant is another factor that affects the efficiency of the immunogen. Ideal formulated 
vaccine should be stable, safe, cost effective, immunogenic and induce desired specific 
immune responses. Unfortunately, our knowledge both of adjuvant functional activities and 
correlation between types of immune responses and protection is still very limited. Thus, 
choosing the appropriated adjuvants for potential vaccine antigen is problematic, and 
normally it is done based on historical data of similar antigens (Coler et al. 2009).  
 In this study, adjuvants that are approved for human clinical trial used have been 
tested. Background information including the expected immune responses is given here in 
short review.  
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3.6.1 Alum 
 Alum or Alumminium salt-based adjuvants are components of several vaccines 
approved for human used. They are used as non-crystalline gels. Alum has a good safety 
profile record and simple to formulate. It is known to provide high antibody titer and long-
last antibody responses (Coler et al. 2009). The molecular mechanism of action of alum is 
still unclear. It has been proposed that alum may improve the formulated antigen availability 
at the injection site, and allows the antigen to be taken up by antigen-presenting cells (APCs) 
(Hem & HogenEsch 2007) and maybe also by denditric cells (DCs) (Morefield et al. 2005). 
The alum mainly enhances Th2 responses and has a little effect on Th1 responses. This is 
maybe a drawn back of using this adjuvant if the Th2 responses are also required for 
protection against intracellular pathogens such as intraerythrocytic malaria parasite (Leroux-
Roels 2010). Nevertheless, Alum was commented as a useful adjuvant for peptide vaccine 
against many pathogens. It can be used with immunostimulatory molecules such as IL-12 or 
CpG, which were shown to enhance Th1 responses (Su et al. 2003). 
3.6.2 CpG 
 Nonmethylated CpG oligonucleotide (CpG) is used as a vaccine adjuvant in both 
preclinical and clinical studies (Mosca et al. 2008). The motifs are considered as PAMPs and 
act as immunostimulants. The CpG is reported to be recognised by TLR9 of B-cells and 
dendritic cells (Rothenfusser et al. 2002). It was reported to induce a type1 cytokine 
production, especially IL-12 and IFN-, while low secretion of type2 cytokines was detected 
(Su et al. 2003).  
3.6.3 Montanides ISA-51 and Montanides ISA-720 
 Montanides are water-in-oil emulsions which share some physical characteristics 
with incomplete Freund’s adjuvant. However, they have been developed with more concern 
for safety and are biodegradable (Aucouturier et al. 2006; Scalzo et al. 1995). Montanides 
have been extensively tested in different vaccine trials including malaria (Coler et al. 2009). 
Montanide ISA 51 is a mineral oil-based adjuvant. The mineral oil used for this adjuvant is a 
white medicinal oil whose toxicology has been well recorded. Local reactions caused by this 
adjuvant such as flu like symptoms and local pain were reported (Aucouturier et al. 2006). 
To improve safety, metabolisable oil was used. Squalene is a natural product from plant or 
animal used in Montanides ISA 720. It has been reported for its ability to enhance strong 
immune responses. The drawback of this adjuvant is that storage in formulated form is not 
possible due to the weak stability of the adjuvant (Aucouturier et al. 2006). 
  38 
3.6.4 Oil-in-water emlusion 
 Emulsions are a powerful enhancer of antibody production, considered as the best 
adjuvants for flu and intracellular pathogen, and promising candidates for human vaccines 
(Mosca et al. 2008). The CoVaccine HT, according to the manufacturer, is an oil-in-water 
vaccine adjuvant containing Sucrose Fatty Acid Sulphate Esters (SFASE) on the oil droplets 
of an emulsion of squalane in water. This adjuvant was designed, mimicking that it contains 
LPS, to elicit TLR4 signaling (Bodewes et. al, 2010). It was claimed to be responsible for the 
magnitude of both T helper 1 and 2 responses, and up-regulation of pro-inflammatory 
cytokines production by dendritic cells, but not CD8+ cell response (Bodewes et al. 2009). 
In this study, another three forms of oil-in-water emulsion adjuvants were tested.  
3.6.5 TLR agonists. 
 Toll-like receptor (TLRs) are receptors, of which function is recognition of PAMPs. 
TLR agonists are used as adjuvants to enhance APCs, resulting in increase of cytokine 
secretion. They also enhance expression of MHC class II, and draw DCs to T cell area in 
lymph node (Schiller et al. 2006). It was also shown that signaling of the TLRs that are 
expressed on B or T cells can support antibody class-switching, memory B-cell activation, 
and suppression of the regulatory T-Cell response (Duthie et al. 2011).  
 TLR-4 was reported to recognize LPS from most Gram-negative bacteria (Carl 
2002). It is only TLR type that uses two signaling pathways known as MyD88/MAL and 
TRIF/TRAM which are responsible for IL-12 (Th1-type response) and IL-6 production (Th2 
type response) respectively (Krummen et al. 2010). TLR-4 agonists, among the TLR 
agnoists, are the most developed adjuvants. Monophosphoryl lipid A (MPL), one of the 
TLR-4 agonist, was reported for its safety profile to be similar to that of alum and also 
showed potential in induction of Th1 immune responses to different pathogens, in different 
animal models (Casella & T. C. Mitchell 2008) .In this study, early-developed TLR-4 
agonists were tested alone or in combination with Alum asa vaccine adjuvant. 
 Both TRL-7 and TLR-8 are found on endosomes of neutrophils, monocytes, and 
entodhelial cells. While T cells have TLR-8, B cells and plasmocytoid DC have TLR-7. 
They were reported as RNA segments enriched for GU or poly-U sequences as an agonist 
and induce Th1 type response (Chang 2010) 
 TLR-9 is a receptor for bacterial DNA, CpG. This Toll-like receptor can be found in 
the endosome of neutrophils, monocytes, eosinophils, T cells, B cells, NK cells, 
plasmacytoid DC and endothelial cells (Chang 2010). The signaling that is triggered by 
agonist such as CpG can be initiated after it is translocated into endosomes (Hemmi et al. 
2000). Study in mice showed that this receptor, in response to CpG, can mediate Th1 signals. 
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TLR-9 of the microphage was reported for its role in the production of inflammatory 
cytokines such as TNF, IL-6, and IL-12. Surface expression of CD40, CD80, CD86 and 
MHC class II, was reported to be up-regulated. When this receptor is triggered, ability in 
DNA binding of the macrophage is increased (Hemmi et al. 2000). Although the TLR-9 is 
important for immune responses mechanism against bacterial infection, in absence of this 
receptor, mice were reported to be also susceptible to parasitic infection, due to lack of IFN 
expression (Foureau et al. 2010). 
4. Intrinsically Unstructured Protein 
4.1 Disordered proteins: Good or Bad? 
 It has been accepted that the behavior of functional proteins is essentially determined 
by protein conformations. Alteration of protein folding, may result in the change of protein’s 
rigid 3D structure and sequentially affect protein functions.  
 Through different diseases studies, the disordered proteins have been implicated to 
be associated with various pathogenesis of human diseases (Uversky 2011a). Some 
disordered proteins were associated with formation of amyloid-like fibrils (Uversky et al. 
2009). This has been considered as a nonnative quaternary structure (Kelly 2003), which is 
the cause of toxic aggregation and leads to pathology in many diseases such as Alzheimer’s 
disease (Uversky & Dunker 2008). However, it has recently been reported that not all 
disordered proteins form aggregation which could be the result of well orchestrated 
protection mechanisms in cells as well as the extreme Isoelectric point (pI) of the IUP that 
make it unlikely for them to reach zero net charge in a physiological environment. (Dunker 
et al. 2002; Turoverov et al. 2010). In addition, fibril formation is an evolutionary conserved 
mechanism and the disordered proteins were reported to have biological functions (Kelly 
2003). 
 The discovery of functional disordered domains and functional disordered proteins 
has challenged the traditional paradigm protein structure and function and more studies of 
the disordered proteins have been carried out (Dunker et al. 2001; Tompa 2002; Wright & 
Dyson 1999). Currently, these functional disorderd proteins are called by many terms such 
as “natively unfolded” (Uversky 2002), “intrinsically unstructured protein (IUP)” (Wright & 
Dyson 1999; Tompa 2002), and “intrinsically disordered protein (IDP)” (Dunker et al. 
2001). All of these names mean the proteins that are unable to gain stable 3D structure 
independently in their native form under physiological conditions. (Dyson & Wright 2005) 
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4.2 Intrinsically unstructured protein in vivo 
 IUP is wide-spread and can be found in every kingdom of living organisms 
(Uversky 2002; Uversky et al. 2005), but more common in eukaryotes (Dunker et al. 2000). 
It was suggested that approximately 33% of eukaryotic proteins contain long disorder 
regions (Ward et al. 2004; Dunker et al. 2000), which are considerably longer in the early-
branching eukaryotes (Mohan et al. 2008). 
 The disordered regions of proteins have different amino acid compositions from the 
ordered protein. Generally, the disordered proteins contain few hydrophobic amino acid 
contents, but are enriched in polar and charged residues. They also has fewer aromatic amino 
acids (Romero et al. 2001; Williams et al. 2001), which generally have lower substitution 
rate than the charged amino acid (Brown et al. 2002). These differences of the amino acid 
composition between ordered and disordered protein may explain why, in general, the 
disordered proteins evolve more rapidly (Brown et al. 2002). Particular amino acid 
sequences are linked to IUPs. Amino acids seen as disorder-promoting amino acid residues 
such as Ala, Arg, Gly, Gln, Ser, Glu, Pro and Lys, were enriched in IUPs, while the order-
promoting amino acids such as Trp, Cys, Phe, Ile, Tyr, Val, Leu, and Asn, were be depleted 
in these proteins (Dunker et al. 2001; Williams et al. 2001). Some IUPs were reported to 
contain multiple tandem repeats of these amino acids (Dyson 2011; Uversky et al. 2000). 
The IUPs are likely to have low complexity regions (LCRs), a biased composition region, 
such as short-period repeats, or a region that consists of few types of amino acids (Romero et 
al. 2001; Ferron et al. 2006). These unique amino acid compositions of IUPs induced their 
flexible conformations and also reflect some interesting behaviour. IUPs are respond to 
extreme treatment such as increase in temperature in an opposite way from the traditional 
globular proteins (Uversky 2002). Based on their intrinsic indifference to denaturing 
conditions, high temperature or extreme pH treatment can be used to isolate them from crude 
protein extracts (Csizmok et al. 2006). 
 IUPs are tightly regulated at different levels. Comparing the synthesis and 
degradation rates, the mRNAs of both ordered and disordered have comparable transcription 
rates, however, the mRNA coding for the IUPs were reported to be degraded more rapidly. 
At the protein level, the IUPs have shorter half-lives, and are more sensitive to protein 
kinases (Gsponer et al. 2008). Although there are some IUPs which have long half-lives, 
they were proposed to be protected from proteolysis by chaperone activity (Dunker et al. 
2001) or by association with a partner (Dunker et al. 2002). According to these facts, they 
are generally less abundant than ordered proteins (Dunker et al. 2002).  
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4.3 Structures, protein interactions and functions  
 The structure of IUPs is very variable ranging from totally unstructured to compact 
disordered ensembles (Uversky 2002; Dunker et al. 2001). Three proposed dynamic 
structures include (1) molten globule, which has no rigid tertiary structure, and is described 
as folding intermediate of globular proteins, (Uversky & Dunker 2010), (2) pre-molten 
globule, and (3) coil-like, both of which are also known as extended disordered protein, are 
considered as unfolded polypeptide chains which have less density than a molten globule 
protein (Uversky 2002) (Figure 1.7).  
  
Figure 1.7: Different forms of IUPs known as (from left to right) Molten globule-like 
(collapsed disorder), pre-molten globule (extended), and coil-like respectively 
(Uversky & Dunker 2010).  
 
 According to the bound stage, the IUPs can be categorised into 4 groups, which 
show different degrees of disorder (Tompa & Fuxreiter 2008) (Figure 1.8). Although they 
are natively unfolded, many of IUPs have been shown to gain good 3D structure in the 
bound stage (Dyson & Wright 2002) but in some cases, the IUP-partner complexes may not 
be able to be described as a single conformation stage. This phenomenon was coined by 
Tompa et al, 2008 as “fuzziness”. Different kinetic mechanisms of binding have been 
proposed. The functional model called “fly-casting mechanism” suggested that the IUPs, 
which have a larger capture radius than ordered proteins, first bind weakly to a distant 
binding site and then folds as the protein gets closer to the partner (Shoemaker et al. 2000). 
Upon binding, the linear motifs of the IUPs, which is known as molecular recognition 
features (MoRFs), undergo a phenomenon known as disorder-to-order transition (Mohan et 
al. 2006), which transforms the unstructured region into helix, beta-strand or other forms 
(Wright & Dyson 2009). Another binding mechanism suggested that IUPs use the primary 
contact site (PCS), which is more exposed than other regions to initiate interaction event 
(Csizmok et al. 2005). The regions that performed these functions are usually relatively short 
parts of the IUP (Wright & Dyson 1999). In some cases, IUPs can also bind to the partners 
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without disorder-to-order transition. This was recently reported by the study of a new family 
of the IUPs involved in immune signalling which can bind to different partners such as IUP, 
well-folded proteins, and lipid bilayers (Sigalov 2011).  
 
  
Figure 1.8: Fuzziness of IUPs (in color) in bounding stage with partner (grey). 
Alternative from having a well-defined 3D structure, the IUP structures in the 
complex can be described as static (a) or dynamic (b-d). The degree of disorder is 
increased from left to right. In the polymorphic model, the IUP may gain multiple 
alternative conformations (magenta and blue ribbons) upon binding to the same 
partner (a). The IUP may serve as a linker (magenta dotted line) between binding 
domains in the clamp model (b). It may serve as the over-hang part of the binding 
region (magenta dotted line) in the flanking model (c) or remain totally unstructured 
in the random model (d). From (Tompa & Fuxreiter 2008) 
 The functions of IUPs can be grouped into four broad categories including (1) 
molecular recognition (as involved in signalling pathways), (2) molecular assembly, (3) 
protein modification (e.g. phosphorylation, methylation, etc.) and (4) entropic chains (also 
referred to as linkers and spacers) (Dunker et al. 2002).  
 The intrinsically unfolded structure of the IUPs allows them to have many functional 
advantages. Disordered regions are flexible and can be easily induced into different 
conformations by environment (Wright & Dyson 1999). The IUPs can highly-specifically 
bind to targets with low affinity (Huang & Liu 2009). This interaction is unstable and can be 
dissociated rapidly (known as “binding staccato”). This allows the interaction to be 
performed quickly and reversibly (Uversky 2011b), which is an ideal property for signal 
transduction (Dunker et al. 2002). Therefore, the IUP can act as a hub protein, which can 
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interact with a number of targets (one-to-many) or bind to a structured  hub protein (many-
to-one) (Dunker et al. 2005). In addition, the IUPs also have the ability to bind the same 
partner in alternative conformations. Although functional information for this alternative 
binding mode of IUPs is unclear, some have suggested that different forms of the complex 
might give different outcomes, and as a result, may allow the IUPs to be a multitasking 
(moonlighting protein) (Jeffery 2009; Tompa et al. 2005). Apart from their role as functional 
sites, unstructured regions can serve as linkers between domains. These linkers enable two 
domains to move close together and some also control distance between functional domains 
(Pearce et al. 2005; Dunker et al. 2002).  
4.4 Studies of intrinsically unstructured protein 
 Methods that are used for protein structure analysis such as X-ray crystallography, 
high-resolution NMR, hydrodynamic methods, proteolytic sensitivity and circular dichroism 
(CD) spectroscopy can be used to detect for disordered protein by searching for residues 
with missing backbone coordinates in 3D structures. (Dunker et al. 2001). Far-UV circular 
dichroism (CD) spectroscopy is often used for IUP study. Although it does not give as much 
specific structural detail as X-ray crystallography and NMR spectroscopy, it is considered as 
a rapid method that provides useful data and requires only small amounts of sample. CD 
result of IUPs is shown as a spectrum which has negative peak at around 200 nm, distinct 
enough from ordered structures (Tompa 2002). This method is suitable for soluble protein, 
which is favourable for IUPs study since generally they are hydrophilic (Dyson 2011).  
 Because of the anomalous sequence composition of the IUPs, development of 
algorithms for disordered region in proteins is possible and currently plays an important role 
in IUP discovery and study (Turoverov et al. 2010). Many computational prediction methods 
have been developed, some of which have been applied for more specific prediction such as 
prediction of amyloid formation (Dyson 2011). Amino acid compositions of the IUPs have 
been used as a predictive parameter of the disorder, yet some study reported that it cannot be 
used independently to get accurate results (Ferron et al. 2006) similar to prediction based on 
low secondary structure content (Liu et al. 2002) or LCR (Romero et al. 2001). Another 
indicator of the disorder is high-sequence variability, which is based on the knowledge that 
the disorder regions are, comparatively, more variable than those of the ordered proteins 
(Brown et al. 2002). Sequence alignment analysis that is based on nucleotide substitution 
rate can be used to identify the IUPs, on this basis (Ferron et al. 2006). Different 
physicochemical paramethers and the databases, on which the programs have been trained, 
have resulted in different outcomes from different predictors. The informatics tools such as 
PONDR, DisEMBL, and RONN are based on datasets of disorder proteins, while predictors 
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such as Foldindex and IUPred rely on different principles (Ferron et al. 2006). In the case of 
the IUPred, it uses the algorithm that can identify the IUP based on the their low 
interresidues interaction energy, which reflects the lack of a well-defined structure 
(Garbuzynskiy et al. 2008).  
 Although each of these prediction methods has a different error rate and there are 
pitfalls in these analyses, it is recommended they be primarily used before more complex 
analysis be further performed (Ferron et al. 2006). Using these analytical tools in 
combination has shown to provide relatively rigorous results.  
4.5 Intrinsically unstructured protein in the malaria parasite 
 In comparison to free-living microbes, pathogenic parasite proteomes were reported 
to have a larger abundance of long disordered proteins (Mohan et al. 2008). The IUPs are 
highly abundant in malaria parasite proteomes, and many of them were suggested to be 
encoded by genes that are unique to this parasite (Romero et al. 1999; Brocchieri 2001; Pizzi 
& Frontali 2001; Gardner et al. 2002; Aravind et al. 2003), Malaria parasites are enriched in 
low complexity regions (LCR) (Aravind et al. 2003; Pizzi & Frontali 2001; Brocchieri 
2001), a typical marker to identify IUPs (Mohan et al. 2008). Based on computational 
studies, around 35% proteins encoded from chromosome 2 and 3 of P. falciparum was 
shown to contain long disordered regions (more than 40 consecutive residues) (Dunker et al. 
2000). However, later studies showed that this result was underestimated and these long 
disordered regions may be harbored in 52-67% of the P. falciparum proteome (Vucetic et al. 
2003). This abundance of LCRs in P. falciparum was strongly correlated with genomic A+T 
content. And the molecular mechanisms such as DNA replication slippage and unequal 
crossover recombination were suggested to be responsible for their expansion (DePristo et 
al. 2006). The repetitive sequences which are enriched in P. falciparum were also reported to 
be in correlation with the abundance of IUPs (Feng et al. 2006).  
 Interestingly, human/primate malaria parasites are more enriched in IUPs than those 
of rodent malaria parasites (Feng et al. 2006). And interestingly, most of the proteins 
expressed during sporozoite stage are IUPs (Feng et al. 2006). IUPs of malaria parasites can 
be frequently found both as hub proteins and non-hub proteins (Mohan et al. 2008). The 
IUPs of malaria parasites has been proposed to have role in facilitation of host cell invasion 
and may be hamper host immune mechanisms (Feng et al. 2006). They were also proposed 
to be involved in pathogenesis, antigen diversification and immune invasion (Ferreira et al. 
2003; Hughes 2004). This idea was proposed based on the P. falciparum sequence analysis 
study which showed that LCRs were under the selective force of the host immune system 
(Hughes 2004) and therefore these repetitive regions for insufficient immune response and 
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immune evasion of the parasite (Hughes et al. 2010; Schofield 1991). Since the IUPs 
generally contain LCRs, these proposed roles of LCR’s may possibly overlap with some of 
the IUPs (DePristo et al. 2006). Arguably, these protein may serve as natural spacers 
between functional domains (Huntley & Golding 2000) or may have some functions that 
have not yet been reported (Pizzi & Frontali 2001).  
 Many of the known and well-characterised malaria proteins, initially studied for 
their potential as vaccine candidates, have been reported for unstructured regions or entire 
lack of tertiary structure. The MSP-2 is shown to be largely unstructured and the N-terminal 
is responsible for forms amyloid-like fibrils under physiological pH (Yang et al. 2007; Yang 
et al. 2010; Low et al. 2007; Adda et al. 2009). C-terminal of MSP-3 and Glutamate-rich 
protein (GLURP) are also vaccine candidates, reported for unstructured regions (Feng et al. 
2006). AMA-1, though generally known as a well-structured molecule (Pizarro et al. 2005), 
contains disordered N-and C-terminal regions, as well as disordered loops within the 
molecule (Nair et al. 2002).  
4.6 Immunity to intrinsically unstructured protein antigens 
 There are numbers of studies suggested that the conformational epitopes are crucial 
for recognition of the protective antibodies. These lead to the idea that the 3D structures of 
the protein antigens should be considered in vaccine design (Hodder et al. 2001; Blackman 
et al. 1990; Crewther et al. 1996; Pan et al. 2004), while the flexible domains has been 
considered to be involved in immune evasion in pathogenic organisms (Dunker et al. 2001). 
For example the study of V3 loops of HIV1 showed that it is flexible and able to gain 
different conformations during the binding stage (Stanfield et al. 1999), which tended to 
complicate the vaccine design and development against HIV (Dunker et al. 2001).  
 Despite the data suggesting that they are not ideal targets for antibodies, the idea of 
binding affinity of antibodies to disordered region might have come as early as in 1984 when 
there was a study which showed that combining sites of many antibodies were highly 
flexible. Interestingly, it showed that anti-peptide antibodies to highly mobile regions react 
strongly with the native protein when compared with antibodies that recognize well-ordered 
regions (Tainer et al. 1984). Another study showed that peptide-mimics of linear epitopes, 
not those of discontinuous epitopes, dominate in affinity selection; and therefore, may 
possibly be a target for peptide vaccine strategies (Craig et al. 1998). For example, IUP of 
HIV-1 called Trans-activator of transcription (Tat) (Foucault et al. 2009) has been shown to 
provide epitopes for specific antibodies of which their presence frequencies are associated 
with slow, or in some cases, non-progression to AIDS (Campbell & Loret 2009). Another 
example supporting the idea that the IUPs are important immune targets was shown by the 
  46 
study in hepatitis vaccine antigen, NS5A of which the intrinsically disordered domain was 
reported to form a fuzzy complex with the host ligand (Gupta et al. 2012) and the vaccine 
developed on this protein was proved to be a good immunogen (Masalova et al. 2010). 
 In the malaria parasite, many of IUPs have been reported as highly immunogenic 
(Feng et al. 2006). The epitopes in the variable region of the MSP-2 were reported to be 
more accessible than the constant terminal regions (Zhang et al. 2008). The Loop II of 
AMA-1, which has been identified as an unstructured domain, was reported to provides 
epitopes for parasite-inhibitory monoclonal antibodies (Collins et al. 2009). Based on the 
studies of these well-known malaria vaccine candidates, it supports the idea that the surface 
IUPs of malaria parasite are important for its survival and they are potentially targets of 
protective immunity. The recent identified surface IUP antigens of malaria such as 
PFF0165c, has also emphasized this idea by showing that it contains the epitopes for 
antibodies that have inhibitory effect in ADCI assay (Olugbile et al. 2009). 
 In the light of present data, it is convincing that malarial surface IUP antigens 
provide epitopes for protective immunity and should be developed as vaccine candidates. 
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Chaptor 2: Materials and methods 
1. DNA preparation 
 Genomic DNA from P. falciparum was extracted from schizont pellets. Parasite 
cultures were washed in PBS twice and then purified using a QiaAmp DNA mini kit 
(Qiagen) according to the manufacturer’s instructions. The DNA was recovered in 100μl of 
elution buffer from the kit. All parasite DNA extracted were stored at –20°C until use. 
 Plasmid DNA. In this study, pET24a (Novagen, UK) was used as the expression 
vector for MSP-3.3C and MSP-1 hybrid, and pET28a (Novagen, UK) for the MSP 
multihybrid construct. Plasmid DNA was purified using QiaAmp DNA mini kit (Qiagen) 
according to the manufacturer’s protocol. 
2. PCR 
 PCR was used to amplify individual gene fragments which were then used in 
cloning reactions (e.g for MSP-3.3C) and to join gene fragments together by overlap PCR 
(e.g. for the MSP-multihybrid construct). Enzymes and buffers were mixed with primers and 
DNA fragments as recommended in the manufacturer instructions (Fermentas). The details 
of PCR steps and conditions, which vary depending on gene to be amplified, are given in 
each chapter. Desired PCR product bands were cut from agarose gels and purified using a 
QiAEGel extraction kit (Qiagen). Stock DNA fragments were stored at -20C before use. 
3. Agarose gel electrophoresis 
 PCR products or DNA fragments were separated by electrophoresis on 1.2% agarose 
gels in TAE buffer (40 mM Tris acetate, 1 mM EDTA). Gels were visualized on UV 
transilluminator (BioRad Gel Doc 1000). 
4. Cloning of P. falciparum genes 
 DNA fragments were prepared, purified and checked for concentration using a 
NanoDrop system before cloning reactions. For sequencing of DNA fragments, PCR 
fragments were cloned into TOPO TA cloning vector kits (pCR4-TOPO, Invitrogen). 
Transformants were selected by growing culture on LB agar with kanamycin overnight, 
before plasmid DNA from selected clones was extracted using a QIAprep spin miniprep kit 
(Qiagen) and sent for Sanger sequencing via the Genepool (http://genepool.bio.ed.ac.uk/). 
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Bacterial clones with plasmids of the desired sequence were then grown in 500 mL volumes 
of kanamycin selective LB media (containing kanamycin at concentration of 50 μg mL
-1
 ) 
overnight. Cultures were then harvested, and plasmid DNA was extracted using QIAfillter 
Plasmid Maxi prep Kit (Qiagen). Plasmid DNA was stored at -20C until use.  
 DNA fragments were cloned into expression vectors using restriction enzyme 
digestion and ligation reactions. Donor gene fragments from pCR4-TOPO plasmids and the 
acceptor expression plasmid were sequentially cut with restriction enzymes (NdeI and 
BamHI for MSP-3.3C, NcoI and NotI for the MSP-multihybrid, New England Biotech, UK) 
Between each restriction enzyme reaction, DNA fragments were resolved by electrophoresis 
on 1.2% agarose gels, before being purified by QIAquick Gel extraction kit (Qiagen). 
Ligation reactions were performed by incubating digested DNA gene fragments and the 
expression vector with T4 DNA ligase (Promega). Ligation reactions were performed from 
16°C to 4°C overnight. Ligation mix was either then used immediately or stored at -20C 
until use.  
 Recombinant plasmids from ligation mixes or plasmid preparations were used for  
transformation into competent E. coli cells. Host strains included XL-1 Blue (Stratagene) for 
plasmid amplification, or BL21(DE3)pLysS or BLR(DE3)pLysS (Novagen) as expression 
hosts. Transformations, were performed according to the manufacturer’s instructions. 
Transformants were grown on LB agar containing 50 μg mL
 -1
 of kanamycin at 37C 
overnight, and cultures were kept at 4C until use.  
5. Screening for clones with inserts 
 To screen for inserted genes in recombinant plasmids, colony-PCR techniques and 
restriction enzyme digestions were used. From selective LB agar plates, colonies were 
picked and dispersed into PCR mixture, including cloning primers. PCR reactions were 
performed using the same conditions as used for gene amplification. PCR products of the 
correct insert size were then detected by agarose gel electrophoresis. In parallel, small 
overnight cultures of selected colonies were grown in selective media. Cultures were then 
harvested by centrifugation, and plasmid DNA purified using QIAprep spin miniprep kits 
(Qiagen). Inserts were detected by restriction enzyme digestion of flanking EcoRI sites for 
detection of insert in pCR4-TOPO plasmids, or the two restriction enzymes used in cloning 
of genes into expression plasmids (NdeI and BamHI or NcoI and NotI). DNA fragments from 
restriction enzyme reaction were separated by electrophoresis. Linear forms of vector 
plasmid and PCR products of insert genes, which were also separated on the same agarose 
gel were used as size references. 
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6. DNA sequencing  
 Plasmid pCR4-TOPO derivatives containing inserts of the correct size were DNA 
sequenced with T7 sequencing primer (5’ TAATACGACTCACTATAGGG 3’ ) and T3 
sequencing Primer (5’ ATTAACCCTCACTAAAGGGA 3’ ). For sequencing of inserted 
gene fragments in pET expression vectors, T7 sequencing primer, T7 Terminator Primer (5’ 
GCTAGTTATTGCTCAGCGG3’ ) and the original PCR amplification cloning primers were 
used. All sequence data was aligned and analysed by comparison with the original gene 
sequences using Geneious R5 software (http://www.geneious.com/).  
7. Growth media for DNA preparation. 
 XL-blue cells containing recombinant plasmids were grown in Luria broth (1% 





 of kanamycin. For LB agar, LB media with 1.5% (w/v) of Bacto-agar and 
appropriate antibiotics was used.  
8. Bacterial culture methods 
 Freshly transformed BL21(DE3) or BLR(DE3) E.coli were used for each round of 
protein expression. A single transformant colony was grown at 37°C in LB media 
supplemented with 0.5% (w/v) glucose and 50µg mL
-1 
overnight. The inoculum was diluted 





kanamycin. Cells were grown at 30°C in a shaking incubator (200 rpm) until the OD600nm of 
the culture reached log phase (OD range 0.4-0.6). Protein expression was induced by 
addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to the culture to a final 
concentration of 1mM. Induced cultures were incubated in a shaking incubator (200 rpm, 
30˚C) for a further 4 hours. To monitor culture growth and protein expression, small samples 
were taken hourly after induction. Cells were harvested by centrifugation at 4,225 g for 5 
minutes at 4C. Cell paste was frozen at -80°C until required.  
 Alternatively, Terrific broth or LBE5052 medium were used instead of LB (in 
studies involving expression of MSP-3.3C or the MSP-multihybrid). Terrific broth contains 
12g L
-1
 Tryptone, 24g L
-1
 yeast extract, 4ml L
-1
 Glycerol with addition of 100mL L
-1
 of a 
filter sterilized solution of 0.17M KH2PO4 and 0.72M K2HPO4. LBE5052 medium is a rich 
auto-induction media that induces protein expression by E. coli cultures via lac-derived 
promoters. Protein expression is induced in cultures when then exhaust the glycerol and 
glucose carbon sources in the medium as they approach stationary phase and begin 
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metabolizing the lactose carbon source (Studier 2005). A litre of this medium contains 10g 
tryptone, 5g yeast extract, 5g glucose, 10g NaCl, 1ml of 2M MgSO4, filtered sterilized 
potassium phosphate mix (20ml of 1M KH2PO4 and 80ml of 1M K2HPO4) and 1ml of 100x 
metals mix. To make the metals mix, 50 ml of FeCl3 stock (0.1M FeCl3-6H2O in 0.1M HCL) 
is mixed with 50 ml of filter sterilized metals solution (1 ml of 1M MnCl2-4H2O, 1 ml of 1M 
ZnSO4-7H2O, 1 ml of 0.2M CoCl2-6H2O, 1 ml of 0.2M NiCl2-6H2O). Both these media 
were supplemented with appropriate antibiotics as for LB based cultures.  
 Large scale bacterial growth protocols, used for process-scale production of MSP-1 
hybrid, are provided in Chapter 3.  
9. Small scale protein purification  
 Fusion proteins used in this study include GST-3D7 MSP-1 Block 2, GST-Palo 
Alto17 MSP-1 Block 2, GST-MAD20 MSP-1 Block 2, GST-Wellcome MSP-1 Block 2, 
GST-RO33 MSP-1 Block 2, GST-MSP-2A (CH150/9), GST-MSP-2B (Dd2), and His-
MSP7. Some of these antigens were provided by Drs. David Cavanagh and Anthony Holder, 
otherwise they were prepared according to the protocols below:  
 Washed overnight E. coli cultures (10 mL) harbouring GST fusion protein 
expression vectors were used to inoculate 1 litre of LB supplemented with 100µg mL
-1 
ampicillin. Cultures were grown at 30˚C with shaking to OD600nm 0.6 and then induced with 
1mM IPTG. Cultures were incubated for a further 4 hours to allow protein expression. Cells 
were harvested by centrifugation at 4,225 xg for 5 minutes at 4C. Cell paste was 
resuspended in 50 mL PBS and frozen at -80°C until required. Cells were lysed by freeze-
thawing and lysates treated with 1U mL
-1
 Benzonase (Novagen). Lysate was separated from 
cell debris by centrifugation at 13,000 xg and 0.45 µm filtered (Acrodisc® Syringe Filters, 
Pall Corporation, USA) before purification on PBS pre-equilibrated glutathione Sepharose 
columns (GSTrap, GE Healthcare) using an AKTA prime system. After sample application, 
columns were washed with PBS and the GST fusion protein was then eluted with a buffer 
containing 50mM Tris pH8, 10mM reduced glutathione. Eluted proteins were collected and 
analysed by SDS-PAGE and concentration measured by Bradford Assay as described in 
section 14.2.  
 For non-tagged proteins (MSP-1 hybrid, MSP-multihybrid, and MSP-3.3C), 
conventional column chromatography purification protocols were used. For all three 
proteins, cell pellets were resuspended in 25mM Tris, pH8.0 (50ml of buffer per 1 litre 
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of Benzonase (Novagen). Soluble lysate proteins were separated from cell debris by 
centrifugation at 13,000 xg and was stored at -80°C until use.   
 High temperature treatment was used as a second step of purification. NaCl at the 
final concentration of 250mM was added to lysates. This solution was then incubated for 20 
minutes at 70°C to denature host proteins and then incubated at 4°C for further 20 minutes. 
Denatured proteins were removed by centrifugation at 13,000 xg for 30 minutes at 4˚C. The 
supernatant was desalted by extensive dialysis against 25mM Tris pH8.0 (buffer changed 3 
times). This partially purified protein solution was stored at -20°C until use.  
 The final step of purification for each of the proteins was anion exchange 
chromatography. For the MSP-1-hybrid, protein was filtered through 0.22m Millex-GP 
syringe filters (Millipore) before applied into column. Proteins were purified by sequential 
step-wise increases in NaCl concentration. For all three proteins, purification steps included 
application of protein mixtures to the column in zero NaCl buffer (25mM Tris, pH8.0), 
extensive washing (>5 column volumes) with the same buffer, an elution of contaminants at 
a low NaCl concentration, and a final elution step of the target protein at a higher NaCl 
concentration. A Q-Sepharose FF column (XK 16/20, GE healthcare) was packed as 
suggested by the manufacturer’s protocol and equilibrated with 10 column volumes of 
starting buffer (25mM Tris, pH8.0) before purification. Details of the purification protocol 
for each protein purification is given in each results chapter. Purified protein fractions were 
assessed for purity and protein concentration by SDS-PAGE and BCA assay respectively. 
High purity fractions were pooled, dialysed against PBS using Thermo SnakeSkin Dialysis 
Tubing (Thermo, Uk), and concentrated using centrifugal ultrafiltration (Amicon, Millipore, 
UK or Vivaspin, Sartorius UK).  
 A similar protocol with modifications for process-scale production was used for 
purification of the MSP-1 hybrid at large scale. The protocol for this is part of the results in 
Chapter 3.  
10. Immunisations 
 Before used purified protein antigens were filtered though a 0.1M 25 mm Acrodisc 
syringe filter with Supor membrane (Pall Corporation, USA) using aseptic technique. For 
most immunogenicity tests, female MF1 mice used in this study. In the MSP-1 hybrid study, 
they were either injected subcutaneously or intraperitoneally. Each immunising dose 
contained 20 µg of protein antigen, which was mixed with adjuvant immediately before  
immunisation. Three doses of vaccine were given at 28 day intervals. At day 70, 14 days 
after the 3
rd
 dose, all animals were exsanguinated under terminal anaesthesia and serum 
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collected for immunogenicity testing. All mouse experimentation was carried out in 
accordance with the Animals (Scientific Procedures) Act 1986 and conforms to the 
Recommendation from the Declaration of Helsinki and the Guiding Principles in the Care 
and Use of Animals. The University of Edinburgh Ethical Review Committee approved the 
project license under which all mouse experimentation was performed on 3rd July 2006, 
reference number PL 13-06. Mice were humanely killed by Schedule 1 methods. 
 Eight New Zealand White rabbits were immunized intramuscularly, using 50 µg per 
dose of MSP-1 Hybrid antigen formulated with CoVaccine HT, following the manufacturer's 
instructions. A 500 µL vaccine dose contained 50 µg of antigen and 10 mg of SFASE. Each 
animal was immunized 3 times at 28 day intervals, with blood samples taken at days 0, 28, 
56 and 70. Rabbit housing and immunization were at BioGenes GmbH (Berlin, Germany), 
and were in accordance with national and international animal welfare regulations. Rabbit 
immunization at this facility was under approval from NIH/OLAW (ID number #A5755-01). 
 Two rabbits (code numbers 6066 and 6067) were immunized intramuscularly with 
five doses each of 100 µg of the recombinant MSP-3.3C protein antigen, formulated with 
Freund's complete/incomplete adjuvant (Biogenes GmbH, Berlin, Germany). Animals were 
immunized on days 0, 7, 14, 28 and 42. Blood samples were collected for serum on days 0, 
8, and 49. 
11. Formulation of protein in adjuvants  
 Formulation of vaccine in this study was done according to the manufacturer’s 
instructions. Adjuvants that were tested in mice for this study included:-  





CpG ODN 7909. For each mouse, a final concentration of 20μg of MSP-1 hybrid or MSP-
3.3C was used for each dose. Antigen was mixed with adjuvant by gentle pipetting, then 
incubated at room temperature for 30 minutes. Unbound antigen was removed by 
centrifugation at 10,000 g for 10 minutes. The pellet was resuspended in 0.9% (w/v) NaCl 
solution, at 100 l per 20µg dose per mouse.  
 B) CoVaccine HT™ (Protherics Medicines Development Limited, a BTG 
International Group Company, London, UK) following the manufacturer's instructions and 
as previously described (Studier 2005; Mahdi Abdel Hamid et al. 2011). CoVaccine HT 
contains 40 mg mL
−1
 of Sucrose Fatty Acid Sulphate Esters [SFASE] in a squalane o/w 
emulsion). A 100 µL vaccine dose contained 20 µg of antigen and 2 mg of SFASE. Briefly, 
CoVaccine HT was mixed gently with 20 g of MSP-1 hybrid or MSP-3.3C. For all groups 
of mice, three doses were given at 28 day intervals.  
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 C) Montanide ISA 51. Groups of five mice were immunized with 20µg doses of 
MSP-1 hybrid formulated by emulsification with Montanide ISA51 adjuvant (ratio 1:1) 
(Seppic, France), following the manufacturer's formulation instructions. A final volume of 
100 l per dose was administered per mouse.  
 D) Montanide ISA 720. Groups of five mice were immunized with 20µg doses of 
MSP-1 hybrid formulated by emulsification with Montanide ISA720 adjuvant (ratio 7:3) 
(Seppic, France), following the manufacturer's formulation instructions. A final volume of 
100 l per dose was administered per mouse.   
 E) Formulated Aqueous TLR-4 Agonist (IDRI-AQ019). AQ019 was formulated 
with 20 g of the MSP-1 hybrid at a ratio of 1:4, to obtain a final volume of 100 l dose per 
mouse. This adjuvant was also tested in combination with Alhydrogel. In this case, MSP-1 
hybrid was formulated first with the Alhydrogel as described earlier before being formulated 
with AQ019. The mixtures were vortexed gently for a few seconds and were stable at 4C 
before being used within 2-4 hours. 
 F) Formulated TLR-4 agonist oil-in-water emulsion (IDRI-EM031). For formulation 
of this adjuvant with the MSP-1 hybrid, the same formulation protocol as for Formulated 
Aqueous TLR-4 Agonist was used.  
 G) Formulated TLR-7/8 Agonist (IDRI-AQ002). For formulation of this adjuvant 
with the MSP-1 hybrid, the same formulation protocol as for Formulated Aqueous TLR-4 
Agonist was used.  
 H) Formulated Oil-in-Water Emulsion (IDRI-EM030). For Formulated Oil-in-Water 
Emulsion, the adjuvant was diluted 1:5 with 20 g MSP-1 hybrid antigen to obtain a final 
volume of 100 l dose per mouse. This adjuvant-antigen mixture was vortexed for a few 
seconds and was stable at 4C before being used within 2-4 hours. 
 I) Formulated TLR-9 Agonist (IDRI-AQ006). For Formulated TLR-9 Agonist, for 
each 100 l dose per mouse, 16 l of the adjuvant was mixed with 20 g of MSP-1 hybrid to 
obtain a final volume of 100 l dose per mouse. 
12. Antibody purification  
 To purify total IgG, sera were diluted 1:10 in PBS, filtered (Acrodisc® Syringe 
Filters, Pall Corporation, USA) and loaded onto pre-equilibrated HiTrap Protein G columns 
using an AKTA Prime system (GE Healthcare). For each purification, the column was then 
washed extensively (~10 column volumes) with PBS before bound antibodies were eluted 
using 0.1 M Glycine-HCl pH 2.7. 1 mL fractions were eluted into 200µL of 1M Tris pH9.0 
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neutralization buffer. Antibodies were then dialysed extensively into PBS using Side-A-
Lyzer Dialysis Cassettes (Thermo, UK) before use.  
13. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
  SDS-PAGE was routinely performed using gels consisting of 4.5% stacking gel 
(0.63 mL 30% acrylamide, 0.56 mL 1M Tris pH 6.8, 50μL 10% SDS, 50μL 10% APS, 3.5 
mL dH2O, 5μL TEMED) and 12% resolving gel (2 ml 30% acrylamide, 1.3 mL 1.5 M Tris 
pH8.8, 50μL 10% SDS, 50μL 10% APS, 1.6 mL dH2O, 4 μL TEMED), unless otherwise 
specified (protocol provided by Dr. David Cavanagh). NuPage Bis-Tris gels (Invitrogen) 
were also used where necessary. Proteins were resolved on these gels at 200V constant 
voltage for 45 minutes in Tris-Glycine buffer (7.55g Tris base, 47g glycine, 25m
L-1 
10%SDS). 
 Gels were stained with silver nitrate solution (MSP-1 hybrid and MSP-multihybrid) 
according to Blum et al., 1987 (Studier 2005; Blum et al. 1987) or Coomassie Blue (for 
MSP-3.3C).  
14. Protein quantitation assays 
14.1 BCA assay 
 Concentrations of the protein from cell lysate, MSP-1 hybrid, MSP-3.3C and MSP-
multihybrid were measured by BCA assay (Pierce) according to the manufacturer’s 
instruction. 25 L of protein samples and diluted BSA solution at concentration of 0, 25, 
125, 250, 500, 750, 1000, 1500, 2000 µg mL
-1
 were apply into a microplate well (Microlon 
high protein binding plates, Greiner, UK). Reagent A and B were mixed at ratio 50:1 then 
the mixture was applied into each well (sample to mixed reagent ratio is 1:8). Plate was 
coverd and incubated at 37°C for 30 minutes then absorbance was measured at OD 570 nm 
by Multiskan Ascent plate reader program (Thermo Labsystems, UK). Protein concentrations 
were calculated by interpolation from a standard curve of BSA diluted in the same buffer as 
used for test samples. 
14.2 Bradford assay 
 Bradford assay (BioRad, UK) was used to measure concentration of GST proteins. 
For microassay procedure, 160 L of protein samples and diluted BSA solution at 
concentration of 0, 40, 80, 120, 160, 200 µg mL
-1
 were apply into a microplate well 
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(Microlon high protein binding plates, Greiner, UK). 40 L Diluted Bradford assay reagent 
(1 in 5 with ddH2O) was applied into each well. The sample and reagent were mixed 
thoroughly and incubated at room temperature for 5 mintures. Absorbance was measured at 
OD 595 nm by Multiskan Ascent plate reader program (Thermo Labsystems, UK). Protein 
concentrations were calculated using the same method as used for the BCA assay.  
15. Western blotting  
 Protein transfer from SDS-PAGE gels to Schleicher and Schuell BA83 nitrocellulose 
membranes (Whatman) was performed at 100V, 350 mA for 90 minutes, using a Mini 
TransBlot Cell (BioRad, UK). Blotted membranes were incubated in Blocking buffer (5% 
(w/v) milk powder in PBS containing 0.05% Tween 20) at 4 °C for at least 1 hour. The 
membrane was then incubated for 1 hour with primary antibody, either monoclonal or 
polyclonal, which was diluted to appropriate concentrations in Blocking buffer. The 
membrane was then washed four times for 5 minutes each in PBS, before a conjugated 
secondary antibody was added and incubated for 1 hour. For horseradish peroxidase-




 4-chloronapthol/0.003% H2O2 
in a solution of 40mM Tris pH8.0, 20% methanol. Bound antibody was detectable as a black 
precipitate on the membrane. For detection of MSP-3.3C, the secondary antibody used was 
Alexa Fluor 680 conjugated goat anti-rabbit IgG (Invitrogen), while Alexa Fluor 700 
conjugated goat anti-mouse IgG (Invitrogen) was used in the MSP-multihybrid study. 
Binding of both of these secondary antibodies was detected in the 700nm emission channel 
using a Li-Cor Odyssey imaging system (LI-COR Biosciences, Ltd., UK).  
16. In silico analysis  
 Molecular weights and pI values of the MSP-1 hybrid, the MSP-multihybrid and 
MSP-3.3C were predicted using the Compute pI/Mw tool 
(http://web.expasy.org/compute_pi/) (Studier 2005; Mahdi Abdel Hamid et al. 2011; 
Gasteiger et al. 2005). IUPred (http://iupred.enzim.hu/) was used to predict unstructured 
domains in the MSP-1 hybrid, MSP-3.3C and the MSP-multihybrid. Further in silico 
analyses on MSP-3.3C are described in Chapter 4.  
17. Mass spectrometry 
 Soluble forms of the proteins in PBS, or protein bands on SDS-PAGE gels stained 
with silver nitrate were used for mass spectrometric analysis. Mass spectrometric analysis of 
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purified proteins was carried out by the SIRCAMS (Department of Chemistry, University of 
Edinburgh, http://www.sircams.ed.ac.uk). For LC-MS, an Ultimate 3000 HPLC system 
(Dionex Corporation, Sunnyvale, CA), equipped with a monolithic PS-DVB (500 µM×5 
mm) analytical column (Dionex Corporation), was used. Samples containing ~1 µg of 
protein were centrifuged (16,100 g for 2 min) immediately prior to injection onto the 
column. Solutions B and C comprised of 2:97.95 and 80:19.95 acetonitrile:water with 0.05% 
formic acid respectively. Samples were injected onto the analytical column, washed with 
buffer B for 5 min, followed by a 20 min linear gradient elution (20 µL min
-1
) into buffer C. 
MS data was acquired on a Bruker 12 Tesla Apex Qe FT-ICR (Bruker Daltonics, Billerica, 
MA) equipped with an electrospray ionization source. Desolvated ions were transmitted to a 
6 cm Infinity cell® penning trap. Trapped ions were excited (frequency chirp 48–500 kHz at 
100 steps of 25 µs) and detected between m/z 600 and 2000 for 0.5 s to yield a broadband 
512 Kword time-domain data. Fast Fourier Transforms and subsequent analyses were 
performed using DataAnalysis (Bruker Daltonics) software. Multiple charge states could be 
observed in this way for each of the major species.  
18. Circular Dichroism (CD) 
 Circular dichrosim analysis was carried out according to the protocol provided by 
Centre for Translational and Chemical Biology, University of Edinburgh 
(http://ctcb.bio.ed.ac.uk). Protein samples (MSP-3.3C or MSP-1 hybrid) were dialysed 




. The CD spectrum of the 
proteins was evaluated on a JASCO J-810 spectropolarimeter. The measurements were taken 
over a wavelength range of 185 to 285 nm at 25ºC pH 8.0 with a 1 mm path length cuvette.  
19. ELISA 
 Individual MSP-1 recombinant proteins based on the 3D7, Palo Alto 17, MAD20, 
Wellcome and RO33 MSP-1 Block 2 serotypes have been described elsewhere (Studier 
2005; Cavanagh & McBride 1997; Mahdi Abdel Hamid et al. 2011; Cavanagh et al. 2004). 
Human sera, monoclonal antibodies and sera from immunized animals were tested by 
previously described ELISA methods from the Cavanagh Lab for recognition of the MSP-1 
hybrid, MSP-3.3C and Block 2 GST fusion proteins (Blum et al. 1987; Cavanagh & 
McBride 1997; Cavanagh et al. 2001).   
 Antigens were coated onto the wells of a 96-well plate (Microlon high protein 
binding plates, Greiner, UK) with 50ng of each antigen in 100μl of coating buffer (15mM 
Na2CO3, 35mM NaHCO3, pH 9.3) added per well. Plates were kept humidified and 
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incubated at 4°C overnight. Plates were washed with washing buffer (PBS (1.9mNaH2PO4, 
8.1mM Na2HPO4, 150mM NaCl, pH to 7.2-7.4) plus 0.05% Tween 20) 3 times using ELISA 
plate washers (Ultrawash Plus, Dynex, UK or SkanWasher 400, Skatron, UK). Wells were 
then blocked with 200µL of blocking buffer (1 %(v/w) non-fat skimmed milk in washing 
buffer) and incubated for 5 hours at room temperature. Plates were washed again and 100µL 
volumes of antibodies or sera (diluted in blocking buffer) were then added to each well. All 
sera were tested across a range of doubling dilutions (1:500 to 1:128,000) against each 
antigen in duplicate wells, with a standard pool of positive sera also tested on each plate, and 
across the same dilution range. After overnight incubation at 4°C, plates were washed three 
times and 100μl of horseradish peroxidase conjugated secondary antibodies (Dako Ltd, High 
Wycombe, UK ) were added to each well at an appropriate concentration. Plates were 
incubated at room temperature for 3 hours and then washed again 3 times. Antigen specific 
antibodies were detected by addition of 100μl of substrate (0.1 mg mL
-1
 O-
phenylenediamine and 0.012% H202) in development buffer (24.5 mM citric acid 
monohydrate and 52 mM Na2HPO4, pH 5.0) per well and incubating for up to 15 minutes at 
room temperature. The reaction was stopped by the addition of 25μl of 2M H2SO4 to each 
well and absorbance was measured at 492nm using a Multiskan Ascent microplate reader 
(Thermo Labsystems, UK).  
 ELISA titres were calculated by interpolation from the fitted standard curve on each 
plate using polynomial logistic regression. Negative antigen control wells in ELISA were 
either coating buffer alone for the MSP-1 hybrid, or GST-coated wells for Block 2 GST 
fusion proteins. For the MSP-1 hybrid study, a pool of sera from mice immunized with 
individual MSP-1 Block 2 antigens were used as a standard when mouse sera were tested. 
Similarly, a pool of anti-MSP-1 hybrid rabbit sera was used as a standard for the MSP-1 
studies in rabbits. The K-1 Block 2 type-specific monoclonal antibody 12.2 was used as a 
positive control in some assays (Wilson et al. 1987). For human serum assays using the 
recombinant MSP antigens, human sera from Ghana, Malawi, Gambia and Sudan were used. 
All human sera were diluted at 1:500 in blocking buffer and assayed as described unless 
specified. Naïve European sera and naïve animal sera were used as negative antibody 
controls for each of these assays.  
19.1 IgG subclass ELISA  
 To analyze for human IgG subclasses a similar ELISA assay was used, which is 
described elsewhere (Cavanagh et al. 2001; Cavanagh et al. 2004). For mouse IgG subclass 
ELISA, plates were coated overnight with 100l
 
of 0.5 µg mL
-1 
antigen in coating buffer. 
Plates were washed twice with washing buffer, then wells were blocked for 2 hours with 
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100μl of 1% (w/v) BSA in PBS at room temperature. Plates were washed three times before 
50μl of doubling serial dilutions from 1:100 downwards of each serum sample was added to 
duplicate wells. After incubation for 2 hours or overnight, plates were washed and 50 µL 
Alkaline Phospatase-labelled anti-IgG subclass antibodies were added at appropriate 
dilutions (1:2000 for anti-IgG1, 1:1000 for anti-IgG2a, 1:2500 for anti-IgG2b and 1:1000 for 
IgG3). After incubation for 1 hour at room temperature, plates were washed and PNPP 
substrate was added. PNPP (para-Nitrophenylphosphate) tablets (Thermo, Uk) were 
dissolved in substrate buffer (61.25mg/l of MgCl2-6H2O, 120ml diethanolamine, adjusted to 




. As antigen standards, plates were coated with 





 downwards. Monoclonal antibody 12.8 (Wilson et al. 1987) was used as a 





19.2 Peptide epitope mapping  
 A set of 133 biotinylated dodecapeptides covering all possible linear epitopes 
contained within MSP-1 hybrid sequence were synthesised by Mimotopes Pyt. Ltd. 
(Clayton, Australia). ELISA plates (Immulon 4 HBX, Thermo Dynex) were coated with 100 
µL of 5 µg mL
-1
 streptavidin (Sigma) and incubated at 37˚C until dry. Plates were stored in 
heat sealed foil pouches with 1 g silica gel at room temperature until use. Reactivity of sera 
against the peptide library was determined by ELISA. Streptavidin-coated plates were 
washed in washing buffer (PBS/0.05% Tween20) and blocked with blocking buffer (1% 
ByCoA, Croda Healthcare, UK dissolved in PBS) for 5 hours at room temperature. Peptide 
library plates were prepared by addition of 300 ng peptide per well, in duplicate, and plates 
were incubated overnight at 4˚C. Sera were added to each well (100 µL at 1:500 dilution) 
and incubated overnight at 4˚C, then washed with washing buffer. Dilutions of a species-
specific HRP-linked secondary antibody (Dako, UK), appropriate to the serum being tested, 
were added to each well and plates were incubated at room temperature for 3 hours. Plates 
were washed three times with washing buffer and OPD substrate was added to each well. 
Reactions were stopped by addition of sulfuric acid and absorbance was read at 492 nm 
using a microplate absorbance reader (Multiskan Ascent, Thermo Scientific, UK). 
Background reactivity was calculated as the mean of all OD values in the lowest two 
quartiles (i.e. below median) plus 6 standard deviations peptides. 
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20. IFA 
 In IFA assays of MSP-3.3C-specific sera, antibodies were tested by IFA on parasites 
of the Wellcome isolate, while antibody reactivity with other strains (3D7, Palo Alto17, 
RO33, and MAD20) were also tested in the MSP-1 hybrid study. IFA slides were prepared 
from standard parasite cultures, which had been synchronized and were checked for the 
desired lifecycle stage by light microscopy. Parasite cultures were washed with RPMI twice. 
Cells were then resuspended in PBS to approximately 3% haematocrit. Aliquots of 25µL 
were pipetted onto the wells of PTFE-coated multispot microscope slides (C.A.Hendley 
(Essex) Ltd, UK). Slides were dried at room temperature and stored in air-tight containers at 
-20˚C with silica gel desiccant before use.  
 Slides were removed from the freezer and immediately fixed with acetone for 5 
minutes, then allowed to dry. Serial dilutions of the tested sera or antibodies were prepared 
in IFA sample buffer (PBS containing 1% bovine serum albumin (BSA) and 0.01% Sodium 
azide). Duplicate spots on each slide were incubated with 25μl of each working dilution of 
antiserum for 30 minutes at room temperature in a humidified chamber. Unbound antibodies 
were removed by immersing slides three times in PBS, for 5 minutes per wash. Slides were 
gently dried for 5-10 minutes at 50°C. Aliquots of 15μl of FITC-conjugated secondary 
antibodies (either swine anti-rabbit or rabbit anti-mouse, Dako, UK) were added to wells at 
the manufacturer’s recommended dilutions. Slides were again washed three times with PBS. 
Slides were immersed in staining solution for five minutes (1:100,000 (w/v) of 4’,6’-
diamino-2-phenylindole (DAPI) and 0.1% (w/v) Evans blue in PBS). Slides were washed 
once with PBS and mounted under coverslips in Citifluor (City University, London). Slides 
were stored at 4°C before examination with a fluorescence microscope using 50X objective 
lens. Incident light of 390-440 and 450-490 nm were used for DAPI fluorescence and FITC 
fluorescence respectively. Endpoint titres against parasite strains were determined as the 
highest serum dilution at which clear schizont-specific fluorescence could be observed. 
21. Statistic analysis 
 ELISA titres between groups were analysed using the non-parametric Kruskal-
Wallis test, with Dunn’s post-hoc test. To compare titres between two groups, a Mann-
Whitney U-test was used. Correlation plots of human antibody reactivity between MSP-1 
hybrid and MSP-1 Block 2 antigens or between MSP-3.3C and MSP7 or MSP-119, were 
analyzed using Spearman’s rank correlation coefficient. GraphPad Prism software 
(GraphPad Software, Inc, USA) was used to produce Figures and perform statistical 
analyses.  
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22. Parasite culturing methods 
 Plasmodium falciparum strain Wellcome was used for most in vitro parasite growth 
experiments. Blood stage P. falciparum cultures were grown at 37˚C, 5% CO2 in complete 
RPMI media at 5% haematocrit, containing O+ blood and 10% heat inactivated human 
serum from the Scottish National Blood Transfusion Service. Culture medium was changed 
daily and cultures were monitored by microscopy of thin blood smears stained with 10% 
Giemsa stain. Parasitaemia was routinely maintained below 5% throughout all experiments. 
 Parasite cultures were synchronised by resuspending pelleted cells in the original 
culture volume of sterile 5% Sorbitol. The mixture was incubated at room temperature for 5 
minutes, then an excess volume (3-5 fold excess) of culture medium minus serum was 
added. Cultures were then centrifuged at 830 g for 5 minutes. The pelleted cells were then 
resuspended in complete medium at 5% haematocrit and cultured as before. 
23. Parasite Growth Inhibition Assays (GIA) 
 In vitro parasite growth Inhibition assays (GIA) were carried out on freshly thawed 
clones of the P. falciparum Wellcome strain according to standard protocols (Bergmann-
Leitner et al. 2006; Darko et al. 2005) using purified IgG from immunized animals. Total 
IgG purified from a naıve non-immunized animals were used as negative controls, or from 
day 0 (pre-immunization) serum samples in the case of Rhesus macaques.  
 All IgG samples were tested in triplicate at 2-fold serial dilutions, from 6 mg mL
-1
 
(rabbit, sheep) or from 10 mg mL
-1
 (Rhesus) in 96-well cell culture plates (Greiner BioOne, 
UK). Parasites were cultured under standard conditions (Arnot et al. 2008). Parasite cultures 
were mycoplasma-free and synchronized at least twice with 5% sorbitol before use in assays. 
Late trophozoite/early schizont stages at a parasitaemia of ~0.3% and 2% final haematocrit 
were used in all assays. The final culture volume was 100 µL/well and parasites were 
incubated for 42 hours. After 42 hours, cultures were tested for growth inhibition using 
pLDH measurement, flow cytometry and Giemsa-stained slide microscopy. GIA was 
performed for testing of the antibodies against both the MSP-1 hybrid and for MSP-3.3C. 
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Chapter 3: MSP Block 1/2 hybrid 
1. Introduction 
 Malaria vaccine research has not been focused on the N-terminal of MSP-1, but 
many studies have indicated that the region of the molecule is a target of protective 
immunity. There is evidence that the N-terminal Block 1 region of MSP-1 contains T-cell 
epitopes in both humans and mice (Pearce et al. 2005; Quakyi et al. 1994; Parra et al. 2000). 
Immunisation with MSP-1 p83, an MSP-1 proteolytic component containing the N-terminal 
part of the MSP-1, showed that this antigen was immunogenic. Moreover, the antibodies 
elicited by this immunization showed a strong in vitro growth inhibitory effect of up to 95% 
(Marti et al. 2005; Woehlbier et al. 2006). And in other studies, vaccination of New World 
monkeys with constructs derived from the N-terminal part of MSP-1 provided partial 
protection from P. falciparum challenge (Pearce et al. 2005; Cheung et al. 1986; Etlinger et 
al. 1991; Herrera et al. 1990; Herrera et al. 1992).  
 Near the N-terminus of MSP-1, located next to Block 1, is MSP-1 Block 2. Block 2 
is very polymorphic, with more than a hundred different Block 2 sequences recorded. 
Despite this extensive diversity, Block 2 sequence polymorphisms can be categorised into 3 
allelic families known as the K1- MAD20- and RO33-like types. The allelic frequencies of 
the 3 types of msp-1 block 2 are maintained at similar levels throughout the global parasite 
population (Pearce et al. 2005; Conway et al. 2000). The K1 and MAD20 Block 2 types, but 
not the RO33 type, contain internal tripeptide repeat sequences and non-repetitive serotype 
specific flanking sequences. The tripeptide repeat sequences of these serotypes are semi-
conserved and vary in both length and amino acid content. Interestingly, each of the 
tripeptide motifs always begins with a serine residue (Musto et al. 1999; Jiang et al. 2000; 
Miller et al. 1993; Cavanagh et al. 2004). The K1 type of MSP-1 Block 2 consists of tandem 
repetitive sequences that are variable in length, (between 5 to 25 tripeptide repeats) and 
allele-specific-conserved sequences on the N-terminal and C-terminal side of the variable 
region. Variation in the repeat of K1 type is limited to only four tripeptide motifs; SAQ, 
SGA, SGP and SGT (Bergmann-Leitner et al. 2009; Jiang et al. 2000). The coding for serine 
in these repeats is always AGT; and SGT is always the last tandem repeat. For MAD20 type 
Block 2 sequences, the C-terminal sequence is SVASGG with the TCA codon used for 
serine in the MAD20 repeats (Jiang et al. 2000), which is frequently used in highly 
expressed genes of P. falciparum (Musto et al. 1999). The tripeptide motifs found in the 
MAD20 type are SGG, SVA, SKG, and SVT (Sallenave-Sales et al. 2000; Jiang et al. 2000; 
  62 
Zwetyenga et al. 1998; Ferreira et al. 2003). Contrasting with K1 and MAD20-types, the 
RO33 type has no repetitive amino acid sequences and is less variable (Ferreira et al. 2003; 
Certa et al. 1987; Cavanagh & McBride 1997; Miller et al. 1993). RO33-type sequences are 
almost identical when observed in parasites collected from different countries (Cheung et al. 
1986; Ferreira et al. 2003; Etlinger et al. 1991; Herrera et al. 1990; Herrera et al. 1992). 
However, several polymorphic residues have been reported in some areas (Sallenave-Sales et 
al. 2000; Zwetyenga et al. 1998). A single non-synonymous nucleotide replacement was 
discovered at codon 64, according to the alignment of Miller et al., 1993, resulting in 2 
dimorphic variations; RO33-type (Aspartic acid) and CSL2-type (Glycine). In this case, the 
polymorphism was reported to be biased in its geographical distribution (Ferreira et al. 
2003). 
 The diversity in length of Block 2 repeats might be a consequence of intragenic 
recombination, a mechanism which either increases or decreases the number of repetitive 
sequences in these genes (Locher et al. 1996; Rich et al. 2000). The strong linkage 
disequilibrium at MSP-1 Block 2 of P. falciparum is maintained in the non-repetitive 
sequences, suggesting that these repeats are cold spots for homologous recombination. This 
was proposed to be a result of less possibility of helical paring and crossing over due to the 
repeat sequence polymorphisms or the negative selection of recombinants by the host 
(Cavanagh et al. 1998; Ferreira et al. 2003).  
 MSP-1 Block 2 is a target of human immune responses to P. falciparum. The level 
of Block 2 specific antibodies is thought to be a marker of recent infection rather than 
immune responses that associated with susceptibility to disease (Cavanagh et al. 1998). A 
positive correlation between the presence of Block 2 specific IgG and reduced incidence of 
clinical malaria in exposed children has been clearly shown in several studies (Conway et al. 
2000; Cavanagh et al. 2004; Polley et al. 2003; Mawili-Mboumba et al. 2003). The 
protective association of Block 2 specific antibodies is additive, as children who have 
antibodies to multiple Block 2 types have even fewer malaria episodes (Woehlbier et al. 
2006; Conway et al. 2000). Protective immunity to Block 2 appears to be short-lived in the 
absence of re-infection (Cheung et al. 1986; Da Silveira et al. 1999; Etlinger et al. 1991; S. 
Herrera et al. 1990; Herrera et al. 1992). However, in another cohort, a positive association 
with protection was present for up to 8 months after sampling (Conway et al. 2000; 
Cavanagh et al. 2004). IgG3 is the predominant subclass elicited against MSP-1 Block 2, 
suggesting that the soluble Block 2 part of the MSP-1 protein, which is shed form the 
parasite during invasion, may be taken up by dendritic cells and trigger a T-cell-dependent 
response (Musto et al. 1999; Cavanagh et al. 2001; Jiang et al. 2000; Cavanagh et al. 2004; 
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Miller et al. 1993). In vitro studies showed that human antibodies against Block 2 are 
effective at parasite killing in ADCI assays (Jiang et al. 2000; Galamo et al. 2009). In an 
earlier study, mouse monoclonal antibodies to Block 2 were able to inhibit parasite growth in 
vitro (Jiang et al. 2000; Locher et al. 1996).///// ,,  
 In developing MSP-1 Block 2 as a vaccine, antigenic diversity is the most 
challenging problem, as ideally any vaccine based on Block 2 should provide protection 
against all parasite strains. Recombinant polypeptides derived from Block 2 representing 
different parasite isolates, including 3D7, Palo Alto, MAD20, Wellcome and RO33, along 
with some isolates from Daraweesh, Sudan were produced. These Block 2 antigens elicited 
serotype-specific antibodies in immunised mice, and were recognised in a serotype-specific 
manner by serum from individuals with malaria infection history (Musto et al. 1999; 
Cavanagh & McBride 1997). Block 2 is therefore immunogenic and contains serotype 
specific epitopes recognized by human antibodies (Sallenave-Sales et al. 2000; Cavanagh & 
McBride 1997; Jiang et al. 2000; Cavanagh et al. 1998; Zwetyenga et al. 1998; Ferreira et al. 
2003). In an unpublished study, protection from parasite challenge was observed in MSP-1 
Block 2 vaccinated Aotus monkeys who had high anti-MSP-1 Block 2 antibody titres 
(Cavanagh; unpublished data). 
 The variation existing in the Block 2 region revealed a limited number of patterns of 
the serine-containing repeat sequences found in the K1 and MAD20 alleles, which is very 
important information for vaccine design (Ferreira et al. 2003; Jiang et al. 2000; Certa et al. 
1987; Cavanagh & McBride 1997; Miller et al. 1993). In order to overcome sequence 
diversity, amino acid sequences of all known Block 2 sequences were collated and repeat 
sequences simplified using the numerical coding used by Jiang et al., 2000 (Cheung et al. 
1986; Jiang et al. 2000; Ferreira et al. 2003; Etlinger et al. 1991; Herrera et al. 1990; Herrera 
et al. 1992). Based on the knowledge gained from the previous studies, a synthetic protein 
construct named MSP-1 Block 1/Block 2 Hybrid (MSP-1 hybrid) was designed. This 
synthetic hybrid was based on combinations of all 12 amino acid repeat sequence motifs 
identified in the K-1 and MAD20 types respectively, together with an RO33 Block 2 
sequence, whilst maintaining the natural similarity of amino acid order and composition 
within wild-type MSP-1 Block 2 seqences as far as possible (Figure 3.1). At the N-terminal 
of this synthetic sequence, the sequence of Block 1 (K-1 type) of MSP-1 was included in 
order to provide cognate help in the form of known human CD4+ T cell epitopes, 
(Sallenave-Sales et al. 2000; Quakyi et al. 1994; Zwetyenga et al. 1998; Parra et al. 2000). 
The synthetic gene, called MSP-1 hybrid, encodes a 348 amino acid protein with a predicted 
molar mass of 31.1 kDa. 
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Figure 3.1: Schematic representation of the MSP-1 hybrid vaccine construct, based 
on the polymorphic N-terminal region of MSP-1.The construct encodes the N-
terminal MSP-1 Block 1 region, the K1 Block 2 synthetic sequence, the RO33 Block 
2 sequence and the MAD20 Block 2 synthetic sequence of MSP-1 of P. falciparum. 
Synthetic Block 2 repeat sequences of the K1 and MAD20 serotypes are indicated 
by vertical and diagonal hatched markings respectively (Figure from (Ferreira et al. 
2003; Cowan et al. 2011)). 
 In general, expression of malaria proteins in heterologous hosts can be problematic 
(Locher et al. 1996; Gustafsson et al. 2004; Rich et al. 2000), not only because the codon 
preferences of the expression host, E.coli, and the malaria parasite are different, but also 
because the some P. falciparum genes, including the MSP-1 hybrid gene sequence,  have 
high repetitive sequence content. To overcome these problems, the DNA sequence of the 
MSP-1 hybrid was codon optimized to be suitable for expression in E. coli hosts, and 
repetitive DNA sequences were minimised by use of multiple abundant serine codons within 
the repeat sequences. The MSP-1 hybrid sequence was synthesised and then cloned and 
expressed as an un-tagged protein in E. coli, and a purification protocol developed. This 
yielded a product of high purity which could be used for pre-clinical studies including 
animal immunization. The MSP-1 hybrid is immunogenic in animals, eliciting specific 
antibodies that recognize all three Block 2 serotypes of P. falciparum. The MSP-1 hybrid 
contains multiple Block 2 epitopes recognised by serum antibodies from malaria exposed 
individuals (Cavanagh et al. 1998; Cowan et al. 2011; Ferreira et al. 2003). 
 In this chapter, I describe (1) how the MSP-1 hybrid can be produced on a large 
scale, using a modified lab-scale production protocol (in collaboration with Dr. Graeme 
Cowan) and (2) characterisation of the MSP-1 hybrid’s biochemical and immunological 
properties.  
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2.  Methods and Results 
2.1 Flask-based MSP-1 hybrid expression 
 The DNA sequence of the MSP-1 hybrid was codon optimized for expression in E. 
coli. The original coding sequence was sent to GeneArt AG, Regensburg, Germany, and 
optimized using the company’s GeneOptimizerH software. The codon-optimized sequence 
contained no purification tag sequences, and consisted entirely of MSP-1-derived sequences, 
with the single amino acid addition of an N-terminal methionine initation codon. The 
synthesized gene was then cloned into the pET24a expression vector (Novagen, UK). The 
expression plasmid was transformed into chemically competent BL21 (DE3) pLysS E. coli 
(Agilent Technologies Ltd, Stockport, UK) and plated on LB agar plates containing 50 µg 
mL
-1
 kanamycin. Starter cultures of 10 mL LB broth containing 50 µg mL
-1
 kanamycin and 
0.5% w/v L-glucose were inoculated with a single colony from a freshly streaked agar plate. 
Erlenmeyer flasks containing 1 litre LB broth, 0.5% w/v L-glucose and 50 µg mL
-1
 
kanamycin were inoculated with 5 mL starter culture. Culture growth was monitored until 
the optical density reached 0.6 AU cm
-1
, then protein production was induced by addition of 
IPTG to 1 mM final concentration. Cultures were incubated for a further 4 hours shaking at 
30˚C then cells were harvested by centrifugation at 5000 g and 4˚C for 15 minutes. Cell 
pellets were stored frozen at -80˚C until further processing. 
 
   
 
Figure 3.2: Bacterial growth curve before induction of protein expression in flask-
based culture of E. coli BLR (DE3) pLysS containing the MSP-1 hybrid recombinant 
plasmid. Optical density of the culture is plotted in the Y-axis against time since 
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2.2 Fed-batch fermentation  
 In collaboration with Dr. Graeme Cowan, the small scale production protocol was 
optimised for MSP-1 hybrid production at large scale (Cavanagh et al. 1998; Cowan et al. 
2011). The same MSP-1 hybrid expression vector and expression host was used as described 
earlier. A 15-litre stirred bioreactor (Applikon Technologies, UK) was filled with 8 litres of 
modified YT medium. pH control was set to maintain pH at 7.2 by addition of 4N H2SO4 or 
30% v/v NH4OH. Dissolved oxygen was monitored and maintained at 20% by manually 
increasing air flow or agitation speed, and temperature was maintained at 37˚C. The 
bioreactor was inoculated by addition of 2% v/v starter culture and culture density was 
monitored throughout the experiment by measurement of optical density (OD) and wet pellet 
mass. Using modified YT media, the culture grew rapidly and within 5 hours had reached 
OD600nm of 1.2 (Figure 3.3). At this point, the culture had a wet weight of 13.47 g L
-1
      
(0.13 g L
-1
 dry weight) in total volume of 8 litres. Upon reaching OD600nm 1.2, batch feeding 




 with an 
exponential increase in feeding rate (µ = 0.1 h
-1
). A litre of this feed medium consisted of 
45g yeast extract, 90g Tryptone, 540g Glycerol 75 l PPG2000 and 10% of 10X salts 
solution (per litre. This solution has 65g KH2PO4, 50 g K2HPO4, 32g NaHPO4.12H2O, 32g 
MgSO4.7H2O, 1g NH4Cl, 900mg FeSO4.7H2O, 900mg CaCl2.2H2O, 225mg MnSO4.1H2O, 
125mg CoCl.6H2O, 97.5mg ZnSO4.7H2O, 50mg AlCl3.6H2O, 45mg Na2MoO4.2H2O, 40mg 
CuCl2.2H2O, and 2.5mg H3BO3). Protein expression was induced by addition of 1 mM final 
concentration of IPTG once a wet pellet weight equivalent to 75 g L
-1
 was achieved. 
Fermentation continued for a further 4 hours with the continued maintenance of the 
parameters described above. Cells were harvested by centrifugation at 5,000 g and the cell 
pellet was stored in aliquots at -80˚C until further processing. At the end of this fermentation 
process, the total volume of culture was 8.9 litres and the wet cell pellet weighed 107.4 g L
-1
 
or 18.87 g L
-1



















Figure 3.3: Growth rates of fed-batch fermentation culture (dark line) and flask-
based culture (dashed line) before induction. Optical density of cultures (Y-axis) is 
plotted against time since inoculation (X-axis).  
  










Figure 3.4: Growth rate of fed batch fermentation culture by wet cell weight (circles) 
and dry cell weight (squares). The first arrow indicates the time point where 
introduction of fed-batch media was started. The second arrow indicates the time of 
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2.3 Development of protein expression and purification methods 
 Pilot expression tests were carried out to establish optimal small-scale expression 
conditions. Expression and induction conditions were modified, with cell growth at 30˚C in 
Luria-Bertani medium containing 1% glucose and induction at 25˚C with 1 mM IPTG for 4 
hours (Figure 3.2). This protocol resulted in high-level expression of MSP-1 hybrid on 
induction as a soluble protein at ~55 kDa in the cell lysate (Fig. 3.5A). The identity of the 
protein was confirmed by Western blotting using a mouse monoclonal specific for the K1 
Block 2 serotype of MSP-1 (mAb12.2, Fig. 3.5B) and with polyclonal sera raised against 
individual MSP-1 Block 2 recombinant proteins (not shown). The major soluble protein in 
the cell lysate was MSP-1 hybrid, with minor degradation products as detected by mAb 12.2 
reactivity (Fig. 3.5B, Lane 2). In 1-liter shaking-flask culture, MSP-1 hybrid accounted for 
an estimated 15% of the total soluble protein, as assessed by densitometry of silver stained 
gels. 
 The protein was then further purified, firstly by heat treatment and secondly by 
anion exchange chromatography. Clarified cell lysate, in 25mM Tris pH8.0 buffer containing 
250 mM NaCl was incubated in a water bath at 70C. This step denatured a large proportion 
of the host proteins, which were observed as a light-coloured precipitate, and which were 
removed by centrifugation. This heating step yielded around 80% pure MSP-1 hybrid 
product (Figure 3.5 lane 4). This was estimated to be 210 mg L
-1
 of cell culture, based on 
BCA assays and protein band intensity. The resulting protein mixture was dialysed against 
column buffer A (25mM Tris pH8.0). An anion exchange chromatography step gradient was 
then performed to further purify the MSP-1 hybrid. Low molecular weight contaminants 
were eluted with 20 mM NaCl in column buffer A and MSP-1 hybrid eluted by application 
of 50 mM NaCl in column buffer A (Figure 3.6). Based on ImageJ analysis of a silver 
stained SDS-PAGE gel, purified MSP-1 hybrid was estimated to be at least 97% pure. One 
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Figure 3.5: MSP-1 hybrid from cell culture and at different steps of purification is 
shown on A) SDS-PAGE stained by silver nitrate and B) Western Blot of an identical 
gel probed with a monoclonal antibody against K1 type Block 2 of MSP-1 
(mAb12.2). Samples analysed are:- lane 1, cells before induction; lane 2, cells after 
4 hours of induction; lane 3, soluble cell lysate; lane 4 soluble fraction after heat-
treatment; lane 5, dialysed soluble fraction from lane 4; lane 6, flow through fraction 
from anion exchange; lane 7, anion exchange purified MSP-1 hybrid protein.  
 
2.4 Scale up of protein purification 
 This purification protocol, used for small-scale production was modified for large-
scale production of the MSP-1 hybrid. Cell paste recovered from bioreactor culture was 
resuspended in column buffer A (25mM Tris buffer pH8.0) at a ratio of 10 mL per gram of 
frozen cells. The same freeze-thaw lysis method as used for small-scale purification was 
performed in 50ml batches. After lysis, DNAse (Benzonase, Novagen, UK) was added at 2U 
mL
-1
 of lysate. The soluble protein lysate was then recovered by centrifugation and stored at  
-20°C until use. For the heat treatment step, a range of different salt concentrations in 
column buffer A and different temperatures were tested on batches of cell lysate from the fed 
batch fermentation culture. All the samples were heated for 20 minutes followed by cooling 
for 30 minutes on ice. Soluble fractions from these treatments were investigated for their 
purity on SDS-PAGE gels and measured for protein concentration by the BCA assay. 
Results of these tests showed that the optimal condition for the best yield and purity was heat 
treatment at 90C without addition of NaCl to the buffer (data not shown). ……............... 
 To ensure that the protein was evenly and thoroughly heated, the heating step was 
performed at 90C for 20 minutes by passing the lysate through a 250ml heat exchanger, 
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which was constructed by Dr. Graeme Cowan from a stainless steel coil immersed in a water 
bath, attached to a Watson-Marlow peristaltic pump. The clarified lysate solution was 
pumped through the heat exchanger with a total passage time at 90˚C of 20 minutes, and into 
a collecting beaker on ice. The denatured lysate was clarified by centrifugation at 5,000x g 
for 30 minutes and dialysed against column buffer A. This process provided 80% pure MSP-
1 hybrid product (Figure 3.7), yielding 1724 mg protein L
-1
 of culture, as estimated by 
ELISA. 
 The partially purified protein was then finally purified by anion exchange 
chromatography using a 200 mL CaptoQ Bioprocess grade Sepharose column (GE 
Healthcare, UK). The same stepwise elution protocol as described for lab-scale purification 
method was used to purify the MSP-1 hybrid. The final product was a highly pure product 
(>97%) with a yield of approximately 550mg L
-1
















Figure 3.6: Anion exchange chromatography purification of the MSP-1 hybrid. 
Conductivity (red line), elution buffer percentage (green line), and protein 
concentration as measured by absorbance at 280 nm (blue line). Red numbers on 
the X-axis represent the fraction number of 50 mL eluted fractions from the CaptoQ 
anion exchange column. MSP-1 hybrid absorbs UV light poorly due to its low 
extinction coefficient, and thus peak elution height is correspondingly low. 
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Figure 3.7: MSP-1 hybrid production at large scale from bioreactor cell culture.  
Individual purification steps are shown on A) SDS-PAGE stained with silver nitrate 
and B) Western Blot probed with mAb12.2. Samples shown are:- lane 1, soluble cell 
lysate; lane 2, heat treated and clarified lysate; lanes 3-4, eluted fractions from 
CaptoQ column.  
 
 Purified MSP-1 hybrid from bioreactor production was tested for the level of 
endotoxin contaminants. Freshly purified MSP-1 hybrid and MSP-1 hybrid sample that had 
been dialysed against PBS were heated at 70C for 20 minutes. Samples were then filtered 
and tested using the Rapid Endotest kit (Lonza). The results suggested that the level of 
endotoxin was low, giving readouts of 72.1 EU mL
-1
 and 8.50 EU mL
-1
 for samples before 
and after final dialysis respectively.  
 
2.5 Properties of the MSP-1 hybrid 
 By mass spectrometry, the MSP-1 hybrid was estimated to have a molecular mass of 
31,113 Da, which is very similar to the predicted molecular weight based on the amino acid 
content (30,987 Da). However, on SDS-PAGE gels the protein resolved at about twice the 
size of its actual molecular weight (Figures 3.5 and 3.7). MSP-1 hybrid also stained weakly 
with Coomassie blue dye, but stained strongly with silver nitrate. The MSP-1 hybrid was 
shown to be a soluble and heat-resistant protein. In column buffer A, the protein was stable 
at temperatures as high as 90C without any significant degradation detected by SDS-PAGE. 
 Using a bioinformatics tool, IUPred (Dosztányi et al. 2005) which predicts the 
disorder tendency of a protein from its amino acid sequence, the algorithm predicts that the 
A)            B) 
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MSP-1 hybrid is generally unstructured with a high disorder tendency in the middle part of 







Figure 3.8: IUPred prediction of disorder tendency in the MSP-1 hybrid. Plot shows 
the disorder tendency of the MSP-1 hybrid protein (Y-axis) along the length of the 
348 amino acid sequence. X-axis represents amino acid position in the MSP-1 
hybrid protein.  
 
 Using circular dichroism, the CD spectrum profile of the MSP-1 hybrid in a low salt 
buffer showed that it had single deep minimum at round 200 nm (Figure 3.9), which is a 
typical pattern for proteins with random coil conformation (Kelly et al. 2005). This suggests 
that the recombinant protein lacks any stable 2D or 3D structures, such as alpha helices or 
beta sheets.  






Figure3.9: Figure shows the circular dichroism spectrum of purified MSP-1 hybrid 
protein, assessed over a 185 to 285nm wavelength range at 25ºC in 10mM 
NaH2PO4 pH 8.0. The distinct valley groove at 200nm is typical of a random coil 
structure.  
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2.6 Protein stability testing 
 For testing the stability of the native MSP-1 hybrid, protein in PBS buffer at 
concentration of 1.26 mg ml
-1
 was incubated at -70C, -20C, 4C, 25C and 37C with 
samples taken and frozen at -70C every five to seven days for 60 days. Samples were 
measured for concentration and investigated for degradation by silver-stained SDS-PAGE 
gels. Results showed that the MSP-1 hybrid could be stored at -20C or 4C for at least 60 
days without any significant detected degradation (data not shown). All samples at all 
temperatures were tested for possible degradation by silver stained SDS-PAGE. At room 
temperature, the MSP-1 hybrid showed minor degradation at 14 days, with two lower 
molecular weight proteins of 36 kDa and 20 kDa observed from day 20 (Figure 3.10, panel 
D). A faster but near identical degradation profile was observed in the sample incubated at 
37C (Figure 3.10, panel E). ///////////////////////////////////////////////////////////////////////////////////////// 
 The MSP-1 hybrid stock was stable for longer periods if “Pasteurised” by heating to 
70˚C for 20 minutes after the final purification step. Stability tests were repeated on MSP-1 
hybrid stocks which had been heated. The protein solution was incubated, sampled, and 
investigated in the same way as described above. At room temperature, the pre-heated MSP-
hybrid could be stored up to 60 days without any visible signs of degradation as determined 
by silver stained SDS-PAGE (Figure 3.10, Panel B). The protein concentration of these 
samples was also very similar and remained stable throughout the whole incubation period 
(data not shown). Mass spectrometry of day 0, day 5 and day 60 samples showed a single 
dominant peak at m/z of 1297, which is the intact MSP-1 hybrid protein. The minor m/z 
species at 1292 is the MSP-1 hybrid without the N-terminal methionine residue, which is a 
result of post-translational production that commonly occurs in E. coli (Hirel et al. 1989). 
The minor species of higher m/z ratios which accumulate over time are the result of salt 
adducts which increase over the incubation period. Low temperature incubation of the MSP-
1 hybrid (at -20C) showed comparable profiles to the starting material both on SDS-PAGE 
and Mass spectrometry (Figure 3.10, Panel A), while high temperature incubation (37C) 
showed similar resistance to degradation. Minor levels of degradation of MSP-1 hybrid can 
be detected at days 56-60 of the incubation period (Figure 3.10, Panel C). 
  
  74 
 
Figure 3.10: Silver stained SDS-PAGE and mass spectrometric profiles to assess 
stability of MSP-1 hybrid incubated for up to 60 days at -20C, 25C and 37C.  
Sampling time points were: lanes 1-12 = day 5,10,14,20,24,28,30,35,42,49,56, and 
60 respectively.  Panels A, B, C = heat-treated MSP-1 hybrid incubated at -20C, 
25C and 37C respectively); Panels D and E = MSP-1 hybrid without final heat 
treatment incubated at 20C and 37C respectively.)  
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D)        E) 
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2.7 Vaccine stability and immunogenicity testing 
 MSP-1 hybrid was also tested for its stability after formulation with CoVaccine HT. 
The protein at the recommended concentration was formulated with adjuvant according to 
the manufacturers protocol and then stored at 4C and 20C for up to seven weeks. Protein 
antigen was extracted from vaccine every week according to the protocol from Miles et al., 
2005 (Hay et al. 2004; Miles et al. 2005). Benzyl alcohol was added to vaccine formulation 
to a final concentration of 10%. It was mixed by vortexing for 20 minutes followed by 
centrifugation at 16,000g for 10 minutes. The mixture separated into three layers, of which 
the protein antigen is in the middle aqueous phase. Recovered protein antigen MSP-1 hybrid 
was removed and stored frozen at -70C until use. Extracted samples were analysed by silver 
stained SDS-PAGE./ 
 MSP-1 hybrid was stable when formulated with the adjuvant for at least 21 days 
stored at 4C. These protein samples showed similar band intensity as the original MSP-1 
hybrid material on SDS-PAGE and were of similar concentration to the same amount of 
MSP-1 hybrid protein not formulated with CoVaccine HT. After 35 days, the concentration 
of the protein appeared to be slightly reduced. However, there was no degradation that could 
be detected by SDS-PAGE.  
 MSP-1 hybrid formulated with with CoVaccine HT and incubated at room 
temperature was stable for up to 21 days, showing very similar band intensity and pattern to 
the unformulated protein on SDS-PAGE. After day 28, some of the MSP-1 hybrid from the 
formulated extract had undergone multimerization. As a result, the amount of 55 kDa 
product was reduced and two bands of ~120 kDa and ~200 kDa could be detected. Western 
blots showed that these larger protein forms were recognised by mAb 12.2 and by polyclonal 
sera raised to the MSP-1 hybrid (data not shown). ////////////////////////////////////////////////////// 
  













Figure 3.11: Characterization of MSP-1 hybrid extracted from vaccine following 
storage at 4C (A: 2-7) and at 20C (B: 2-7). Samples were sampled at days 7, 14, 
21, 28, 35, 42, and 49 (lanes 2-7 respectively). Unformulated MSP-1 hybrid was run 
on each gel as a control (lane1).  
 
 Immunogenicity of MSP-1 hybrid incubated at room temperature for 60 days was 
performed in mice. Protein samples were mixed with CoVaccine HT immediately prior to 
immunisations. Control material consisted of MSP-1 hybrid that had not undergone any 
incubation prior to use (i.e. day 0 sampled). Each mouse received three doses of the 
immunogen and the sera were collected at the end of the experiments. The sera were tested 
against the MSP-1 hybrid antigen by ELISA. Incubation conditions did not significantly 
decrease the immunogenicity of the MSP-1 hybrid. Most of the mice from both experimental 
and control groups were able to produce specific antibodies to the MSP-1 hybrid; two mice 
of the non-incubated MSP-1 hybrid group (day 0 sample) failed to produce specific 
antibodies (Figure 3.12). Both immunisation of day 0 and day 60 MSP-1 hybrid yielded 
antigen specific antibodies that were detected by ELISA, giving median titres per group of 
1.48 x10
5
 and 1.74 x10
5
 respectively. Antibody titres of the two groups were not 





A)      B) 
 












Figure 3.12: Antibody titres in mice immunised with MSP-1 hybrid as measured by 
ELISA. MSP-1 protein that had been stored at -20C (day0) and had been stored at 
room temperature for 60 days (day 60) were both formulated with CoVaccine HT. 
Mice that were vaccinated with these formulations showed no statistically significant 
difference between the 2 groups in specific antibody titre to the MSP-1 hybrid. 
Horizontal bars represent the median titre for each group.  …. 
 
 These sera also recognised all five MSP-1 Block 2 antigens from all three Block 2 
serotypes. Furthermore, there was no statistically significant difference between the in the 
median titre of the two immunisation groups to 3D7, Palo Alto17, MAD20, and Wellcome 
Block 2 antigens (Mann-Whitney U test, p=0.1852, p=0.5204, p=0.1476, and p=0.07815 
respectively). However, RO33 specific antibody titres of the day 60 group were significantly 





































Figure 3.13: MSP-1 Block 2 serotype specificity and titres of sera from day 0 (Panel 
A) and day 60 (Panel B) immunisation groups assessed by ELISA. Each serum was 
tested against the recombinant proteins indicated on the X-axis. Corresponding IFA 
titres of the same sera to five strains of parasite are shown in Panels C (day 0) and 
D (day 60) respectively. Horizontal bars indicate the median titre of each group. .    
…………………………………………………… 
A)      B) 
 
C)      D) 
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 The same serum samples were used in IFA against five different strains of parasite, 
namely 3D7, Palo Alto17, MAD20, Wellcome and RO33, representative of all three MSP-1 
Block 2 serotypes. IFA reactivities agreed closely with ELISA results, confirming that 
antibodies to five serotypes of the MSP-1 Block 2 could be elicited by immunisation with 
the MSP-1 hybrid. This confirmed that these antibodies recognise natural protein targets on 
the parasite surface. Comparing antibody reactivities between the groups, the median IFA 
titres against parasite strains Palo Alto17, MAD20 and Wellcome were not significantly 
different (Mann-Whitney U test, p=0.2079, p=0.2283, and p=0.6361 respectively). However, 
IFA titres against 3D7 and RO33 serotypes of the day 0 and day 60 samples were 
significantly different (p=0.0013 and p=0.0287 respectively, Figure 3.13 C and D). 
 The isotype distribution of antibodies produced by these immunisations were also 
determined by ELISA. Subclasses IgG1, IgG2a, IgG2b and IgG3 were all detected against 
the MSP-1 hybrid, to a greater or lesser extent. Surprisingly, median ELISA titres of the day 
60 group appeared to be higher for all subclasses than those of the day 0 group. However, 
these were not statistically significant differences (Mann-Whitney U test, p=0.4710, and 
p=0.1485 for IgG2b and IgG3 respectively), except in the case of the IgG1 (p=0.0022). The 
IgG2a level of the day 0 group was higher than in the day 60
 
group, but again it was not 









Figure 3.14: Isotype distribution of specific IgG antibodies against the MSP-1 hybrid.   
IgG subclass titres from all mice immunised with A) day 0  MSP-1 hybrid and B) 60-
day incubated MSP-1 hybrid showed similar profiles of anti-MSP-1 hybrid 
antibodies.  
A)      B) 
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2.8 Routes of immunisation  
 Not all routes of immunisation are suitable for the MSP-1 hybrid antigen. Groups of 
mice that were injected subcutaneously (s.c) with the MSP-1 hybrid formulated with 
Montanide™ ISA51, Montanide™ ISA720, Alhydrogel™, Alhydrogel™ with CpG ODN 
7909, or CoVaccine HT™ elicited higher antibody titres than those immunised 
intraperitoneally (i.p) with the same formulations (Figure 3.15). IFA testing of the same sera 









Figure 3.15: Antibody titres of sera from mice immunised with MSP-1 hybrid in 
combination with different adjuvants. For each adjuvant, two groups of mice were 
injected either subcutaneously (s.c.) or intraperitoneally (i.p.). Adjuvants a 
immunisation routes are displayed on the X-axis. ELISA titres (Y-axis) against the 
MSP-1 hybrid in the i.p. groups were low or undetectable, whereas much stronger 
responses were detected in the majority of MF1 outbred mice immunised with the 
same vaccine formulation injected s.c.  
 
2.9 Potency testing of MSP-1 hybrid 
 The potency of the MSP-1 hybrid was tested in inbred mouse strains BALB/c and 
C57/BL6. Each group of ten mice were immunised by s.c. injection of either 10 or 50 µg 
MSP-1 hybrid in Alhydrogel™. Immunisations were carried out seven days apart for a total 
of three doses. The mice were exsanguinated 14 days after the last immunisation. The sera 
were collected and tested against MSP-1 hybrid by ELISA. A pool of sera from five mice 
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immunised with MSP-1 hybrid in combination with CoVaccine HT from another experiment 
was used as a positive control to produce a standard curve to assess titres between groups.  
 Specific antibodies to the MSP-1 hybrid were detected in all four groups of mice. 
BALB/c mice immunised with 50µg MSP-1 hybrid had the highest median titre (3.78x10
3
). 
BALB/c mice in the 10 µg group had lower levels of specific antibody response (median 
titre 1.71x10
3
), but the titres of two groups were marginally not statistically significantly 
different (p= 0.063; Mann-Whitney U test). For the C57/BL6 mice, the 10 µg group 
responded well to the MSP-1 hybrid, (median titre 2.06x10
3
), with two mice not responding. 
By contrast, most of the C57/BL6 mice from the 50µg group failed to respond to the MSP-1 
hybrid. Although the ELISA titres of the responding mice were as high as most of the mice 
from 10µg group, the two groups were significantly different by statistical analysis (p = 








Figure 3.16: Potency test antibody titres against the MSP-1 hybrid antigen assessed 
by ELISA. Sera from mice immunised with either 10µg or 50 µg of MSP-1 hybrid in 
combination with Alhydrogel™ were tested. Horizontal bars represent the medians 
of each group.  
 
2.10 Adjuvant formulation, compatibility and immunogenicity testing 
 Adjuvants that were used with the MSP-1 hybrid in this study were compatible with 
or have been in human use, including 1) Montanide™ ISA51, 2) Montanide™ ISA720, 
(both from Seppic, France) 3) Alhydrogel™ (Brenntag Biosector, Denmark) (with or without 
CpG 7909 ODN), 4) Covaccine HT™ (Protherics Medicines Development Limited, A BTG 
International Group Company, London, UK), 5) Formulated Aqueous TLR-4 Agonist (with 
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or 6) without Alhydrogel™), 7) Formulated TLR-4 agonist in oil-in-water emulsion, 8) 
Formulated Oil-in-Water Emulsion, 9) Formulated TLR-7/8 agonist aqueous formulation 
and 10) Formulated TLR-9 agonist aqueous formulation (adjuvants 5,7,8,9,10 are provided 
by Dr. Darrick Carter of IDRI (Seattle, USA). All these adjuvants were tested by 
immunisation of MF1 mice. Sera from immunisations were tested against MSP-1 hybrid by 
ELISA and checked for their ability to cross-react with parasite surface antigens by IFA. 
Details of immunisation protocols are given in Materials and Methods. 
 Different adjuvants elicited different levels of antibodies in each immunisation 
group. The immunisation group with the highest median ELISA titre was the CoVaccine HT 
formulation. All 8 mice in this group had antibodies against MSP-1 hybrid and their titres 
were similar, producing a median titre of 8.90X10
6
. Montanide ISA51 and Montanide 





Alhydrogel, either with or without CpG, also elicited specific antibodies against MSP-1 




respectively. However, the titres of 
individual mice from each of these groups differed widely from each other. Stronger 
antibody titres were observed in groups of the Aqueous TLR-4 Agonist, either with or 




respectively. Similar median titres were observed with the Formulated Oil-in-Water 





). Most of the mice failed to respond when aqeous TLR7/8 agonist was used as 




 Comparing Montanide ISA51, Montanide ISA720, and Alhydrogel with CpG, 
aqueous TLR-4 agonist (both with and without Alhydrogel), the antibody titre of the 
CoVaccine HT group was not statistically different (p<0.05 or less; Kruskal-Wallis test). 
Nevertheless, a non-parametric Mann-Whitney U test suggested that median titre of the 























    
Figure 3.17: ELISA titres of sera from mice that were immunized with MSP-1 hybrid 
in combination with different adjuvants. Differences between the CoVaccine HT 
group and Alhydrogel, oil-in-water emulsion, TLR-4 agonist oil-in-water, TLR7/8 
agonist aqueous, and TLR-9 agonist aqueous were statistically significant (Kruskal-
Wallis test) Asterisks represent statistical significance; *p<0.05, **p<0.01, 
***p<0.005.  
 Sera were further tested against individual MSP-1 Block 2 antigens by ELISA. The 
CoVaccine HT group had antibodies to all three serotypes of Block 2, including K1-like type 
(3D7 and Palo Alto), RO33 type and MAD20-like type (MAD20 and Wellcome) (Figure 
3.20, Panel A). Block 2- specific antibodies were also observed in the Montanide ISA51 and 
Montanide ISA720 group (Figure 3.18 Panels A and B). Specific antibodies to 3D7, Palo 
Alto17 and RO33 were detected in a group of mice that were immunised with MSP-1 hybrid 
in combination with Formulated Aqueous TLR-4 Agonist, however this ELISA was unable 
to detected specific antibodies to MAD20 and Wellcome antigens (Figure 3.18 Panel C). 
Similar results were obtained in the Aqueous TLR-4 Agonist plus Alhydrogel formulated 
group. Most sera from this group were able to recognise 3D7, Palo Alto and RO33 antigens. 
Only one serum recognised the MAD20 and Wellcome antigens (Figure 3.18 D).   
 IFAs were performed to test cross-reactivity of these sera to the same panel of five 
parasite strains. IFA results showed the same general trend as the ELISA results (Figure 
3.19). The sera from the groups immunised with antigen plus Alum, and Alum+CpG also 
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showed positive signals against parasites, although the signals were very low and sometimes 




















Figure 3.18: ELISA analysis of serotype specificity of antibodies yielded from 
immunization of MSP-1 hybrid formulated with different adjuvants. A=Montanide 
ISA51, B=Montanide ISA720, C= Aqueous TLR-4 agonist, D= Aqueous TLR-4 
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Figure 3.19: IFA-reactive serotype specificity of mouse antibodies from 
immunization with MSP-1 hybrid formulated with different adjuvants. A = Montanide 
ISA51, B = Montanide ISA720, C = Aqueous TLR-4 agonist, D = Aqueous TLR-4 
agonist with Alum. Titres (Y-axis) are plotted against parasite strain on the X–axis 
for each serum sample. 
 
2.11 Immunogenicity and serotype specificity in different animals 
 Immunisation of the MSP-1 hybrid in combination with CoVaccine HT raised 
consistently high titre and multiple serotype reactivities in the serum of mice. This 
adjuvant/antigen combination was further tested as a vaccine formulation in different 
animals. ELISA and IFA assays were performed as described earlier to assess the 
immunogenicity of the MSP-1 hybrid in larger animals and non-human primates.  
2.11.1 Mice 
 Immunisation of the CoVaccine HT/MSP-1 hybrid formulation in mice elicited 
antibodies to all five Block 2 antigens tested. Medians ELISA titres to each Block 2 protein 
were very similar and as high as the antibody titre to the MSP-1 hybrid (median of 
A)      B) 
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8.90X10
6










respectively (Figure 3.20 A). Although all of sera were able to recognise 
the immunogen, some sera failed to recognise some of the Block 2 antigens.   
 IFA testing of the same antisera again showed that the sera from the CoVaccine 
formulated MSP-1 hybrid immunised mice had specificity to all five parasite serotypes. 
There were differences in the titres observed between individual Block 2 serotypes. In 
comparison to 3D7, Palo Alto and RO33, median IFA titres to MAD20 and Wellcome strain 













Figure 3.20: Block 2 serotype specificity of sera from mice that were immunized with 
MSP-1 hybrid in combination with CoVaccine HT. Titres (Y-axis) are plotted against 
individual MSP-1 Block 2 antigens on the X –axis (Panel A) or individual parasite 




 ELISA was performed to investigate the IgG subclass distribution of the antibodies 
elicited by MSP-1 hybrid in combination with CoVaccine HT. Strong reactivity of IgG1, 







 respectively, while IgG3 reactivity was low or undetectable in some 
sera (median 6.55x10
1
) (Figure 3.21). 
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Figure3.21: IgG subclass titres in mice immunised with MSP-1 hybrid in combination 
with CoVaccine HT. Titres (Y-axis) for individual mice are plotted . against IgG 
subclass on the X-axis. Horizontal bars represent median titres of each group.   
  
2.11.2 Rabbits 
 Serum samples from each animal were collected after each of three immunisations 
with MSP-1 hybrid formulated in CoVaccine HT. Animals were immunised as described in 
Materials and Methods (section 12). The serum sample from each time point was tested by 
ELISA and by IFA. MSP-1 hybrid specific antibody titres increased over the course of the 
immunisations and reached a median of 3.87 X10
6
 at day 70 (Figure 3.22 Panel A). 
However, there was one rabbit that failed to respond to any Block 2 antigens or the MSP-1 
hybrid antigen (data not shown). Sera from the 7 rabbits that were able to recognise all the 
Block 2 antigens tested and the titres between individual rabbits were consistent. Both 
ELISA and IFA antibody reactivity to each Block 2 serotype increased with repeated 
immunisation.  Sera collected after the last immunisation showed similar antibody titres to 




respectively), while the median titre 
to RO33 was slightly lower (6.02 x10
5
). The median Ab titre to the Wellcome Block 2 
antigen was the highest, giving a readout of 9.05 x10
5
, while anti-MAD20 titres were 8.54 
x10
5 
(Figure 3.22 B) IFA reactivity with parasites correlated broadly in specificity and titre, 
























      
 
Figure 3.22: Immunogenicity testing of the MSP-1 hybrid in rabbits. A) ELISA titres 
(Y-axis) are plotted against days since the beginning of the immunisation schedule. 
Arrows show immunisation points. Sera from the final bleed were tested against B) 
five Block 2 antigens by ELISA and (C) by IFA with five different strains of P. 
falciparum. 
  
2.12 Epitope mapping of anti-MSP-1 hybrid sera 
 A panel of 132 N-terminal biotinylated 12-mer peptides, representative of all major 
linear epitopes in the Block 2 region of MSP-1 were used to fine-scale map antibody 
responses in all immunized and responding animals. This panel included all known repetitive 
sequences from the K1 and MAD20 serotypes, peptides from all non-repetitive regions of all 
three serotypes, and a panel of 19 peptides covering the junctions between the individual 
Block 2 serotypes. Due to the reduced sensitivity of this assay with small volumes of 
available sera, animals that were seronegative were not tested. In the remaining 25 mice, 6 
rabbits and 5 rhesus monkeys, reactivity with peptide epitopes was observed across all three 
B)      C) 
       
 x 
 
A)     
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Block 2 serotypes, with some exceptions. Generally, mice showed a more oligoclonal 
response to Block 2, with a narrower number of reactivities, and with less broad recognition 
of individual variant peptides. The pattern of peptide recognition of individual mouse sera 
were similar. However, compared to other animals, fewer peptides were recognised by sera 
from mice. Repetitive regions and middle part of the RO33 sequence clearly provided 
epitopes that were recognised by the majority of sera from mice, while some also showed 
reactivity to flanking sequences of the K1-like region and the MAD2- like region (Figure 
3.23). 
 Mapping of sera from rabbits showed a broader reactivity, recognising epitopes from 
all three serotypes, although more epitope reactivities in MAD20-like type region were 
detected. Using different adjuvants also resulted in different serum recognition patterns. It 
was noted that the sera from the group immunised with the CoVaccine HT formulation 
recognised more peptides than the group with Freund’s adjuvant (Figure 3.24 A and B). 
Reactions of the sera from a sheep that had been immunised with Freund’s formulated MSP-
1 hybrid was similar to reactivity in rabbits and mice (Figure 3.24 C). Similarly, in rhesus 
monkeys, reactivity of the antibodies to all three serotypes of Block 2 was observed (Figure 
3.24 D).  
 Recognition of neo-epitopes was also observed in some of these immunised animals. 
The sera that were reported to be positive to the junction peptides were found more in mice 
and less in rabbits and monkeys (Figure 3.24). However, almost all antibody reactivity in 
individual serum samples that showed reactivity with the ‘non-natural’ junctional peptides 
was explained by antibody specificities in the same sera to peptides from individual ‘natural’ 
Block 2 sequences. 
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Figure 3.23: Peptide epitope recognition of sera from mice that were immunized with 
MSP-1 hybrid in combination with A) Montanide ISA51, B) Montanide ISA720, (C) 
Alhydrogel™ (D) Alhydrogel™ with CpG, and (E) CoVaccine HT. Reactivity of each 
group of mice for each peptide is plotted as a column against peptide sequence on 
the X-axis. Whiskers on each bar represent the standard deviation (SD)of ELISA 
readings. Dashed lines represent the mean background signal for all peptides. The 
small Figure on the right of each panel shows serum recognition to the neo-epitope 
peptides. 
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Figure 3. 24: Peptide epitope recognition patterns of sera from A) rabbits that were 
immunized with MSP-1 hybrid antigen in combination with CoVaccine HT and B) 
Freud’s adjuvant. Peptide recognition of sera from C) sheep immunized with MSP-1 
hybrid with Freund’s adjuvant and D) Rhesus monkeys immunized with MSP-1 
hybrid formulate with CoVaccine HT. Dashed lines represent mean background 
signal for all peptides. Small Figure on the right of each panel shows serum 
recognition to neo-epitope peptides. ……………………………………………………..
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3. Discussion  
3.1 Properties and production of the MSP-1 hybrid 
 MSP-1 hybrid was codon-optimised construct containing the sequence and antigenic 
polymorphism present within the majority of MSP-1 Block 2 alleles found within the P. 
falciparum parasite population. It contains all polymorphic Block 2 sequences known to be 
the recognised by human and mouse antibodies elicited by natural infection and 
immunisation respectively. Apart from MSP-1 Block 2 sequences, this antigen also contains 
T-cell epitopes from MSP-1 Block 1 region, which have been demonstrated to be recognised 
by T cells from humans exposed to malaria and essential for immunogenicity of this antigen 
in pre-clinical testing (Parra et al. 2000; Quakyi et al. 1994; Cowan et al. 2011).  
 As an IUP, the MSP-1 hybrid antigen is thermostable because it has a high 
frequency of small, polar, hydrophilic amino acids and lacks a hydrophobic core. The MSP-1 
hybrid exhibits several properties of IUPs, as observed in this study, where the MSP-1 
hybrid migrated on SDS-PAGE as a protein of around twice its actual molecular weight, 
because IUPs are known to bind poorly to SDS and therefore cause the anomalous migration 
of these proteins on SDS-PAGE gels (Tompa 2002). The hydrophilic amino acid-rich 
sequence also made this protein antigen bind poorly to Coomassie Blue dye, which binds 
aliphatic amino acid residues (Tompa 2002).  
 The MSP-1 hybrid was easily expressed in in the heterologous host E.coli with high 
yield in laboratory flasks and in a bioreactor using modified Luria Bertani media, and could 
be easily purified by the simple three-step protocols that have been developed during this 
work. This is mainly due to the particularly unstructured (IUP) properties of the protein, its 
lack of disulphide bonds and its thermostability. Codon optimisation of the MSP-1 hybrid 
construct also enabled even higher-level expression than has been seen with non-optimised 
Block 2 proteins (Cavanagh & McBride 1997). The heat stability of the protein not only 
made this antigen easy to handle during purification steps, but also allowed it to be partially 
purified by high temperature treatment. In addition, refolding steps are not required for the 
MSP-1 hybrid. ………… ………… ………… ………… ………… ………… …………  
 In this project, the lab scale and bioprocess scale protocols developed have 
established ideal conditions for cell growth and are suitable for expression of the MSP-1 
hybrid protein as a soluble intact protein on a large scale. The DNA sequence of the MSP-1 
hybrid plasmid in the starting culture and the harvested bioreactor culture were checked by 
DNA sequencing and found to be identical, suggesting that this DNA sequence is stable 
during the period of large scale protein expression, which is substantially longer than that of 
the original flask-scale protocol. Cycles of freezing and thawing proved to be the most 
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suitable method for lysing host cells. In a previously attempted protocol, a French press, 
which is commonly used to process large-scale cell cultures, was used. Although more of the 
soluble MSP-1 hybrid could be harvested using this method, the sample contained more 
proteins and biomaterial contaminants as estimated when lysates were run on SDS-PAGE. 
Downstream purification steps more were also more problematic and less efficient, including 
the heating step. It provided a partially purified sample that contained more contaminants 
than the heat-purified sample prepared from the freeze-thaw process. This less pure sample 
from the French press also created additional difficulties in the development of the anion 
exchange chromatography step, resulting in lower yield and a less pure end product. The 
final purification protocol for the MSP-1 hybrid is simple, requires relatively unsophisticated 
equipment and chemicals and is easily scalable. The heating step is a very efficient 
purification step for small-scale as well as large-scale purification. Heating excluded the 
majority of host cell contaminants without significant loss of the MSP-1 hybrid product. 
More importantly, this process did not damage the primary structure of the MSP-1 hybrid. 
Anion exchange chromatography, which is used as the final step of purification, can be 
adapted to accommodate larger sample sizes, and a scaled-up protocol was easily developed 
based on the small-scale purification method. The dialysis step, which is performed before 
the chromatography step, is time consuming. Nevertheless, it proved to be essential for the 
efficiency of the chromatography step. This is because the MSP-1 hybrid binds very weakly 
to the anion exchange column and can be lost with other contaminants if the ionic strength of 
the sample is too high. …………………………………………………………………. 
 Endotoxin levels in the final purified product were assayed by Lonza, using the LAL 
kinetic chromogenic technique. The MSP-1 hybrid product was shown to have 72.1 EU mL
-1
 
in the eluted fractions form the anion exchange step and 8.50 EU mL
-1
 in the final dialysed 
product. 
 
One limitation of this assay is that the sample has to be soluble, however this was 
not a problem for the MSP-1 hybrid. The final MSP-1 hybrid product was reported to have 
less endotoxin than the protein after the last anion exchange chromatography step, given that 
the concentration of MSP-1 hybrid in the two samples was the same. Since endotoxins are 
heat-resistant, and therefore not destroyed during the purification process, it is possible that 
the dialysis step was responsible for eliminating endotoxins from the final sample during 
buffer exchange, as endotoxins may bind to dialysis tubing membrane. Endotoxins are 
lipopolysaccharide (LPS) complexes of gram-negative bacterial cell walls, which are 
common contaminants in bacterial based biological products and should always be kept at a 
low level in vaccine production. They are pyrogens, which can mediate pathological 
disorders (Blatteis et al. 2000). Clinically, endotoxins have been identified as agonists of 
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TLR-4, and can trigger the signal cascade for cells such as macrophages to secrete pro-
inflammatory cytokines, leading to endotoxic shock. As little as 4ng kg
-1
 of endotoxin 
(approximately 40-80 EU mL
-1
), can precipitate inflammatory stimuli such as TNF- and 
IL-6. This, sequentially, can cause physiological changes in human blood such as 
hyperactivation of leucocytes (Wilson et al. 2001). For drugs and vaccines quality control, 
regulatory agencies such as the United States Pharmacopeia (USP) and the European 
Medicines Agency (EMEA) set strict guideline for acceptable pyrogen contamination levels 
in final products. Although there is no clear recommendation on acceptable endotoxin level, 
previous data of the endotoxin levels in commercial vaccines can give a rough idea of what 
could be acceptable endotoxin levels. The recommended endotoxin levels of recombinant 
subunit vaccines as well as polysaccharide vaccines should not exceed 20EU mL
-1
 in animal 
studies, since high purity is expected from this kind of vaccine. Guidelines for acceptable 
endotoxin level in vaccines may also differ according to each animal study and licensed 
vaccine. The readout of immune responses is critical data in evaluating the antigen in 
vaccine studies. Therefore in general, the level of endotoxin should be as low as possible to 
reduce immune responses to endotoxin which might interfere with immune responses 
induced by the antigen itself (Brito & M. Singh 2010). With this purification process, we 
have achieved endotoxin levels close to those needed for a viable human vaccine.    
3.2 The potential of MSP-1-hybrid as vaccine  
3.2.1 Antigenicity 
 The MSP-1 hybrid is recognised by serum antibodies and mAbs from animals that 
have been immunised with Block 2 antigens, as well as serum antibodies from naturally 
infected Africans. Antibody reactivity in malaria exposed children to the MSP-1 hybrid was 
as strong as, or stronger than the reactivity observed to individual MSP-1 Block 2 antigens. 
This confirms that this synthetic protein contains epitopes which are recognised by 
antibodies from naturally infected humans (Cowan et al. 2011). MSP-1 Block 2 epitopes are 
the target of antibodies that are significantly associated with protection against clinical 
malaria (Conway et al. 2000; Polley et al. 2003; Mawili-Mboumba et al. 2003; Cavanagh et 
al. 2004). In this project I showed that in a cohort of Ghanaian children there was a 
statistically significant correlation between possession of antibodies against the MSP-1 
hybrid and reduced risk of experiencing clinical malaria symptoms in the following 
transmission season. Although the statistical significance of this association was confounded 
by age, it remained close to significance. This is because the tested sera were collected from 
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a small cohort of 278 children with a wide age range (3-15 years) where Block 2 antibody 
positivity frequency is relatively low (Cavanagh et al. 2004; Cowan et al. 2011).  
3.2.2 Immunogenicity   
 Despite its relatively small size (31 kDa), MSP-1 hybrid elicited polyclonal 
antibodies reactive with P. falciparum parasites of all three Block 2 serotypes in mice, 
rabbits, and Rhesus monkeys. Sera from animals immunized with this antigen display a 
broad reactivity with all three MSP-1 Block 2 serotypes in both IFA, ELISA and peptide 
mapping. In this study, adjuvants licensed for human use were tested in mice and found to be 
capable of raising specific antibodies against the MSP-1 hybrid. Montanide adjuvants were 
expected to raise strong immune responses, since they share some physical characteristics 
with incomplete Freund’s adjuvant. However, some studies reported that Montanide ISA-51 
and ISA-720 were the cause of sterile abscesses in recent human trials (Wu et al. 2008; 
Roestenberg et al. 2008). Because of this, other human compatible adjuvants should be used. 
Alhydrogel (Alum) is an adjuvant with a good profile, which has been shown to enhance 
Th2 responses in animals and humans (Leroux-Roels 2010). Nevertheless, it did not provide 
the high and consistent antibody titres by comparison with other adjuvants in this study. CpG 
adjuvant was expected to stimulate B-cells through TLR-9 signalling, but when used 
together with Alum in this study it did not improve specific antibody titres. Similarly, mice 
that were immunized with another TLR-9 agonist gave as high a median titre as the group 
with CpG plus Alum, although the level of reactivity within the group seemed to be more 
consistent. Agonists of TLR-4, uniquely, are thought to elicit both Th1 and Th2 responses 
(Duthie et al. 2011), and thus to enhance specific immunity against both intra-erythrocytic 
malaria parasites and merozoites, which are present outside the red blood cells. Using the 
TLR-4 agonist, both alone and in combination with Alhydrogel, elicited similar antibody 
titres to the MSP-1 hybrid in mice. Since high antibody titre is likely to be an important 
property of any invasion-blocking-erythrocytic-stage vaccine, these two adjuvants are 
interesting adjuvant candidates which are able to trigger stronger antibody responses. The 
TLR-7/8 agonist formulated with the MSP-1 hybrid was tested, but this group produced the 
lowest antibody titre of all the adjuvant groups. However, this experiment was inconclusive 
since it has been  suggested that TLR-8 is non-functional in mice. This makes any 
extrapolation from mice to humans more difficult (Jurk et al. 2002; Hemmi et al. 2002). The 
CoVaccine HT is thought to be a good antibody enhancer (Mosca et al. 2008). When 
immunizing together with the MSP-1 hybrid, it raised specific antibodies as high as those in 
the group with Alhydrogel™. A similar level of antibody titre was seen in the group with the 
TLR4 agonist in an oil-in-water emulsion. Of the tested panel of adjuvants, CoVaccine HT 
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was the most efficacious adjuvant for the MSP-1 hybrid. The CoVaccine HT is an oil-in-
water adjuvant consisting of synthetic sucrose fatty acid sulphate ester (SFASE) immobilised 
in the oil droplets of a submicron emulsion of squalene in water. It has been shown in a 
number of studies to provide TLR-4 signalling (Bodewes et. al, 2010; Bodewes et al. 2009). 
Statistical analysis of the data from each immunisation group showed that the antibody 
levels in the CoVaccine HT group were as high as the groups containing aqueous TLR4 
agonist (both with and without Alum) and higher than the groups immunised with oil-in-
water based adjuvants (oil-in-water emulsion and TLR-4 agonist oil-in-water). Using MSP-1 
hybrid formulated with CoVaccine HT, MSP-1 hybrid specific polyclonal antibodies were 
produced at high titres. Antibodies elicited by the MSP-1 hybrid formulated with CoVaccine 
HT recognised MSP-1 Block 2 protein antigens of all three serotypes and recognised the 
surface MSP-1 antigen on all five strains of P. falciparum parasite tested. In addition, 
peptide epitope mapping confirmed that the MSP-1 hybrid elicits antibodies against epitopes 
in both repetitive regions and non-repetitive serotype-specific regions of all three Block 2 
serotypes. The experiments in outbred mice (MF1 mice) and inbred mice (BALB/c and 
C57/BL6) showed that similar titres of specific antibody to all three serotypes could be 
elicited in each strain of mouse. The studies in rabbits and monkeys showed that MSP-1 
hybrid was immunogenic in larger, outbred animals including non-human primates, and that 
boosting of antibody responses to the MSP-1 hybrid protein occurred with each of three 
immunisations.   
 Interestingly, intraperitoneal immunisation of animals with the MSP-1 hybrid proved 
to be much less efficient than when animals were immunised subcutaneously. An 
explanation of this result has not yet been experimentally determined, but it is possible that 
the protein may be susceptible to the degradative environment in the peritoneum, due to the 
abundance of macrophages in this cavity. Secondly, the intrinsically unstructured nature of 
the antigen could make it more susceptible to digestion by proteases. Both factors could 
result in lower immunogenicity and therefore lower antibody titres. By contrast the MSP-1 
hybrid elicited much higher antibody titres when delivered subcutaneously. It is possible that 
the MSP-1 hybrid is taken up by dendritic cells in this environment and subsequently 
processed in lymphoid tissue to stimulate antibody production. 
3.2.3 Stability 
 An ideal blood stage malaria vaccine would be highly stable and require minimal 
cold chain costs. This study has shown that the MSP-1 hybrid is stable at ambient 
temperatures (at 25°C and 37°C) over incubation periods of up to 60 days without any 
significant degradation or decrease in antigenicity or immunogenicity. This is a significant 
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factor for vaccine transport as well as storage at sites where the refrigeration is sometimes 
difficult or unreliable.  …………………………………………………………………… 
 The MSP-1 hybrid was also shown to be very stable in combination with the 
adjuvant CoVaccine HT: it can be maintained at ambient temperature for around 20 days 
without significant change in protein concentration and/or primary structure. The protocol 
used in this study to extract the protein antigen from vaccine was initially developed for 
characterisation of vaccine antigen from water-in-oil adjuvants, such as Montanide ISA720. 
However, it was also efficient in extracting MSP-1 hybrid from an oil-in-water adjuvant 
formation such as CoVaccine HT. This vaccine formulation has not yet been tested for 
immunogenicity in animals following this long incubation period. Future studies on the 
potency, stability and immunogenicity of this vaccine formulation should be completed to 
assess the viability of this combination.   
3.2.4 Immune responses raised by immunisation with MSP-1-hybrid 
 Sera from these immunisations showed antibody specificity for all Block 2 antigens 
tested and reactivity with P. falciparum parasites of five different strains, representing all 
three Block 2 serotypes. Using CoVaccine HT, all four isotypes of IgG were detected in 
mouse sera. These included the cytophilic antibody subclasses IgG2a and IgG2b. These two 
antibody subclasses in mice are counterparts of the human IgG1 and IgG3 according to their 
similarities in biological and functional activities. It has been reported that they share 
functions in fixing complement and binding protein antigens (Carvalho et al. 2002; M. R. 
Clark 1997). They have also been reported to be involved in opsonisation which mediates 
phagocytosis by macrophages (Stevenson & Riley 2004). In humans, the two cytophilic 
subclasses are the most abundant antibody isotypes in individuals who are protected from 
malaria (Bouharoun-Tayoun & Druilhe 1992). IgG1 and especially IgG3 are also reported to 
be the most effective isotypes for antibody-dependent cellular inhibition (ADCI) and 
immune phagocytosis assays (Bouharoun-Tayoun et al. 1995; Groux et al. 1990). IgG1 and 
IgG3 anti-MSP-1 hybrid antibodies were also detected in immunised mice. Mouse IgG1 was 
considered to be similar to human IgG4 in its ability to bind to mast cells, while mouse IgG3 
and human IgG2 share the ability to recognise carbohydrate epitopes (Hussain et al. 1995). 
However, these has so far been no evidence that these two antibody isotypes correlate with 
protection from malaria (Bouharoun-Tayoun & Druilhe 1992; Rzepczyk et al., 1997; R. 
Taylor et al. 1998; Oeuvray et al. 1994)./ 
 An important role for antibodies against MSP-1 Block 2 in protection from malaria 
has been suggested by a number of studies. However, there has yet to be evidence of any 
parasite inhibitory effect of these antibodies in in vitro GIA, either against individual Block 
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2 serotypes or by antibodies against the MSP-1 hybrid (Valero et al. 1996; Cowan et al. 
2011). However, human antibodies to Block 2 have shown activity in parasite inhibition in 
the presence of monocytes in the ADCI assay (Galamo et al. 2009), in a manner similar to 
several  other vaccine candidates such as MSP-2 and GLURP (Theisen et al. 1998; Stubbs et 
al. 2011).  
 In this project formulations of the MSP-1 hybrid with adjuvant were expected to 
induce high antibody titres to all three serotypes of the MSP-1 Block 2. Experiments were 
designed to measure and compare levels of specific antibodies elicited by formulation with 
different adjuvants, and their IgG subclass distribution. However, different adjuvants may 
trigger other immune responses that may link to protective immunity. For example, this 
study showed that specific antibodies could be produced by immunisation of the MSP-1 
hybrid with Alum. However, in other studies, Alum has been reported not to have special 
potential in the boosting of the Th1 and cytotoxic T-lymphocyte (CTL) responses, which are 
thought to be important in the controlling of intracellular pathogens such as malaria parasites 
(Coler et al. 2009). Further study on cytokine production, B-cell differentiation and other 
immune responses to these immunizations will provide more informative data on the 
mechanisms by which these adjuvants work, which hopefully will help in assessment of 
these adjuvants’ potential as well as allow us to learn more about immune responses to 
vaccination.  
 One of the goals of Malaria Vaccine Technology Roadmap is to “pursue multi-
antigen, multi-stage, and attenuated whole-parasite vaccine approaches” 
(www.malariavaccine.org/files/Malaria_Vaccine_TRM_Final_000.pdf -page 4). This is due 
to the fact that blood stage malaria parasite antigens are often polymorphic and using of 
mono-allelic vaccines have been shown to be ineffective (Ogutu et al. 2009) or effective 
against only homologous parasite strains or serotypes (Flück et al. 2004; Genton et al. 
2002).Therefore, the vaccine targeting multiple antigens and/or multiple stages of parasite 
lifecycle is needed to be developed. Instead of focusing on the conserved domains of 
candidate antigens, the MSP-1 hybrid antigen overcomes the polymorphism issue by design. 
As a multimeric vaccine constructs, it is strongly immunogenic in all three species of tested 
animals, including non-human primates, able to elicit immune responses that recognize 
multiple parasite strains, and contains a target of antibody-dependent cellular parasite 
inhibition activity in vitro (Galamo et al. 2009). These promising evidence and its unique 
biophysical properties of the protein antigen support the further development of this blood 
stage (and theoretically liver stage (Szarfman et al. 1988; Krzych et al. 1995)) vaccine based 
on MSP-1 Block 2. A vaccine that target the extensive antigenic polymorphism and multiple 
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stages of lifecycle of P. falciparum could essentially support the goals of the Global Malaria 
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Chapter 4: MSP-3.3C 
1. Introduction 
 Characteristics of the MSP- hybrid IUP, described in an earlier chapter in this thesis, 
encouraged us to speculate that other IUPs in the Plasmodium genome might be suitable 
candidates for a vaccine against malaria. Using the available genomic data and bioinformatic 
tools, we looked for putative parasite surface proteins that contained unstructured regions. 
One of the IUP containing proteins identified was a member of the MSP 3/6 family, 
expressed by gene PF10_0347, previously known as H101 (Pearce et al. 2005). This protein 
family was of interest to us, as this region of the parasite genome, including GLURP and 
LSA-1, is specific to Plasmodium falciparum.  Since the beginning of my work on MSP-3.3, 
the gene products of the MSP-3/6 family have subsequently been proposed as a possible 
family of target molecules which merit development as malaria vaccines (Singh et al. 2009; 
Bang et al. 2011). The originally identified prototype member of the MSP-3/6 family, MSP-
3 (now known as MSP-3.1, (Singh et al. 2009) was predicted to have unstructured regions 
(Burgess et al. 2005) and some members of this family are already being investigated as 
potential vaccine candidates (Oeuvray et al. 1994; Druilhe et al. 2005; Sirima et al. 2011; 
Hisaeda et al. 2002). We decided to investigate and characterise the intrinsically unstructured 
part of the protein expressed by gene PF10_0347 to see whether another parasite IUP, from a 
conserved, P. falciparum-specific gene family would have similar beneficial vaccine 
properties of ease of expression, thermostability and potential immunogenicity to that of the 
much more polymorphic IUP, the MSP-1 hybrid antigen (Cowan et al. 2011).  
 Many proteins of malaria parasites contain extensive regions of so-called ‘low 
complexity’ sequence (Gardner et al. 2002; Pizzi & Frontali 2001; Brocchieri 2001). Some 
are encoded by genes that lack orthologues in other organisms, which causes difficulty in 
predicting their structure and function from the data of homologous proteins. So far little is 
known about the structure or function of the newly identified protein encoded by 
PF10_0347, MSP-3.3. The MSP-3.3 protein, like other MSP-3/6 family proteins, has been 
reported to be expressed during the asexual stage of the parasite as a merozoite surface 
protein (Singh et al. 2009; Pearce et al. 2005). While any functional or structural data on 
MSP-3.3 remain to be generated, it has been suggested that MSP-3 family members may 
have an important role in the biology of P. falciparum (Singh et al. 2009). It has been 
reported that MSP-3.3 is recognized by human antibodies elicited by natural infection 
(Pearce et al. 2005) and that human IgG to the C-terminal region of this protein has 
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monocyte-dependent parasite inhibition effects in ADCI assays in vitro (Demanga et al. 
2010). 
 In this part of the project the gene sequence of PF10_0347 was analysed and a non-
tagged recombinant protein derived from the C-terminal unstructured region of PF10_0347 
gene (hereafter called MSP-3.3C in this thesis) was expressed and purified as a potential 
malaria vaccine candidate. This protein has been investigated for its biochemical 
characteristics, and its interactions with biomolecules of the immune system, in the hope that 
it can be further developed as a novel malaria vaccine.  
2. Materials and results 
2.1 Sequence analysis  
2.1.1 Gene sequence of the PF10_0347 
 The gene sequence of PF10_0347 3D7 and the single nucleotide polymorphisms 
between different isolates were available in the Plasmodium genome resource, PlasmoDB 
(http://plasmodb.org). Sequence homologies between PF10_0347 and other MSP-3 family 
members were determined using BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and 
ClustalW (Larkin et al. 2007; S. Singh et al. 2009). The Simple Modular Architecture 
Research Tool (SMART) (http://smart.embl-heidelberg.de/) and ProSite 
(http://expasy.ch/prosite) were used to look for known protein domain sequence homologies 
within this amino acid sequence. / 
 The PF10_0347 gene is located on chromosome 10, in a region of the genome that is 
unique to P. falciparum, which contains all the other MSP-3 family members in one 
contiguous. MSP-3.3 shows little variation in sequence between parasite isolates. The 
PlasmoDB online malaria genome database describes only four non-synonymous single 
nucleotide polymorphisms (SNPs) in PF10_0347 and only two of these are within the C-
terminal-unstructured region. Of these two, one is located at residue 282 where Adenine is 
changed into Thymine, causing an amino acid change from Glutamine (Q) to Proline (P), the 
other is located at residue 349, where Thymine is mutated into Adenine resulting in change 
of Asparagine (N) into Lysine (K) (Figure 4.1).  
  






Figure 4.1Amino acid sequence of P. falciparum (3D7A) PF10_0347. The shaded 
area represents the amino acid sequence of the cloned unstructured region of MSP-
3.3, hereafter referred to as MSP-3.3C. Coloured letters represent the identified 
non-synonymous SNPs (Data from PlasmoDB). 
 
2.1.2 Predicted protein domains and homologies to other 
P.falciparum proteins 
 The PF10_0347 gene is present only in P.falciparum and no true orthologue has 
been found in any other Plasmodium species, based on sequence alignments.  Bioinformatic 
analysis shows that the derived amino acid sequence contains several different domains. 
MSP-3.3 contains a very short low complexity domain at the N-terminal end and a SPAM 
domain (secreted polymorphic antigen associated with merozoites) in the C-terminal half. 
Other domains such as a leucine zipper domain and other low complexity domains are also 
present. These domains and regions, such as the Glutamic acid-rich domain and the Glycine-
rich domain that were identified by us and by Singh et al. (Singh et al. 2009) are shown in 
Figure 4.2.  
 ClustalW was used to produce a multiple alignment of the MSP-3-like ORFs 
namely, MSP-3 (recently redesignated as MSP-3.1), MSP-6 (MSP-3.2), PF10_0347, (MSP-
3.3), MSPDBL1 (MSP-3.4), MSP-11 (MSP-3.7) and MSPDBL2 (MSP-3.8). Other proteins 
that contain an MSP-3-like ORF have similar N-terminal signal domains to that of MSP-3.3. 
The MSP-3.3 sequence also shows a signature asparagine-arginine-leucine (NRL) sequence 
typical of other members of the MSP-3 protein family. Interestingly, a C-terminal region of 
these proteins is relatively conserved between the proteins (Figure 4.3). MSP-3.3 has one 
unique feature not found in all other MSP-3family members, namely a PEXEL motif, 
usually only found in proteins exported from the intra-erythrocytic parasite into the 
cytoplasm or onto the surface of the host red blood cell (Marti 2004). 
MKKIVNIIFY   ILYLYIYKRN   LVQNENVNKS   NLRKGLSTNN   SENGIKSLKD 
EDEHINIIGD   DFSAFSYGGY   PIYETTGSLG   TGVESVKAID   GESG/ATSMDSK 
PKENKISTEP   GADQVSIGLV   NESDSSLEND   KKKKENVKKE   MLGTEKEGSP 
DSHDSSKEKL   NLNDNSKWSD   FLKNI/MVTFGG FGPTVVHDVS   DTLSDISKDE   
VTQKTTKDIG   STLLDFFLPL   PTKNTNTYEK   KNENKNVSNV   DSKTKSNEKG   
RPPTYSPILD   DGIEFSGGLY   FNEKKSTEEN   KQ/PKNVLESVN LTSWDKEDIV   
KENEDVKDEK   DEDDEEEEEK   YENEIIKQPE   DILDEEEVLE   EEILEENKN/KD 
TVDTSDLEKK   NIPDLSNDNN   YYSLIYKNYK   DNDKSEKTAQ   TLITALISLL 
NGKNELDATI   RRLKHRFMEF   FTYN 




Figure 4.2: Schematic diagram of MSP-3.3 showing predicted structural domains 
and sequence homologies. N-terminal signal domain (bright pink), PEXEL motif 
(Bright green), NRL signature sequence of MSP-3 family (Blue), Glycine-rich region 
(yellow), Glutamic acid-rich region (green), putative leucine-zipper domain (pink), 
SPAM domain (red), and low complexity domains (grey). Two black arrows indicate 
enzyme SUB1 cleavage sites. Two black horizontal lines underneath the diagram 
indicate the regions which have been predicted by Singh et al., to be targets of 
protective antibodies of MSP-3 (Pearce et al. 2005). The dark shaded background 




CLUSTAL O(1.1.0) multiple sequence alignment 
 
MSP-3.3      MKKIVNIIFYIL---YLYIYKRNLVQNENVNK--SNLRKGLSTNNSENGIKSLKDEDEHI 
MSP-3.1      MKSFINITLSLFL-LHLYIYINNVASKEIVKKYNLNLRNAILNNNSQIENEE--NV--NT 
MSP-3.2      MNKIYNITFLFIL-LNLYINENNFIRNELINEKNHNLRNGSMYNNDKILSKN--EV--DT 
MSP-3.4      MKKIYSIFFSLFI-LNLHIYIKNIKCNDLINYNDSNLRNGLLNNSLDLTNGL-NN-K--- 
MSP-3.7      MNKFLNIIFYIFLILNFSFFQSNATSKEIQKDEQKNLRNGSSINNNKNIENK--NDNIET 
MSP-3.8      MIYILSIVFYIFF-LHIDIYVNIYSTCFVVNEGNPNLRNNIINDDELKGKAY-NN-TIDA 
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MSP-3.3      NIIGDDF-----------------------------------------SAF------SYG 
MSP-3.1      TITGND------------------------------------------------------ 
MSP-3.2      NIESNE-----------------------------------------------NSIHESG 
MSP-3.4      ---DNSF------------ID--SKIEEHENKSYQNKDNNISI-----VGQDVPITSVYS 
MSP-3.7      QYEASEY-----------------------------------------IEKQNDILNMYN 
MSP-3.8      NNQNIEYNKNLKHNVNSSHISKFSDIMDQEDKGDNENSHDIKFEEKKNINKSLDAESNYG 
                 .                                                       
 
MSP-3.3      GY----------------------PIYETTGSLGTGVESVKAIDGESGTS-M-D------ 
MSP-3.1      --------------------------FSGGEFLWPGY----------------T------ 
MSP-3.2      ------------------------HKIDGEEVLKANV----------------D------ 
MSP-3.4      SKIINANDLEGNSIDDTKGLSVTNSGFDDGSAFGGGLPFSGYSPLQGNHNKCPDENFCKG 
MSP-3.7      DE----------------------KEKNNNNSLDTNVTKNTVIDNSNKFQSIED------ 
MSP-3.8      IN---EISITGN---DSNSDNSNQNIFPDGSELAGGIPRSIYTIN-LGFNKCPTEEICKD 
                                            :                            
 
MSP-3.3      --------------------------SKPKENKISTEPGADQVSIGLVNESDSSLENDKK 
MSP-3.1      --------------------------EELKAKKAS-----EDAEKAANDAEN-------- 
MSP-3.2      --------------------------DITYKKKNV-----DDSEIPFS------------ 
MSP-3.4      IKNVLSCPPKNSTGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNIN---KVWHRIKD 
MSP-3.7      --------------------------NNVYNKGIF-----VGTGIKLNDSQT-------- 
MSP-3.8      FSNLPQCRKN--VHERNNWLGSSVKNFSSDNKGVLVPPRRQSLCLRITL---QDFRTKKK 
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MSP-3.3      KKENVKKEML-------------------------------------GTEKE---GSPDS 
MSP-3.1      -------------------------------------------------------ASKEA 
MSP-3.2      ------------------------------------------------------------ 
MSP-3.4      EK-NFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNI 
MSP-3.7      -------------------------------------------------------TS--- 
MSP-3.8      KEGDFEKFIYSYASSEARKLRTIHNNNLEKAHQAIRYSFADIGNIIRGDDMMDTPTSKET 
                                                                         
 
MSP-3.3      HDS--------SKEKLNLNDNSKWSDFLKN---------------------------I-- 
MSP-3.1      EEA--------AKEAVNLKESDKSYTKAK------------------------------- 
MSP-3.2      --------------GYDI---QATYQF--------------------------------- 
MSP-3.4      NRALDKILRN-ETSNDKIKKRVDWWEANKSAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQ 
MSP-3.7      DNY--------KNERYQIDDEKLKYGGSFD------------------------------ 
MSP-3.8      ITYLEKVLKIYNENNDKPKDAKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNIDDIPQ 
                            .                                            
 
MSP-3.3      --VTFGGFGPTVV-----------HDVSDTLSDISKD-EV-------------------- 
MSP-3.1      ----------EA--------------C-TA---ASKAKKA-------------------- 
MSP-3.2      ----------------------------PS---TSGGNNV-------------------- 
MSP-3.4      YLRWFREWGTYVCSEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWV 
MSP-3.7      --TIFSGFVNLLT-----------PSS-PTQNDGSTGRNV-------------------- 
MSP-3.8      FLRWFREWGTYVCEESEKNMNTLKAVCFPKQPRT-EANPALTVHENEMCSSTLKKYEEWY 
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MSP-3.3      -----------------------------------------------------------T 
MSP-3.1      -----------------------------------------------------------V 
MSP-3.2      -----------------------------------------------------------I 
MSP-3.4      NRRRPEWKGQCDKFEKEKSKYEDTKSITAEKYLKEICSECDCKYKDLDNTFKEFKDNVTL 
MSP-3.7      ------------------------------------------------------------ 
MSP-3.8      NKRKTEWTEQSIKYNNDKINYTDIKTLSPSEYLIEKCPECKCTKKNLQDVFELTFDGKAL 
                                                                         
 
MSP-3.3      QKTTKD----------------IGSTLL--DFFLPLP---TK------------------ 
MSP-3.1      ETALKA----------------KDDAEK--SSKADSISTKTK------------------ 
MSP-3.2      PLPIK------------------QSGEN--QYTVTSISGIQK------------------ 
MSP-3.4      LKAVIDNKKNQDSLTTTSLSTSINSVRDSSNLD--------------------------- 
MSP-3.7      PPPSEP----------------NVDTPD--PPTAPAP----------------------- 
MSP-3.8      LEKLKKEESP--------VSNSVNALPEPGQITLPDPSLKQTTQQENQPVVETPVTTAVI 
                                                                         
 
MSP-3.3      -----------NTNT--YEKKNENKNVSN-VDS-KTKSN----E-KGRPPTYSPILDDGI 
MSP-3.1      --------------E--YAEKAKNA--YEKAKNAYQKANQAVLK-AKEASSYDYI--LGW 
MSP-3.2      -----------GANG--LTGATENITQVVQANSETNKNPTSHSN-STTTSLNNNI--LGW 
MSP-3.4      --QRGNITTSQGNSH--R------ATVVQQV-DQTNRLDNVNSVTQRGNNNY----NNNL 
MSP-3.7      ------------------VKVPEDAKLSSSPRPEGPRANNRNEN-NQNTDPYNHY--FAW 
MSP-3.8      NEHQGQTEPNKGDNNNERENHESNVGSIQEV-NQGSVSEESHSK-TIDPSKI----DDRL 
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MSP-3.3      EFSGGLYFNEKKSTEENKQKNVLESVNLTSWDKEDIVKENEDVKDEKDEDDEEEEEKY-E 
MSP-3.1      EFGGGVPEH--KKE-----ENMLSHLYVSSKDKENISKENDDVLDEKEEEAEETE----- 
MSP-3.2      EFGGGAPQN--GAAEDKKTEYLLEQIKIPSWDRNNIPDENEQVIEDPQEDNKDEDEDE-E 
MSP-3.4      ERGLGSGALPGTN-IITEEKYSLELIKLTSKDEEDIIKHNEDVREEIEEQQE-------- 
MSP-3.7      EIGGGAPTY--KPENNKNDNILLEHVKITSWDKEDIIKENEDTKREVQETEDTDETED-T 
MSP-3.8      ELSSGSSSLEQHSKEDVKKGCALELVPLSLSDIEQIANESEDVLEEIEEEINTDGEIEYI 
            * . *                 *. : :   * ::* ...::.  : :*  .         
 
MSP-3.3      NE-------------IIKQPEDILDEEE----------VLEEEILEENKN---------- 
MSP-3.1      --EEELEEK--NEEET----ESEISEDE----------EEE-EEEEEKEEENDKKK---- 
MSP-3.2      TETENLETEDDNNEEIEENEEDDIDEES----------VEEKEEEEEKKEEEEKKE---- 
MSP-3.4      -------D-------IEED-EEELENEGEETKEEDDEEKNETNDTEDTDDTEDTEDIEEE 
MSP-3.7      DETEETEDM---------EDENEIVEDQ----------LQENEDDEDNVNLEDI------ 
MSP-3.8      TEEEIKED-------IEEETEEDIEEETEEE---TEEETEEEADEETVKEIEDKPE--QE 
                                *. : ::             *    *   :           
 
MSP-3.3      -----------DTVDTSDLEKKNIPDLSNDNNYYSLIYKNYKD-NDKSEKTAQTLITALI 
MSP-3.1      ---EQ--EK----EQSN-----ENNDQKKDMEAQNLISKNQNNNEKNVKEAAESIMKTLA 
MSP-3.2      ---EKKEEKKPDNEITNEVKEEQKYSSPSDINAQNLISNKNK-KNDETKKTAENIVKTLV 
MSP-3.4      NKEKELSN-------QQQSEKKS--ISKVDEDSYRILSVSYKD-NNEVKNVAESIVKKLF 
MSP-3.7      -------NK---NTRNDIFEEQIKLDSTQDDKAQKLISNEYK--KTEEKKSLEDHVNLLF 
MSP-3.8      IKNKSLEEK-QIDKNTDTSEKKGFNNSEKDEKARNLISKNYKN-YNELDKNVHTLVNSII 
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MSP-3.3      SLLNGKNELDATIRRLKHRFMEFFTYN 
MSP-3.1      GLIKGNNQIDSTLKDLVEELSKYFKNH 
MSP-3.2      GLFNEKNEIDSTINNLVQEMIHLFSNN 
MSP-3.4      SLFNDNNNLETIFKGLTEDMTDLFQK- 
MSP-3.7      NFLQTNNQLDPSLKDLENELTFFLNNY 
MSP-3.8      SLLEEGNGSDSTLNSLSKDITNLFKN- 
             :::  *  :  :. * . :   :    
 
Figure 4.3: Multiple alignments of MSP-3 like ORFs produced by Clustal Omega. 
Predicted domains were showed; N-terminal signal domain (Bright Pink), PEXEL 
motif (Bright green), Signature sequence of MSP-3 family (Blue), Glycine rich motif 
(yellow), Glutamic acid rich (green), Leucine-zipper domain (Purple).  
 
2.1.3 Prediction of unstructured regions in MSP-3.3 and selection of 
sequence for  
 For prediction of unstructured regions in MSP-3.3, the derived amino acid sequence 
of PF10_0347 from P. falciparum (3D7 strain) was analysed for unstructured domains using 
IUPred (http://iupred.enzim.hu/) (Dosztányi et al. 2005). IUPred analysis of the protein 
expressed by PF10_0347 gene showed that it was predominantly unstructured; only 41 
residues at the C-terminal end are predicted to have any stable secondary structure. In this 
project, I cloned and expressed part of the C-terminal region of MSP-3.3 that showed high 
disorder tendency. This spanned the region from nucleotide 1,409,962 to 1,410,358 on P. 
falciparum chromosome 10. This unstructured region contains part of the predicted SPAM 
domain, the glutamic acid-rich region and several regions of predicted low-complexity. All 
these domains contain amino acid residues that are also common in intrinsically unstructured 










Figure 4.4: Disorder tendency prediction of the putative protein PF10_0347 (MSP-
3.3) according to IUPred (Dosztányi et al. 2005). Numbers on the x-axis represent 
the position of amino acid residues in MSP-3.3. The shaded area shows the region 
of MSP-3.3 that was cloned and expressed in this study.  
2.2 Gene cloning 
 Since the PF10_0347 gene has no intron, it can be directly amplified from genomic 
DNA by PCR and then cloned and transformed into an expression host. A 300bp gene 
fragment of the unstructured-region of PF10_0347 was amplified from 3D7a genomic DNA 
using the forward primer (5’ ATCATATGGAGAAGAAAAATGAAAATAAAAATGTAC 
3’ and the reverse primer 5’ GTGATTTAGAAAAGAAATAAGGATCCCAT 3’. Cycling 
conditions for PCR were performed as follows: initial denaturisation 94C for 2 minutes, 
followed by 30 subsequent cycles with 1) denaturing at 94C for 30 seconds, 2) annealing 
50C for 30 seconds, and 3) primer extension at 72C for 30 seconds. The resulting PCR 
product of approx. 300bp was then purified and cloned into pCR4-TOPO using the TOPO 
TA kit for cloning (Invitrogen, UK), and transformed into E.coli TOP10 cells. The insert was 
sequenced to ensure that it was free of mutations. This fragment of PF10_0347 was then 
cleaved from pCR4-TOPO plasmid by sequentially cutting with restriction enzymes NdeI 
and BamHI (NEB). The purified fragment was then cloned into pET24a plasmid (Novagen, 
UK). The inserted fragment was again checked by restriction enzyme analysis and DNA 
sequencing before a recombinant plasmid stock was made. 
2.3 Protein expression  
 Fresh transformation of recombinant plasmid of MSP-3.3C into the expression host, 
E.coli BLR (DE3) pLysS (Agilent Technologies Ltd, Stockport, UK) was performed for 
each round of protein expression. Cells were grown in selective media with 1% (w/v) 
glucose supplementation overnight and diluted the next morning 1:200 in culture media (LB 
or Terrific broth with 0.5% glucose). Cultures were grown at 37C in a shaking incubator at 
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200 rpm. Culture density was monitored until the OD600nm was 0.6, before Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added at a final concentration of 1mM to induce protein 
expression. Induced cultures were incubated at 30C for either 4 hours or overnight (12-15 
hours) before being harvested by centrifugation at 5,000 G at 4C for 15 minutes at 4C. 
Culture samples were taken at appropriate time points and use to detect the expressed protein 
and to measure the level of expression by resolution on SDS-PAGE.  
 MSP-3.3C protein was expressed readily in E. coli BL21 (DE3) LysS using standard 
LB media supplemented with glucose. Cell cultures grew exponentially and reached mid-log 
phase (OD600nm = 0.6) 6 hours after incubation (Figure 4.5 Panel A). Two hours after 
induction, it could be visualised on SDS-PAGE as a band of just under 28 kDa in size 
(Figure 4.5 Panel B). Cell cultures were usually harvested 4 hours after induction, yielding 
around 7 grams of wet cells per litre of culture. Alternatively, cell cultures could be further 
incubated overnight (16 hours). This longer expression period did not increase biomass of 
the culture, although a MSP-3.3C band of somewhat higher intensity could be detected on 
SDS-PAGE (data not shown). Cells cultured in Terrific broth produced similar growth 
curves. However, the biomass from cultures grown in Terrific broth was slightly lower than 
















































Figure 4.5: A) Growth curve of MSP-3.3C before and after induction. Cell culture 
grew exponentially until it reached log phase, when the culture was induced (see 
arrow). B) Amount of MSP-3.3C protein, shown as a protein product just under 28 
kDa in size: 1=cell lysate before induction, 2-5 = cell lysate from culture at 1 hour 
intervals post-induction respectively, 6= cell lysate 16 hours (overnight) after 
induction. 
2.4 Protein purification 
 Cell pellets were resuspended in 25mM Tris-Cl pH8.0 at a ratio of 10ml buffer per 
0.5-1g of cells. Three cycles of freeze-thawing were performed to rupture the cells. Soluble 
cell lysate proteins were then separated from the insoluble fraction by centrifugation at 
15,000 G for 15 minutes at 4C. As the solution became viscous, 1 unit per ml DNase 
(Benzonase, Novagen) was added and the lysate incubate on ice until viscosity decreased.  
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2.4.1 Heat treatment 
 NaCl was then added to the lysate to a final concentration of 250mM, and then 
incubated in a water-bath at 90C for 20 minutes, transferred to ice and incubated for further 
20 minutes. Denatured proteins were removed by centrifugation at 15,000 G at 4C for 20 
minutes. The heat-treated supernatant protein solution was dialysed extensively against 
25mM Tri-Cl pH 8.0 (SnakeSkin Dialysis Tubing, 3.5K MWCO; Thermo Scientific).  
 High temperature treatment (90C) provided partially purified MSP-3.3C. This 
method allowed the denaturation of globular protein contaminants and other non-soluble 
complexes to be excluded, while MSP-3.3C remained in the soluble fraction. By empirical 
experimentation, I found that a concentration of 250mM NaCl in the buffer was essential for 
MSP-3.3C solubility. Without additional salt in the heat treatment buffer, more of the MSP-
3.3C protein was observed in the non-soluble fraction and less was recovered as soluble 
protein (data not shown). After this heat treatment, the MSP-3.3C could be seen as the major 
soluble protein, which was visualised by Coomassie blue stained SDS-PAGE (Fig 4.6, lane 
1).  
2.4.2 Anion exchange chromatography 
 An Anion Exchange Chromatography CaptoQ FF column (GE Healthcare, UK) was 
used as a final polishing step to purify MSP-3.3C protein to homogeneity. The columne was 
equilibrated with five column volumes of binding buffer (25mM Tris-Cl pH8.0) before 
applying the clarified, heat-treated lysate. The column was then washed with twice the 
column volume of binding buffer. Protein fractions eluted out at the different concentration 
of salt were measured using the BCA protein assay (Pierce) and examined for quality and 
purity on SDS-PAGE and Western Blotting. Details of the BCA Assay, SDS-PAGE and 
Western blotting are described in Chapter 2 (Materials and Methods section 15). The ImageJ 
program was used to estimate purity of protein samples.  
 For the first trial, a continuous gradient of NaCl from 0 to 1M in binding buffer was 
used in order to optimise the purification. A continuous gradient of NaCl concentration in 
the buffer ranging from 0 to 1 M was applied to the column continuously during elution step. 
The eluted fractions were measured for protein concentration at 280 nm absorbance. These 
eluted samples were also subjected to further analysis. They were measured for protein 
concentrations by the BCA assay and run on SDS-PAGE gels in order confirm its identity, 
size and purity. The initial results showed that MSP-3.3C was eluted from anion exchange 
column by the eluting buffer that contains approximately 300 to 400 mM NaCl (Figure 4.6).  
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Figure 4.6: (A) Anion exchange chromatography profile of gradient elution for MSP-
3.3C; Blue line represents OD at 280 nm, Red line represents conductivity of elution 
buffer. MSP-3.3C was found in the 3rd peak of the eluting sample, which can be 
collected during application of approximately 30-40% of elution buffer. (B) BCA 
assay of eluted samples showing that most of the proteins can be collected during 
30% elution and 40% elution respectively. (C) SDS-PAGE shows protein samples 
collected at different points during elution (M=marker, 1=lysate, 2=fractions contain 
MSP-3.3C product. Black arrow indicates samples containing MSP-3.3C 
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 Based on this information, the protocol was further developed to determine 
conditions that provided the best yield of MSP-3.3C with the lowest level of contaminants. 
Using step-wise elution conditions, buffers containing NaCl concentrations ranging between 
150 to 500 mM were tested sequentially. Samples from each elution step were again 
analysed using the same methods as described earlier. The results from each purification 
were used to adjust the eluting conditions to narrow down the ranges of concentrations 
required for the greatest elimination of contaminants and the purest MSP-3.3C elution 
profile. In this study, we developed a successful 3-step-elution method for anion exchange 
chromatography and purification of MSP-3.3C which involved (1) contaminant elimination 
with 200mM NaCl, (2) 350mM NaCl elution of the MSP-3.3C protein and (3) a column 
washing step using 1M NaCl (Figure 4.7).  
 This optimised protocol was suitable for shaking-flask culture, yielding almost 10 
mg of MSP-3.3C per 1 litre of cell culture or approximately 2.45 mg per each gram of wet 
cells. Using the ImageJ program (Image J http://rsb.info.nih.gov/ij/index.html), the purity of 
MSP-3.3C in each purification step including cell lysate, heated lysate and final purified 
product from chromatography column was estimated. It was established that the final 
product is at 92.64% pure. Even though this purification method provided high purity 
protein, there was a considerable loss of the desired protein during each step of purification 
(Table 4.1).  
 Purified MSP-3.3C protein was dialysed extensively against PBS. The protein was 
concentrated, using a Vivaspin 6 concentrator (Vivaproducts, to a suitable storage 
concentration (around 1mg mL
-1
) before being filtered through a 5 kDa NMWL Amicon 

















Figure 4.7: Coomassie Blue stained SDS- PAGE from each step of purification of 
MSP-3.3C.  M=marker, 1, culture before induction; 2, culture at 4hours after 
induction; 3, soluble proteins from cell lysate; 4, heat-treated lysate; 5, anion 














% Yield recovered 
from previous 
purification step 




27.04 7.21 76.83 5.54 59.76 
AEX product 9.96 2.65 92.64 2.45 44.22 
 
Table 4.1: Amount of MSP-3.3C recovered during each step of purification. 
Concentrations of protein were measured by BCA assay. Percentage of purity was 
analysed from intensity of bands on SDS-PAGE and calculated using ImageJ. 
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2.5 Properties of MSP-3.3C 
2.5.1 Molecular weight and pI 
 Protein products from each step of purification were sampled and investigated for 
purity and quantity by SDS-PAGE and BCA protein assay. MSP-3.3C is visualised as ~25 
kDa protein on Coomassie Blue stained SDS-PAGE gels (Figure 4.6). Interestingly, this 
observed molecular weight estimated by migration in SDS-PAGE was significantly different 
from the results of in silico analysis and mass spectrometry.  
 Molecular weight and pI of MSP-3.3C were predicted by the Compute pI/Mw tool 
(http://web.expasy.org/compute_pi/) (Gasteiger et al. 2005). Based on the amino acid 
sequence of this molecule, MSP-3.3C was predicted to have the molecular weight of 15.41 
kDa and a theoretical pI of 4.22. Mass spectrometry confirmed this prediction with an 
observed molecular weight of 15.57 kDa (Figure 4.8).  
 
 
Figure 4.8: Diagram of mass spectrometry result showed that major product of final 
purified MSP-3.3C. was 15.57 kDa protein. MSP-3.3C protein was prepared in PBS. 
The protein mass was analysed by ESI (electrospray ionisation) mass spectrometry. 
X-axis represents a relationship between the mass to charge ratio (m/z) and Y-axis 
represents signal intensity of the ions (%intensity).  
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2.5.2 Circular Dichroism (CD) 
 The lack of predicted 3D structure in MSP-3.3C protein was confirmed by circular 
dichroism. MSP-3.3C was dialysed in 10mM NaH2PO4 pH8.0 to a concentration of 2 mg/ml 
and the CD spectrum evaluated on a JASCO-810 spectropolarimeter. The measurements 
were taken over a wavelength range of 185 to 285 nm at 25ºC, pH 8.0 with a 1 mm path 
length cuvette (Centre for Translational and Chemical Biology, University of Edinburgh). 
 The CD spectra obtained from MSP-3.3C showed a single deep spectral minimum 
around 200 nm, a Figure close to zero at 220nm, and no maxima observed in the far UV, 
which corresponds to a protein with a lack of secondary structure (Tompa 2002) (Figure 
4.9). The spectrum shown indicates no evidence for the presence of any significant amount 









Figure 4.9: Circular dichroism profile of MSP-3.3C showing the deep valley at 
220nm, characteristic of unfolded proteins. 
2.6 Antigenicity of MSP-3.3C 
 ELISA and IFA protocols used are as described in Chapter 2. (Materials and 
Methods section 19 and 20). For ELISA, MSP-3.3C was coated onto plates at a 
concentration of 0.5 g l
-1
 in coating buffer. Sera of rabbits and mice were tested across a 
range of doubling dilutions from 1:1000. Human sera were tested at 1:500 dilution.  
 Human sera from malaria-endemic regions (Sudan, Malawi, Ghana, and Gabon) 
were used in ELISA to assess the antigenicity of the MSP-3.3C antigen. A panel of 98 sera 
selected as positive for at least one other merozoite surface proteins (MSP-1 or MSP-2) were 
used to assess the frequency and strength of recognition of MSP-3.3C in naturally exposed 
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individuals. Serum IgG reactivity with MSP-3.3C was weak in all sera tested, with ELISA 
readouts <OD 1.0 in all samples tested at 1:500 dilution. Frequency of antibody positivity 
was lower than for other conserved antigens such as MSP-119. Of the 98 sera tested, 41 sera 
were also positive for MSP-3.3C. 
Correlation between immune recognition of MSP-3.3C and other parasite surface 
proteins was also tested. MSP-3.3C-positive sera were also positive for MSP-7 (Spearman’s 
Rho=0.4050; p<0.0001), and to MSP-119  (Spearman’s Rho=0.5057; p<0.0001) (Figure 
4.10). However, there was no correlation between antibody responses to MSP-1 Block 2 
antigens and MSP-3.3C (Data not shown). 
        







Figure 4.10: Correlation between antibody reactivity of malaria-exposed human sera 
to MSP-3.3C and reactivity with MSP-7 (Panel A) and MSP-119 (Panel B). 
 
 Human sera that were antibody positive for MSP-3.3C antigen were further analysed 
for IgG subclasses. Specific IgG to MSP-3.3C in these sera were biased towards IgG3. There 
was a correlation between reactivity of IgG1 and IgG3 in ELISA assays (Spearman’s 
rho=0.3450; p<0.0001), but this correlation was heavily biased towards the IgG3 subclass 
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Figure 4.11: Specific IgG3 and IgG1 subclass reactivity in the 98 human sera to 
MSP-3.3C. Reactivity with MSP-3.3C was positively but weakly correlated. The 
majority of MSP-3.3C positive antibodies in these selected sera were however 




 Purified MSP-3.3C was used as an immunogen to test for immunogenicity in mice, 
in combination with two adjuvants that are licensed for use in humans. Two groups of 5 
outbred female MF1 mice (Mus musculus) were immunised with the MSP-3.3C protein 
antigen in combination either with 0.64% Alum (Alhydrogel) or CoVaccine HT (detailed 
description of these adjuvants can be found in Chapter 2. (Materials and Methods section 
12.2). The immunogen was prepared by mixing 20µg of protein antigen with adjuvant at a 
1:1 ratio. A total of 3 doses were given subcutaneously at 30 day intervals. Mice were 
exsanguinated under terminal anaesthesia on day 70.  
 Results showed that immunisation of this antigen with these two adjuvants yielded 
specific antibodies that can be detected by ELISA. Sera from only 2 out of 5 mice in the 
CoVaccine HT group showed distinct reactivity to MSP-3.3C, while sera from all mice in 
the Alum group showed low reactivity to this antigen. The median ELISA OD for specific 
antibody responses of the two groups, using the different adjuvants, were very close; 0.313 
for the Alum group and 0.5245 for the CoVaccine HT group. There was no statistically 
significant difference in the ELISA reactivity between these two groups (Mann Whitney test; 
p>0.05) (Figure 4.12 panel A) 
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2.7.2 Rabbits 
 Two rabbits (code numbers 6066 and 6067) were immunized intramuscularly with 
five doses each of 100 µg of the recombinant MSP-3.3C protein antigen, formulated with 
Freund's complete/incomplete adjuvant (Biogenes GMBH, Berlin, Germany). Animals were 
immunized on days 0, 7, 14, 28 and 42. Blood samples were collected for serum on days 0, 
8, and 49. Approximately 70 ml of sera was collected from each rabbit at the end of the 
immunisation schedule. In rabbits, with this stronger adjuvant combination, higher titre 
antibody responses were observed. Results from ELISA showed that antigen specific titre to 
MSP-3.3C in each immunised rabbit increased with each immunisation, although reactivity 
of the sera from rabbit number 6066 (R6066) increased more rapidly than that of rabbit 6067 
(R6067). However, the final serum sample from both animals reached OD492nm of over 1 in 
both cases (Figure 4.12B). 
 
  




















Figure 4.12: ELISA results show reactivity of MSP-3.3C immunised sera. (A) Mice 
that were immunised with MSP-3.3C in combination with Alum showed lower 
median of reactivity to the MSP-3.3C antigen comparing with the CoVaccine HT 
group. (B) Level of rabbit-antisera response to MSP-3.3C had increased though 
course of immunisation. Both animals were immunised on days 0, 7, 14, 28 and 42 
(arrow). Sera were collected three times, on the day 0, 8 and 49.  
 
2.8 Purification and Characterisation of Anti-MSP-3.3C antibodies  
2.8.1 Covalent coupling of MSP-3.3C to an NHS-Sepharose column  
 MSP-3.3C specific IgG was purified using a NHS-activated Sepharose column, 
which had been prepared by coupling it with purified MSP-3.3C protein. The column was 
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concentration of 7mg mL
-1
 in coupling buffer (0.2 M NaHCO3, 0.5 M NaCl, pH 8.3) was 
bound to a 1 mL NHS-activated Sepharose column, incubated at room temperature for 30 
minutes, and washed sequentially with Buffer A (0.5M ethanolamine, 0.5M NaCl, pH 8.3) 
and Buffer B (0.1M sodium acetate, 0.5M NaCl, pH4) according to the manufacturer’s 
protocol. The column was finally washed with coupling buffer and stored in 0.05 M 
Na2HPO4 + 0.1% NaN3, pH 7.0 until use.  
2.8.2 Antibody purification 
 Sera from rabbits R6066 and R6067, immunised with MSP-3.3C (see section 2.7 
above) were purified for either total IgG or MSP-3.3C-specific IgG using affinity 
chromatography protocols described earlier in Materials and Methods section 13. 
 Total IgG from sera of the rabbits immunised with MSP-3.3was purified using a 
Protein G column. Each of ml serum yielded 13 to 14 mg of total IgG. This purified IgG was 
then further purified for specific MSP-3.3C IgG and total IgG depleted of MSP-3.3C-
specific antibodies (hereafter referred to as depleted IgG). An aliquot of 7 ml serum from 
R6066 yielded 1.5 mg of MSP-3.3C specific IgG and 78 mg of depleted IgG. For R6067, 
2mg of MSP-3.3C specific IgG and and 96mg of depleted IgG were produced from the same 
volume of serum. 
2.8.3 Antibody specificity  
 ELISA and IFA were used to confirm the specificity of these IgG preparations for 
purified MSP-3.3C protein as well as to native MSP-3.3C protein on the surface of fixed 
parasites. Depleted IgG from both rabbits showed very low reactivity to MSP-3.3C by 
ELISA and gave negligible fluorescent signals in parasite IFA, whereas total and MSP-3.3C-
specific IgG from these two rabbits showed very strong reactivity to both purified protein 
and native protein on fixed parasites (Figure 4.13 and Figure 1.14). ………………….


















Figure 4.13: ELISA titrations of purified rabbit antibody reactivity with MSP-3.3C 
protein. Total and MSP-3.3C-specific IgG purified from both rabbits R6066 and 
R6067 recognised MSP-3.3C protein, while ELISA reactivity of the depleted IgG 
pools from both rabbits was very low. 
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 Dilutions  
Sample 1/100 1/200 1/400 1/800 1/1600 End point 
concentration 
(µg/ml) 
Sera R6066 +++/++ ++/++ +/+ +/- -/- n/a 
Sera R6067 +++/++ ++/++ ++/+ +/- -/- n/a 
Total IgG R6066 +/+ +/- -/-   252 
Total IgG R6067 +/+ -/-    284 
Specific IgG R6066 ++/++ +/- -/-   4.3 
Specific IgG R6067 +++/++ ++/+ +/- -/-  2.45 
Depleted IgG R6066 -/- -/-    n/a 
Depleted IgG R6067 -/(+/-) -/-    n/a 
 
Table 4.2: Schizont-rich cultures of P. falciparum (Wellcome) were used to make 
IFA slides to test serum and IgG reactivity to fixed malaria parasites. IFA signals 
were scored according to the brightness of parasite-specific FITC fluorescence 
against background, with location of parasites on each slide confirmed by DAPI 
staining. Each sample dilution was tested in duplicate. IFA signal scores were given 
as very strong (+++), strong (++), weak (+), indeterminate (+/-) and no signal (-/-). 
Concentrations of the tested antibodies were measured by BCA assay and the end 
























Figure 4.14: IFA reactivity with fixed parasites of purified antibodies from anti-MSP-
3.3C rabbit sera. Panel A: MSP-3.3C specific IgG, MSP-3.3C-depleted IgG and total 
IgG from rabbit R6066 Panel B: rabbit R6067. All the samples showed here were 
tested at 1/100. 
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2.9 MSP-3.3 stage-specific localisation 
2.9.1 Parasite culturing and IFA slide preparation 
 Parasites of the Wellcome strain were synchronised at ring stage over several cycles 
using treatment with 5% sorbitol treatment. Samples were sequentially collected at ring, 
trophozoite, and schizont stages. In each case the culture was washed twice in RPMI and 
resuspended in PBS to achieve approximately 5% parasitaemia and 2% haematocrit. 25 l of 
this culture was applied to each spot of multispot glass slides (Hendley, Essex) and dried. 
Slides were wrapped in lint-free tissue and sealed in bags containing silica dessicant and 
stored at -20C until use.  
2.9.2 MSP-3.3 localisation 
 Indirect immunofluorescent assays (IFA) showed that the rabbit sera were able to 
recognise the surface of blood stage parasites. IFA titres of each of the 2 rabbit samples were 
similar for all blood stages (rings, trophozoite, schizonts and free merozoites). The intensity 
of the IFA signal was weak at ring stage, and increased as parasites developed in the 
erythrocyte, with the strongest signal at the schizont stage (Figure 4.15). The target of anti-
MSP-3.3C antibodies appeared to be evenly distributed over the surface of the parasite, and 





















Figure 4.15: IFA with anti MSP-3.3C IgG. MSP-3.3 is present throughout the blood-
stage cycle (from left to right: ring (R), early trophozoite (ET), middle stage 
trophozoite (MT), later stage trophozoite (LT), schizont (S) and free merozoites (M)) 
and is located on the surface of parasites. IFAs were performed using purified total 
IgG. DAPI-staining shows the location of parasite DNA.  
 
2.10 Growth Inhibition Assay (GIA)  
 P. falciparum (Wellcome strain) parasites were cultured according to the protocol 
described earlier in Chapter 2. (Materials and Methods section 23). Parasites were 
synchronized at least twice by sorbitol treatment. GIA assays were started at the mature 
trophozoite stage.  GIA assays were performed in triplicate for each antibody tested. MSP-
3.3C total IgG, depleted MSP-3.3C IgG, anti-AMA-1 IgG (positive control) and naïve IgG 
control (negative control) were titrated from 6mg mL
-1 
to 0.75 mg mL
-1
, while specific MSP-
3.3C IgG was titrated from 1mg mL
-1
 to 0.125mg mL
-1
. 50l of antibody sample at the 
desired concentration was added to each well in a sterile 96-well plate (Greiner BioOne, 
UK). 50l of synchronised trophozoite stage parasite culture (in 2x concentration of normal 
culture media) were then added to each well to give a final concentration of 0.5% 
parasitemia and 4% haematocrit and incubated at 37C in a humidified CO2 incubator at 5% 
CO2. After 40-42 hours, control (i.e. untreated) parasite cultures on each plate were checked 
to confirm that they had reached trophozoite stage, by making Giemsa-stained thin smears 
from these wells. Parasite cultures were then harvested for flow cytometry and pLDH 
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analysis. Thin smears were also taken from each well and Giemsa stained to assess parasite 
morphology in test and control cultures.  
 For assessment of pLDH activity assay, 50l of parasite culture from each well was 
harvested and washed in ice cold PBS by centrifugation. All but 50l of the supernatant was 
removed and then plates were frozen in order to lyse parasites. For the pLDH assay, plates 
were brought to room temperature, 100l freshly prepared LDH buffer (100 mM Tris pH 8) 
containing 40 mM sodium L-lactate, 0.25% Triton X-100, 0.5 µg of 3-acetylpyridine 
adenine dinucleotide (APAD), 0.1 Unit of Diaphorase and 20 µg of Nitro Blue Tetrazolium) 
was added into each well. Plates were incubated in the dark at room temperature and read at 
650nm (Multiskan Ascent, Labsystems Inc.) after 5, 10, 15, and 30 minutes. 
 For flow cytometry, 30l culture from each well was stained with Coriphosphine O 
at 2g mL
-1
 and parasitaemia measured with a Becton Dickinson LSRII flow cytometer, 
using 488 nm laser for excitation and FL1 and FL3 channels (525/50nm for green 
fluorescence and 670/24nm for red fluorescence). Flow cytometry data was analysed using 
FlowJo software (Tree Star Inc. Ashland, Oregon). Growth inhibition was calculated using 
the equations:  
 
A) pLDH Growth Inhibition (%) =  100 – [(A650parasites with test antibody – A650uninfected 
red cell control)/( A650parasites with no antibody – A650uninfected red cell control)] x 100 
 
B) Flow cytometry Growth Inhibition (%) = 100 – [(%parasitaemia with test antibody – 
%uninfected red cell control)/(%parasitaemia with no antibody – %uninfected red cell 























Figure 4.16: Scatter plots from Flow Cytometre. A) The area in which the RBC 
population was selected is shown in pink box. The number of event is shown as 
98.2%. B) Scattergram of P. falciparum malaria-negative sample and (Uninfected 
RBC) C) Scattergram for malaria-positive sample (infected RBC) showing the 
parasitemia as 1.43%. Scattergram of the positive control and negative control are 
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Figure 4.17: P. falciparum population when treated with purified anti-MSP-3.3C IgG 
at the concentration of 6, 3, 1.5, and 0.75 mg ml-1. The parasitemias were titrate 
from 0.1, 0.15, 0.77 and 1.28 respectively (for sample 6066; left panel) and 0.12, 
0.54, 1.14 and 1.39 respectively (for sample 6067 (right panel).  
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2.10.1 In vitro parasite inhibition by antibodies to MSP-3.3C 
 Purified total IgG to MSP-3.3C from two rabbits was tested in in vitro parasite 
growth inhibition assays (GIA). A standard pool of purified rabbit anti-AMA-1 IgG (BG98 
standard, BPRC, Netherlands) was used as the positive (i.e. inhibitory) control and purified 
naïve rabbit IgG as the negative control for all assays. Antibodies from both rabbits showed 
remarkably potent growth inhibition against Wellcome strain parasites by both measurement 
of parasite-specific lactate dehydrogenase (pLDH) activity and by flow cytometric analysis 
of parasitaemia. 90-95% inhibition was achieved when parasite cultures were treated with 
the total IgG at the highest concentration of 6mg mL
-1
. The effect was titratable down to 0.75 
mg mL
-1
, the lowest IgG concentration tested in this assay, where inhibition was 15% 
(Figure 4.17A). Similar results were also shown in the measurement of pLDH, where 100% 
inhibition was observed in cultures treated with 6mg mL
-1
 total IgG. A titratable effect down 
to 50% inhibition was observed with IgG at 0.75mg mL
-1
 (Figures 4.18B). The specific 
parasite growth inhibition seen was equivalent in potency to that observed with the control 































Figure 4.18: GIA of P. falciparum (Wellcome) using anti-MSP-3.3C antibodies. 
Purified anti-MSP-3.3C total IgG (from rabbits R6066 and R6067 are shown as 
black line with dark circle and dark square symbol respectively). Inhibition by anti-
AMA1 total IgG (BG98) is shown as a dashed line. Inhibition by total IgG from naïve 
rabbit sera is shown in black line with open circle symbol. Panel A shows results 
obtained using the pLDH assay, Panel B shows flow cytometry measurements of 
parasitaemia in cultures.  
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 To verify this strong inhibitory effect, the assay was repeated five times by myself, 
Dr. Alison Creasey, Dr. Graeme Cowan and Mr. Kakra Dickson. Consistently strong parasite 
killing effects were observed in all assays. At the highest concentration of anti-MSP-3.3C 
IgG (6 mg mL
-1
), 97-100% parasite inhibition was observed, as measured by pLDH assay, 
which titrated to 25-34% inhibition at 0.75mg mL
-1 
IgG (Figure 4.19A). Similar inhibition, 
ranging from 83.4%-85.4% at 6mg mL
-1
 to 7.3-9.2% at 0.75mg mL
-1
 was observed using 
flow cytometry measurements of parasitaemia on aliquots of the same cultured parasite 
material (Figure 4.20A). To confirm these findings independently, aliquots of anti-MSP-
3.3C total IgG were sent for testing to the PATH Malaria Vaccine Initiative Growth 
Inhibition Assay–Reference Center, NIAID, Rockville, USA.  In initial testing, parasite 
inhibition at 6mg mL
-1
 total IgG was reported as 99-100% by pLDH assay. Antibody 
preparations were re-dialyzed and independently tested in the NIAID standard pLDH assay 
at concentrations of 6mg – 0.67mg mL
-1
 IgG. In these assays, inhibition was recorded as 98-
99% at 6mg mL
-1
, titrating to 32-49% at 0.67mg mL
-1
 for the two IgG preparations (Figure 
4.19C). Thus, these potent inhibition results were independently confirmed, with a notable 
degree of similarity, by the GIA Reference Center 
 To exclude the possibility of a non-specific antibody inhibitory effect in the two 
total IgG preparations, GIA was repeated using MSP-3.3C antigen-specific affinity-purified 
IgG, as well as the flow-through IgG (i.e. MSP-3.3C-depleted IgG) collected from an MSP-
3.3C-Sepharose conjugate column. As measured by pLDH assay, MSP-3.3C- specific IgG 
strongly inhibited parasite growth at considerably lower concentrations than total IgG from 
MSP-3.3C immunized rabbits, giving 100% inhibition at a concentration of 1mg mL
-1
, which 
titered to a mean inhibition of 21.6% at 0.125mg mL
-1 
(Figure 4.19B). By contrast, the MSP-
3.3C depleted IgG fraction showed only weak inhibition (mean 41% at 6mg mL
-1
), higher 
than the negative control total IgG from naïve rabbit sera, but this inhibition was not seen at 
lower concentrations (Figure 4.19B). Similar parasite inhibitory effects were observed using 
flow cytometry to detect parasitaemia (Figures 4.20A and 4.20B). Notably, as has been 
observed before in our laboratory (Arnot et al. 2008), flow cytometry measurement of 
parasite nucleic acids gives consistently lower growth inhibition measurements than the 
pLDH assay. This difference is particularly marked when using antibodies in GIA against 
some targets, such as MSP-119 and MSP-3.3C, and less so when measuring growth inhibition 
with anti-AMA-1 IgG (Figures 4.19 and 4.20, panels A and B).  
 
 






















Figure 4.19: GIAs results of P. falciparum (Wellcome) as measured by pLDH. Panel 
A shows the result of the assays using purified anti-MSP-3.3C total IgG, while Panel 
B shows the result when MSP-3.3C antigen-specific affinity-purified IgG and MSP-
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3.3C-depleted IgG were used. Panel C shows the result of the GIA of P. falciparum 


















Figure 4.20: GIAs results of P. falciparum (Wellcome) as measured by flow 
cytometry. Panel A shows the result of the assays using purified anti-MSP-3.3C total 
IgG, while Panel B shows the result when MSP-3.3C antigen-specific affinity-purified 
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2.10.2 MSP-3.3C Antigen Reversal GIA 
 We attempted to reverse the strong inhibitory effect of MSP-3.3C antibodies by pre-
incubating total anti-MSP-3.3C IgG with MSP-3.3C protein prior to the GIA assay. In the 
course of development of the controls for this assay, we found that the MSP-3.3C protein 
itself could exert an inhibitory effect on parasitaemia. As measured by flow cytometry, 6 mg 
mL
-1
 of soluble MSP-3.3C protein showed about 65% GIA inhibition. We speculated that 
these high amounts of protein in the culture medium might be limiting the parasite’s access 
to culture nutrients, or interfering with parasite invasion by blocking unknown erythrocyte 
receptors usually bound by parasite-associated MSP-3.3 during parasite invasion.  
 Recombinant MSP-3.3C protein was then coupled to magnetic beads, using the 
protocol provided by the manufacturer. MSP-3.3C protein at a concentration of 7 mg mL
-1
 
was dissolved in conjugation buffer (0.1M MES, 0.9% NaCl pH4.7) and mixed with 1mL of 
a suspension of MagnaBind Carboxyl Derivatized beads (ThermoScientific). 10mg mL
-1 
EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in coupling buffer was freshly made 
by dissolving 10mg EDC in conjugation buffer. For 1 ml of protein-beads mixture, 10 µl of 
EDC solution was added. The mixture was incubated for 30 minutes at room temperature, 
before excess MSP-3.3C was washed off. The magnetic beads were separated from the 
solution by magnet bar and the supernatant from the coupled beads was aspirated. The beads 
were washed three times with 1 ml PBS. They were stored at 4C before use. BCA assay 
was used to detect non-immobilised MSP-3.3C in the washing solution, and therefore 
estimate the amount of MSP-3.3C bound to the beads. MSP-3.3C protein coupled beads 
were used in ELISA to measure binding to anti-MSP-3.3antibodies.       …………          
 MSP-3.3C in this immobilized form was expected to neutralise MSP-3.3C specific 
antibodies but interfere less with parasite cultures. When tested by the ELISA, it was shown 
that 50 µl of bead suspension can up take at least 5mg mL
-1
 of antibodies in 50µl solution or 
0.25 mg of antibodies (data not shown). In the antigen reversal assay, 20µl of beads 
suspension was therefore added to the culture in the presence of the anti-MSP-3.3C IgG, 
which was titrated as before in GIA from 6mg mL
-1
 to 0.1875mg mL
-1
. Culture with the 
same amount of bead suspension in the absence of antibodies was set up as a control. These 
beads were expected to decrease the inhibitory effect of the antibodies to MSP-3.3C. 
However, not only was the expected reversal effect not observed, but the inhibitory effects of 
antibody were still very strong. The culture that was treated with 6mg/ml of total IgG (from 
rabbit no. 6066 and 6067) and the antigen-coated beads showed inhibition at 79.5% and 
79.24% respectively (Figure 4.21). 
 









Figure 4.21: GIAs results of P. falciparum (Wellcome) as measured by flow 
cytometry shows the result of the assays using purified anti-MSP-3.3C total IgG 
from rabbit no.6066 and 6067 in present of MSP-3.3C-coated beads. 
 
2.10.3 Morphological analysis 
 Microscopic observation of Giemsa stained thin smears from all the GIA 
experiments showed that parasites that had been treated with MSP-3.3C antibodies had 
different morphology from the control groups. The morphology and size of parasites at 
schizont stage from anti-AMA1 treatment wells was very similar to both untreated parasite 
cultures and cultures treated with naïve rabbit IgG. In the presence of anti-MSP-3.3C IgG, 
parasites were smaller in size and had denser morphologies within infected red blood cells. 
High concentrations of anti-MSP-3.3C antibodies (3-6 mg mL
-1
 total IgG or 0.5-1 mg mL
-1
 
of MSP-3.3C specific IgG) resulted in pyknotic parasites and poorly-developed ring stage 
parasites as detected in Giemsa stained smears (Figure 4.22). Normal parasite morphology 
was evident at lower antibody concentrations (0.5-1.5 mg mL
-1
 of total IgG, 0.125-0.25 mg 
mL
-1
 of MSP-3.3C specific IgG). However even at lower antibody concentrations, most 
parasites developed at a slower rate than those in the cultures with naïve rabbit IgG or anti-
AMA-1 control IgG. In addition, some parasites in the cultures that were treated with anti-
MSP-3.3C appeared to be free of their surrounding red cells (Figure 4.22). /////////////////////// 
 Treatment with depleted-anti-MSP-3.3C IgG showed little effect on parasite 
morphology (Figure 4.22). The parasites that were treated with these antibodies were smaller 
in size to the control culture. Morphology of the culture that was treated with MSP-3.3C 
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immobilized to beads was also similar to that of the control. However, when the soluble 
form of the MSP-3.3C was present in the culture, parasites were smaller than those of the 
control and appeared to have arrested at the trophozoite stage rather than developing into 





Figure 4.22: Giemsa stained thin smears of parasite cultures from GIA. 
Morphological abnormalities observed included (A) pyknotic parasites, (B) parasites 
apparently outside red blood cells, (C) collapsed ring stage parasites and (D) 
swollen, vacuolar trophozoites in cultures treated with either total purified anti-MSP-
3.3or specific purified anti-MSP-3.3C IgG.  Anti-AMA1 IgG-treated cultures had 
morphology comparable to that of control cultures treated with naïve IgG. Cultures 
treated with recombinant MSP-3.3C protein, either in solution or on beads are 
shown for comparison.  
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3. Discussion  
3.1 PF10_0347 is conserved and belongs to the MSP-3-multigene 
family 
 The DNA sequence of PF10_0347 is very conserved between isolates. Published 
reports show no evidence that the PF10_0347 gene is under balancing selection (Tetteh et al. 
2005). The few mutations reported are neutral mutations (Pearce et al. 2005), possibly 
created by gene duplication events (Cowman & Crabb 2002). The MSP-3.3 protein has a 
very small number of amino acid variations. Most of the observed point mutations in 
PF10_0347 are synonymous changes, and this high degree of conservation leads to the 
hypothesis that this protein may be crucial for parasite survival (Singh et al. 2009). Non-
synonymous SNPs lead to changes in properties of proteins such as polarity, charge, and 
hydrophobicity. These mutations may also alter tertiary structure in particular regions or 
domains, which may result in change of protein conformation as a whole. Disorder tendency 
is another protein property that likely to be affected by amino acid changes. Using IUPRED, 
all published mutant sequences of PF10_0347 were assessed for the disordered tendencies of 
their protein products. No significant changes in the unstructured regions of the protein were 
seen, and some of variants had even higher average disorder tendency compared to the 
sequence of 3D7  (data not shown). It would seem that even though there are variations in 
PF10_0347 sequence, the structure and functions of this gene product should remain similar, 
unless these mutations are involved in post-translational modifications. 
3.2 Predicted domains of PF10_0347 
 Members of the MSP-3 protein family have neither a transmembrane domain nor a 
GPI-anchor-associated region and thus may be present on the surface of parasite by 
interaction with other surface proteins (Pearce et al. 2005). These MSP-3 protein members 
share 3 major common domains known as the Signature motif domain, the Glutamic acid-
rich domain and the C-terminal region.  
 The Signature motif domain consists of an NLRNA/NLRNG motif and is located 
near the N-terminal of all MSP-3 family protein sequences. For the PF10_0347 gene 
product, there is also a short amino-terminal sequence, RNLVQ, located just before this 
family signature sequence. This short motif (R/KxLxE/Q) is termed the Plasmodium export 
element (PEXEL) (Sargeant et al. 2006) and is important for protein trafficking from the 
parasite into the erythrocyte (Marti et al. 2005). 
 Toward the C-terminus, there is a Glutamic acid rich region (referred to as the acidic 
region in Pearce et. al., 2005). This amino acid sequence has also been found in the MSP-3 
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homologues of P. vivax. Although much larger in size, the MSP-3 homologue in P. vivax is 
located at the same position relative to the C-terminal of the PF10_0347 gene product. This 
suggests that, for these two species, the function of this region is conserved (Pearce et al. 
2005). The role of this domain in the malaria parasite has yet to be confirmed. However, it is 
hypothesized that it may interact with part of a surface protein which is positively charged. 
Thus, it may allow the MSP-3-like proteins to stay on surface of the parasite as peripheral 
membrane proteins (Galinski et al. 1999). Studies on the Glutamic acid rich region in other 
organisms has suggested another possible role for this region. It may act as a calcium-
binding domain (Carafoli 1997) and may be involved in the membrane fusion process 
(Grishanin et al. 2002). These interesting data suggest that this region may responsible for 
interaction of MSP-3.3 with other surface proteins of the parasite or may also play a role in 
interactions with the host cell.  
 The C-terminus of the MSP-3 protein family is also relatively conserved, according 
to sequence alignments. It contains heptad repeats of which the first and fourth residues are 
hydrophobic amino acids. This pattern of amino acid sequence is known to form an -helical 
structure which is also known as a leucine-zipper. According to a biophysical study on the 
C-terminal region of MSP-3, this leucine-zipper region allows the MSP-3 molecule to be 
self-assembled, forming a tetrameric structure, suggesting that other proteins that contain 
this domain may also form this intermolecular structure (Gondeau et al. 2009). The leucine-
zipper domain was demonstrated to be essential for the trafficking of MSP-3 to the 
parasitophorous vacuole (Mills et al. 2002). Apart from this function, it may also have a role 
in promoting efficient binding of other proteins; using the C-terminal domains as a core, they 
can be assembled as branches of a homo-oligomer. Oligomeric structures which have 
binding domains protruding from the core can have high avidity for their targets due to their 
multivalency (Terskikh et al. 1997).  
 Sequence alignments and results from cross-reactivity assays of antibodies raised to 
the glutamic acid-rich regions of these proteins suggest that they have very similar epitopes, 
except for MSP-3.3 which shows the lowest level of antibody cross-reactivity (Singh et al. 
2010; Pearce et al. 2005; Demanga et al. 2010). Apart from these long common domains, 
there is a small region known as the glycine-rich domain. This short motif is centrally 
located, just next to the glutamic acid-rich region, in MSP-3, MSP-6, MSP-11 and MSP-3.3. 
The function of this small domain still remains unknown, but it has been shown to be a target 
of antibodies in ADCI assays (Oeuvray et al. 1994). 
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3.3 Expression and localisation of MSP-3.3 
 The members of the MSP-3 family have unique expression profiles compared with 
other gene families expressed during the asexual blood stage. They are all located 
continuously on the same chromosome and lack introns, a characteristic of genes that are 
rapidly regulated (Jeffares et al. 2008). Interestingly, the expression profile of PF10_0347 is 
different from other family members. Unlike MSP-3 or MSP-6, which have only one peak of 
expression at 42 hr (mid-schizonts), the PF10_0347 expression profile peaks at 14 hours 
after invasion (mid-late trophozoite) and then again at 36 hours (mid-schizont) (Bozdech et 
al. 2003) . This multiple expression peak profile is characteristic of genes with unusual 
signal time-modulated expression and PF10_0347 is one of 21 genes with this expression 
profile (Fedorov & Leinine.). This unique expression profile raises further questions about 
the role of MSP-3.3 during the parasite life-cycle. Why do the parasites need to produce 
MSP-3.3 twice in one cycle? Is there a common use of MSP-3.3 at two different stages of 
parasite development, or does MSP-3.3 have a different function at different stages of 
parasite development? All these questions remain to be debated and await further study of 
this protein.  
 In this project I have shown that MSP-3.3 is present throughout the intraerythrocytic 
stage of the parasite and in the free merozoite stage. Western Blots using MSP-3.3C specific 
antibodies showed that MSP-3.3 is processed during schizont maturation before the release 
of free merozoites. Full-length MSP-3.3 is ~60 kDa by SDS-PAGE and can be detected in 
schizont protein extracts. Using merozoite protein preparations, the rabbit antibodies raised 
to MSP-3.3C detected two smaller MSP-3.3 proteins of approximately 40 and 50 kDa. The 
processing of MSP-3.3 is assumed to be a caused by the enzyme subtilisin-like protease 1 
(Sub1), for which there are two recognition sites in the N-terminal region of MSP-3.3 (Ellen 


























Figure 4.23: Western blot showing reactivity of anti-MSP-3.3C IgG to protein 
extracts of P. falciparum 3D7. Purified IgG from rabbit R6066 immunised with MSP-
3.3C was used to detect parasite MSP-3.3. Full length MSP-3.3 has a predicted size 
of 48 kDa, but migrates at ~60kDa due to its IUP properties. This 60kDa protein can 
be detected in schizont extracts of wild type parasites (LS=late schizont proteins), 
as well as other three knockout lines (MSP-3del = MSP-3 knockout line; MSP6del = 
MSP6 knockout line; and MSP-348del = PF10_0348 knockout line). However, the 
full-length protein was undetectable in merozoite extracts (Mero), and smaller 
processing products of MSP-3.3 ~ 45-50kDa were detected. Antibodies to MSP-
3.3C did not show cross-reactivity to protein extracts from normal red blood cells 
(RBC). (Figure produced by Ellen Kneupfer, NIMR, Mill Hill).  
 
 Pearce et al., 2005 reported that the MSP-3.3 (referred to therein as H101) could not 
be detected in merozoite extracts by Western Blotting. In the same publication, another 
proteolytic cleavage site was identified (Pearce et al. 2005) However, the antisera used in 
that study were raised against full length MSP-3.3 fused to GST. The sensitivity of the 
blotting technique and the possible differential specificities of the antibodies raised by 
immunisation may explain these differing results. The antisera raised to H101 reacted with 
full-length MSP-3.3 but also with the truncated delta-H101 protein produced by KO 
parasites, indicating a substantial reactivity with the N-terminal part of MSP-3.3, and no 
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reactivity with the smaller, more C-terminal processing products of MSP-3.3 that we have 
observed (Figure 4.2). It is not clear why MSP-3.3 is processed, but the cleavage step may 
expose some functional domain of this protein for a different function in the subsequent 
stages of parasite development, such as in the schizont maturation step or merozoite invasion 
step. Another possibility is that MSP-3.3 is processed to be shed along with other MSP-3 
family protein complexes that are removed from the merozoite surface during invasion, such 
as the MSP-1/MSP-6 complex. Again, further studies should allow better understanding of 
the role of this protein. 
 Some studies have suggested that certain protein motifs provide a signal that is 
important for protein transportation. Interestingly, MSP-3.3 contains a short PEXEL motif, 
which has role in protein translocation to the RBC cytosol via the parasitophorous vacuolar 
membrane (PVM) (Marti et al. 2005). Whether this protein is further exported to Maurer’s 
clefts and then to the iRBC surface is still unclear, as at least some MSP-3.3 protein is 
cleaved downstream of the PEXEL motif, as shown in Figure 4.2. It has been reported that 
disruption of PEXEL motifs can affect protein transportation from the parasitophorous 
vacuole (PV) to the iRBC membrane (Marti et al. 2005). 
3.4 Postulated functions of MSP-3.3 
 The functions of MSP-3.3 may be similar to those of MSP-3, since they have similar 
size and share some common domains and sequence structure. It is possible that MSP-3.3 is 
associated with other MSPs and forms part of the protein coat of the merozoite. MSP-3.3 
may be involved in parasite surface protein interactions and may also play a role with other 
proteins in binding to host RBCs and subsequent invasion steps. However, mutant parasites 
that contain truncated PF10_0347 genes demonstrate that this gene is not directly crucial for 
erythrocyte invasion and growth of parasites, at least in vitro (Pearce et al. 2005). The same 
study proposed that MSP-3.3 could be used as an alternative when other MSP-3 protein 
family members are blocked or malfunctioning. Nevertheless, these mutant parasites still 
contain a substantial part of this PF10_0347 gene and still express a truncated protein 
product. Thus, there is a possibility that the truncated protein is still able to sustain at least 
part of its normal function (Pearce et al. 2005). 
3.5 Recombinant antigen MSP-3.3C 
 In this project, an MSP-3.3C recombinant protein was expressed, representing the 
long unstructured region of MSP-3.3 from the 3D7 strain of P.falciparum. MSP-3.3C was 
produced for the purpose of structural, immunological, antigenic and functional studies of 
this region of this MSP-3 family member. The ultimate aim of the project was to investigate 
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MSP-3.3C as a suitable vaccine candidate, and therefore did not contain any non-parasite 
protein sequences. Protein tags, such as GST or HIS tag were intentionally excluded from 
this construct in order to preserve antigenic integrity and prevent contamination with toxic 
residues such as Cu2+, Ni2+, Co2+ or Zn2+, which can possibly be co-purified with the 
proteins when metal-chelating resins are used. 
 It has been postulated that many malaria proteins are poorly expressed in 
heterologous hosts because of codon usage bias (Mohan et al. 2008). The presence of 
intrinsically unstructured regions has also been associated with low expression yields, 
possibly due to genetic instability of repetitive DNA inserts or the proteolyically sensitive 
nature of these unfolded proteins (Feng et al. 2006). However, this does not seem to be the 
case for the MSP-3.3C, which showed no genetic instability in E coli and was expressed 
efficiently as a soluble protein. The MSP-3.3C protein can be successfully produced at 
laboratory scale using a simple purification protocol. It is hoped therefore that this protocol 
can be further developed for industrial scale production. With optimal growth conditions, 
and fermentor scale-production, MSP-3.3C can be produced in bulk. To improve yields of 
expressed product further, codon optimisation (Zhou et al. 2004) or codon harmonisation 
(Angov et al. 2008) could be considered. Other options such as using alternative expression 
hosts (Yadava & Ockenhouse 2003) or richer nutrient media may also enhance the 
production of this recombinant protein.  
 The purification protocol for MSP-3.3C was developed based on the knowledge 
obtained from the MSP-1 Hybrid study (Chapter 3). The fact that MSP-3.3C is thermostable 
made production and purification of this protein straighforward. A two-step purification 
scheme proved to be very simple and efficient, providing a high quality product. However, 
there was substantial loss of product during these two steps. To further improve product 
yield, heating conditions and chromatography protocols could be further improved to reduce 
losses. It seems probable that, like the MSP-1 Hybrid, MSP-3.3C vaccine production will 
prove to be scalable.  
 MSP-3.3C appears to be an IUP, both by biophysical analysis and by its biochemical 
properties. This allows it to be maintained at ambient temperature without significant loss of 
immunogenicity. MSP-3.3C migrated anomalously on SDS-PAGE, at almost double its 
actual size, as IUPs bind poorly to SDS due to their amino acid composition.  
3.6 Antigenicity and immunogenicity 
 The antigenicity of the MSP-3.3C protein was demonstrated by its recognition by 
human sera from malaria exposed Africans. Thus recombinant MSP-3.3C shares epitopes 
with MSP-3.3 protein from parasites. Antibodies to MSP-3.3C were of IgG3 and IgG1 
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subclasses, although biased towards IgG3, like many other parasite IUPs (Cavanagh et al. 
2001; Taylor et al. 1998; Singh et al. 2004). This is in agreement with data from Singh et al., 
2009 who used hyperimmune sera, where IgG1 and IgG3 were detected to the C-terminal 
part of MSP-3.3 (Singh et al. 2009). My ELISA assays with human sera from Africa 
produced important data about MSP-3.3 reactivity in a naturally exposed population, but 
number of sera tested were not sufficient to draw conclusions about the frequency of positive 
anti-MSP-3.3C in naturally exposed individuals. The sera used were selected for high 
reactivity to at least one other merozoite surface protein. Thus, they represented only a sub-
set of infected individuals. For future studies, larger collections of sera from different 
populations, especially those in which clinical data of the individuals have been recorded, 
will be needed. Some work has begun in this area with our collaborators in Burkina Faso, 
where MSP-3.3 specific antibodies are reported to be of low frequency and low titer in most 
individuals tested (Cherif et al. 2012). Since MSP-3.3C is an IUP, I have assumed that this 
antigen contains continuous linear epitopes. However, it would be useful to investigate of 
sub-regions of this protein and map the epitopes recognised by naturally infected sera, with 
the aim of identifying antibody reactivities that correlate with protection. 
 I have shown that recombinant MSP-3.3C shares similar epitopes with MSP-3.3 of 
parasites. Using rabbit antibodies raised against MSP-3.3C, IFA showed specific MSP-3.3 
staining patterns around the parasite nucleus. The structure of this staining becomes more 
organised and denser as parasites mature towards schizont stage. In contrast with a previous 
study (Pearce, Hodder, et al. 2004a), I found reactivity in one particular area of the free 
merozoite. MSP-3.3 is confirmed as a merozoite surface protein that may play a role in host 
RBC binding and/or invasion. More sensitive imaging methods such as confocal microscopy 
should be used to learn more about this protein’s subcellular and stage-specific localisation. 
 Unstructured regions in malaria proteins are reported to be poorly triggering weak 
immune responses (Dunker et al. 2002; Feng et al. 2006). In this study, we showed that 
MSP-3.3C was poorly immunogenic in mice. However, using a stronger adjuvant, higher 
titre antibodies were elicited in rabbits. Thus, I believe that there is still room for 
improvement of the immunogenicity of this novel protein antigen. A range of adjuvants that 
may enhance production of specific antibodies will be considered for future tests. Adjuvants 
which are derivatives of the Montanides, which were used to raise specific antibodies to C-
terminal region of the PF10_0347 in other studies, may also be considered (Singh et al. 
2009). Note that, unlike other previous publications, this is the very first MSP-3.3 
recombinant protein without a protein tag in its construct. Using this protein should prevent 
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undesired immune responses against GST protein and this should make the results easier to 
interpret.  
3.7 Function of MSP-3.3C-specific antibodies in in vitro assays 
 The growth inhibition assay (GIA) has been used in malaria vaccine research as a 
tool for measuring antibodies’ functionality in vitro. GIA can assist in the assessment 
process of malaria vaccine development, because of the limited range of in vivo animal 
models. GIA measures the ability of antibodies to disrupt parasite growth, development 
and/or invasion. Like other functional assays, it is informative, yet has limitations. In this 
study, two methods of measurement of parasitaemia were employed to confirm results and to 
provide a broader understanding of the process of inhibition. The pLDH assay is designed to 
measure parasite lactate dehydrogenase activity (LDH), which is important for intracellular 
metabolism of the parasite. The pLDH assay only detects living parasites. Assay of LDH 
activity can vary depending on accuracy of pipetting, ambient temperature, the density of 
parasites in culture, as well as high background signal absorbance by RBC components. 
Alternatively, parasite cultures can be stained with fluorescent nuceloic acid binding dyes 
and analysed by flow cytometry. This more sensitive method allows us to group parasites 
into subpopulations based on their DNA content and size, so that each stage of the 
intraerythrocytic parasite can be distinguished. In addition, Giemsa-stained thin smears of 
parasite cultures were taken in order to observe the morphology of parasites. Combining 
these measuring methods provided us with very useful information regarding the potential 
functions of antibodies to MSP-3.3C and the function(s) of MSP-3.3 itself. 
/////////////////////////////////////////////////…………………………………………. 
 Many previous studies have sought to show associations between specific antibodies 
to malaria antigens and protection from disease, although knowledge of the molecular 
functions of these antibodies is incomplete. Effects of different antibodies on the parasite 
have been shown to be diverse, possibly due to variation in antibody affinity (Reddy et al. 
2012), isotype (Cowan et al. 2011) or paratope (Bergmann-Leitner et al. 2006). Apical 
membrane antigen-1 (AMA-1), for example, is known to be a target for antibodies which 
have the ability to inhibit parasite invasion (Coley et al. 2007) blocking the functional region 
of AMA-1 (Dutta et al. 2005), and treatment with anti-AMA-1 results in lower numbers of 
parasites. The GIAs in this experiment showed that the specific antibodies to MSP-3.3C 
have the ability to kill parasites. The higher the concentration of purified total IgG, the lower 
the parasitaemia in the treated culture. Affinity-purified antibodies from the same sources 
confirmed that it was MSP-3.3C specific antibodies rather than background antibodies that 
were responsible for the parasite killing effect. The stronger GIA activity of affinity-purified 
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antibodies observed in this experiment may show that the presence of non-specific anti-
idiotypic antibodies can hamper the activity of the specific antibodies (Wåhlin et al. 1990). 
In addition, GIA with MSP-3.3C depleted IgG showed that the non-specific antibodies from 
the two immunised rabbits did not have a significant inhibitory effect on parasites. The 
parasite killing effect of purified total IgGs was consistent between individual GIAs. The 
same IgG samples were also tested in GIAs by Dr. Carole Long’s laboratory at the NIH 
using the P. falciparum 3D7 strain. In these experiments, the samples were re-dialysed and 
filtered before use, as initial GIA results were so strong, Dr. Long’s laboratory suspected 
contamination of the IgG preparation. The result confirmed that antibodies from both the 
immunised animals had strong killing effects with up to 100% growth inhibition. All these 
data confirmed that the antibodies against MSP-3.3C could kill the parasite in vitro..  
 As mentioned earlier, although the GIA is an informative assay, it does not provide 
direct information on how these specific antibodies affect parasites. Importantly, these 
assays showed us that these antibodies not only decreased parasitaemia, but also caused 
abnormalities of parasite morphology. Unlike anti-AMA-1 Abs, anti-MSP-3.3C Abs caused 
parasites that had successfully invaded into new red blood cells to decrease in size. The 
growth or development rate of anti- MSP-3.3C cultures also appeared to be slower, although 
this was impossible to quantify in these assays. While the untreated or naïve rabbit IgG 
cultures had developed into late-trophozoites, parasites that were treated with anti-MSP-3.3C 
were arrested at early blood-stage forms that contained condensed nuclei. These malformed 
parasites were not producing pLDH and so were not contributing to measurements in pLDH 
assays. This suggests that anti-MSP-3.3C antibodies function in a very different way from 
the function of antibodies to AMA-1. /////////////////////////////////////////////////////……………… 
 It has been suggested that some antibodies with functional activity may not show a 
direct invasion inhibitory effect, but may still cause disorder in post-invasion parasites 
(Arnot et al. 2008). Malformed morphologies in antibody-treated parasites have been 
reported in several different studies (Ahlborg et al. 1996; Bergmann-Leitner et al. 2006). 
Several models of antibody function have been proposed, but the molecular mechanism 
these antibodies use is not very well understood. However, we speculate that antibodies to 
the MSP-3.3C are likely to have both an invasion and an intracellular growth inhibition 
effect. If antibodies only inhibit parasite invasion, there will be fewer parasites in treated 
cultures than in control cultures, but morphology and lifecycle stage of parasites in both 
cultures should be very similar. The best example of this model are antibodies to AMA-1, 
which block parasite invasion (Arnot et al. 2008). In contrast, antibodies that target proteins 
such as MSP-142 have been reported to affect growth of parasites, halting development of 
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parasites from trophozoite stage onward. As a consequence, these treated parasites were 
blocked at the schizont stage, and termed “Stalled schizonts” (Bergmann-Leitner et al. 
2009). Another vaccine candidate MSP-119 has been shown to trigger specific antibodies that 
have functional activity on post-invasion parasites. Although these antibodies do not show 
strong invasion inhibition effects, misshapen parasites were seen in the treated cultures: 
these included collapsed ring forms, pyknotic nucleoli in trophozoites and swollen vacuolar 
late trophozoites (Pearce et al. 2005; Arnot et al. 2008). Antibodies raised to a megadalton 
protein called Pf322-C231 have been shown to cause abnormal schizont growth, including 
an absence of segmenters (Balogun et al. 2011). In anti-MSP-3.3C treated cultures, the 
majority of ring stage parasites contained crumpled nuclei, especially in cultures with higher 
concentrations of IgG. At lower IgG concentrations, deformed trophozoites, which were 
small with packed and darkly stained nuclei, were observed together with the tiny ring forms 
described above.  
 Three phenomena of antibody functional activity may be taking place during the 
blood-stage cycle: I) Antibodies to MSP-3.3C are able to block parasite invasion, possibly 
by interfering with the binding process of the parasite to the red blood cell and causing a 
drop in parasitaemia. This phenomenon is obvious at high IgG concentrations, suggesting 
that it may require quite a lot of specific IgG to opsonise free merozoites; II) Anti-MSP-3.3C 
antibodies are able to bind to MSP-3.3, do not prevent parasite invasion, but may be carried 
in with successfully invading merozoites, and continue to affect parasite growth and 
development (Bergmann-Leitner et al. 2009) presence of anti-MSP-3.3C IgG during schizont 
stage provides an opportunity for antibodies to enter iRBC (Taraschi 1999). The membrane 
of the infected erythrocyte is more permeable, especially immediately before rupture (Lyon 
et al. 1997). Alternatively, antibodies may enter the iRBC via the parasitophorous duct, a 
pore with a thin tube structure that extends into the parasitophorous vacuole (Goodyer et al. 
1997; Pouvelle & Gysin 1997). The fact that MSP-3.3 is expressed throughout the blood-
stage of the parasite suggests that any or all these hypotheses may be possible. The 
antibodies may be able to attack the parasite at any stage if they are allowed to reach the 
target antigen. Based on our current data, it is not clear what might be the molecular 
mechanism of the antibodies that affect intra-erythrocyte growth inhibition. These antibodies 
may bind directly to an active site on MSP-3.3 that is crucial for parasite development, 
resulting in slowed development and defects in parasite structure integrity.  
 In GIA, antibodies did not block schizont development when antibodies might have 
access to infected cells, interfere with parasite development and prevent cell rupture. It may 
be that longer incubation times may be required for the anti-MSP-3.3C to function 
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efficiently. GIA is an assay which can only detect whether anti-MSP-3.3C has any inhibitory 
effect on malaria parasites, as samples were harvested at only one time point, after cultures 
had been allowed to grow for one cycle. In order to understand the process in a detail, time 
point measurements during GIA would be very useful. MSP-3.3C used to immunise rabbits 
in this study were formulated with a strong adjuvant (Freund’s), producing a mixture of 
antibodies that are different in idiotype and serotype. Future production of MSP-3.3C 
monoclonal antibodies as well as more studies on antibody-protein interactions would help 
to enhance our understanding of the activity of anti-MSP-3.3C antibodies.  
 It has been suggested that the flexibility of the IUPs may make them poor targets of 
immunity and that they might be involved in evasion of host immune responses (Feng et al. 
2006). Biologically, antibodies generally act with other immune cells in response to a 
pathogen. The principal theory of the antibody-dependent cellular-inhibition assay (ADCI) is 
that antibodies inhibit multiplication of blood-stage malaria parasites in cooperation with 
monocytes (Bouharoun-Tayoun et al. 1990). This assay has been used by others for human 
antibodies to MSP-3.3, which have ADCI effects in vitro (Singh et al. 2009; Demanga et al. 
2010). It will be interesting to see if this MSP-3.3C protein, which shares sequence similarity 
to C-terminal sequences of other MSP-3 family members will also be a target of antibodies 
with ADCI activity. 
3.8 Disordered region of the PF10_0347 protein: function and 
relationship with immune responses 
 Bioinformatics analysis has shown that long-disordered proteins are enriched in 
early branching eukaryotes (Mohan et al. 2008). In the malaria parasite genome, they are 
surprisingly abundant. It has been proposed that IUPs may play important roles in multiple 
protein-protein interactions. IUPs are proposed to to act as hub proteins that can interact with 
multiple partners (one-to-many model) or to allow a single protein to be associated with 
many different IUPs (many-to-one model) (Dunker et al. 1998). These abilities can benefit a 
pathogenic protozoa’s fitness by facilitating interaction with host cells (Feng et al. 2006). 
Another role of IUPs is to act as a junctional sequence between globular domains. The 
unstructured region that has been studied in this project has no reported functional 
domain(s). It is possible that instead of acting as a functional site, this region may form a 
flexible junction that links other functional domains (Olson et al. 2005; Fuxreiter 2011). This 
kind of junction may assist in rapid binding to host ligands and allow access to many 
different protein partners. 
  In this study, some interesting properties of the MSP-3.3C were discovered. In GIA, 
to confirm that the specific inhibitory effect was caused by antibodies to MSP-3.3C, 
  153 
recombinant MSP-3.3C in a soluble form and as an immobilised form were introduced into 
parasite cultures, either in the presence or absence of antibodies to MSP-3.3C. However, the 
antigen-reversal effect was not achieved by any of these forms of the MSP-3.3C antigens. 
Conversely, the MSP-3.3C protein showed a growth inhibitory effect alone, although of 
lower potency than that of anti-MSP-3.3C antibodies. It is possible that the MSP-3.3C 
antigen competed with parasites for binding the surface of red cells, blocking parasite 
adhesion. Alternatively, this protein might access infected red blood cells and result in 
slowed development of the parasite. Since the soluble protein is smaller and more flexible 
than when it was attached to magnetic beads, the protein could act more rapidly. This may 
explain why soluble MSP-3.3C inhibited parasite growth to a greater extent than bead-
immobilised MSP-3.3C. The sequence of MSP-3.3C does not contain any homology with 
known RBC binding domains, but experimentation will be required to confirm whether the 
MSP-3.3C has a function in erythrocyte binding. 
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Chapter 5: Construction and expression of the MSP-
multihybrid vaccine antigen 
1. Introduction 
 Developing a vaccine is a lengthy process and it is even more challenging when the 
pathogen is as complex as malaria. Recombinant protein-based antigens are widely used 
because once production and purification protocols have been developed, they can be 
manufactured on a large scale and their quality can be easily monitored. However, it is 
unlikely that they will be as immunogenic as a live-attenuated vaccine. This suggests that 
protective immunity might require the production of antibodies against multiple targets 
(Bruder et al. 2010). Evidence from a number of studies supports this idea, showing that 
protective responses are against polymorphic and variable regions. It is possible that a 
protective immune response relies on several different responses against variable or 
polymorphic antigen epitopes rather than a response to a single antigen or epitope (Bruder et 
al. 2010; Marsh & Kinyanjui 2006).  
1.1 Multi-component vaccines 
 A multi-component vaccine is a modified antigen that contains selected multiple 
regions, domains, allelic types of antigen or epitopes. Depending on the design, the multi-
component vaccine may consist of epitopes that represent all known polymorphism of the 
target antigen or contain more than antigenic type or may be a combination of both. This 
kind of protein antigen is expected to provide more targets for immune responses, overcome 
polymorphism of parasite antigens, and therefore increase the efficacy of such vaccine.  
 Prior knowledge of the polymorphisms of the malaria parasite as well as data from 
immunological studies, molecular epidemiological studies and subunit vaccine trials is 
important and can provide very useful information. For example, studies on the diversity of 
MSP-119 in Kenya revealed a bias in the different polymorphisms of this antigen in the 
parasite population (Takala et al. 2007; Ferreira et al. 2003). The failure of a subunit vaccine 
trial to provide efficient protection to individuals in this area suggested that the immune 
responses raised by this vaccination targeted only the parasites with the minority form of the 
MSP-142 in population (Ogutu et al. 2009). Since allele-specific immunity cannot cross-react 
with other parasite strains, this subunit vaccine was ineffective in that region. Therefore, in 
such cases, a multi-component vaccine should provide better protection (Takala & Plowe 
2009). Moreover, it was suggested that vaccines containing only one allelic type of the 
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polymorphic antigen may induce a limited spectrum of immune responses which may then 
select for parasites expressing alternative alleles. Therefore, an effective vaccine against the 
polymorphic antigens must be able to provide protective immune responses to all the allelic 
types.  
 Apart from the potential to raise broad immune responses, multi-component 
vaccines are reported to be more immunogenic than their individual components. It has been 
demonstrated that the antibodies raised by a chimeric protein can recognize native antigens 
on the surface of parasites and also show an inhibitory effect in GIA, while the specific 
antibodies produced by immunization of the individual components (domain III of AMA-1 
and MSP-119) failed to do so (Pan et al. 2004). Or in case of MSP-Fu24, which contains the 
C-terminal part of Pf MSP-119 and of PfMSP-311, the ADCI activities of antibodies elicited 
by MSP-Fu24, protein fusion were comparable to those generated by immunization of each of 
the two component antigens (Mazumdar et al. 2010). 
1.2 Design of the MSP-multihybrid: a multi-component vaccine 
 There is encouraging data to support the idea of creating a multihybrid MSP vaccine 
based on the MSP-1 hybrid and the 2 allelic forms of MSP-2. Studies on MSP-1 Block 2 
have shown that it provides targets for naturally induced antibodies associated with 
protection against clinical malaria episodes (Polley et al. 2003; Cavanagh et al. 2004; 
Conway et al. 2000). Antibodies to MSP-1 Block 2 have parasite killing properties as 
measured by ADCI assays (Jiang et al. 2000; Galamo et al. 2009). A monoclonal antibody to 
one MSP-1 Block 2 variant has been shown to inhibit parasite growth in vitro (Jiang et al. 
2000; Locher et al. 1996). These antibody responses are however strain-specific (Conway et 
al. 2000; Cavanagh et al. 2004; Cavanagh & McBride 1997; Draper et al. 2010; Cavanagh et 
al. 1998; Sallenave-Sales et al. 2000; Zwetyenga et al. 1998; Ferreira et al. 2003). Since the 
allelic frequencies of the gene encoding the MSP-1 Block 2 region are under balancing 
selection throughout the global parasite population (Conway et al. 2000), individuals with 
antibodies to more than one strain of parasite are likely to be better protected (Conway et al. 
2000; Cowan et al. 2011). Vaccine antigens such as the MSP-1 hybrid elicit broadly cross-
reactive immune responses covering all three MSP-1 Block 2 serotypes and is a potential 
vaccine candidate.  
 MSP-2 is another parasite surface protein antigen under balancing natural selection 
(Conway 1997), suggesting that it may be an important target of antibodies affecting survival 
of the malaria parasite. The immunogenicity and target regions for specific antibodies to  
MSP-2 have been reported in a number of studies (Taylor et al. 1995; Aubouy et al. 2003).  
Several regions of MSP-2 are recognised by antibodies that have a parasite inhibitory effect 
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(Clark et al. 1989), parasite killing activity (Flueck et al. 2009), or are correlated with 
protection from clinical symptoms (al-Yaman et al. 1995; Polley et al. 2006; Metzger et al. 
2003; Osier et al. 2010). MSP-2 has N- and C-terminal conserved regions, which are 
reported to be recognised by sera from naturally exposed individuals (Zhang et al. 2008), 
some of which have ADCI activity (McCarthy et al. 2011). However, most antibodies 
against MSP-2 target the variable regions of the molecule (Taylor et al. 1998; Metzger et al. 
2003; Felger et al. 2003; Tami et al. 2002). Moreover, antibodies to one type of variable 
region of MSP-2 do not cross-react with other variable region types (Taylor et al. 1995; 
Franks et al. 2003; Flück et al. 2004). The effect of this serotype-specific response to MSP-2 
was seen in the study by Genton et. al., in 2002 in which the Combination B vaccine, based 
on only one allelic form of MSP-2 was used to immunize populations in sub-Saharan Africa 
where both serotypes of MSP-2 can be found. As a result, this vaccine induced immune 
responses that selected against one allelic form of the parasite and allowed the other parasite 
serotype to persist in vaccinees (Genton et al. 2002). It has subsequently been suggested that 
any recombinant vaccine based on MSP-2 should combine different serotypes to provide 
immune protection against the whole range of parasite strains (Flueck et al. 2009; Flück et 
al. 2007).  
 The aims of this part of my PhD project were to 1) produce a multi-component 
vaccine based on two potential vaccine candidates, the MSP-1 hybrid and the two allelic 
types of MSP-2 and 2) investigate the resulting recombinant protein for its biochemical 
properties, antigenicity and immunogenicity. 
2. Materials and results 
2.1 Predicted properties of the MSP-multihybrid 
 The MSP-multihybrid was predicted to be 81.17 kDa in size and have theoretical pI 
of 4.84, based on its amino acid sequence. Since the MSP-1 hybrid and MSP-2 are all IUPs, 
this MSP-multihybrid was also predicted to have similar properties. The theoretical protein 
construct was predicted to be largely unstructured usng the IUPred prediction tool 













Figure 5.1: Disorder tendency profile of the MSP-multihybrid antigen, predicted by 
IUPred (Dosztányi et al. 2005), Disorder tendency on the Y axis is plotted against 
amino acid position in the theoretical protein sequence. High disorder tendency 
throughout the sequence predicts that this protein antigen is generally unstructured. 
 
2.2 Gene cloning 
2.2.1 PCR 
 The MSP-multihybrid DNA construct was produced by joining sequences of MSP-1 
hybrid, MSP-2A and MSP-2B by PCR. Full-length MSP-2A (CH150/9) and MSP-2B (Dd2) 
constructs were gifts from Dr. David Cavanagh. Like the MSP-1 hybrid, they were codon 
optimized for expression in E.coli. Initially, three hybrid gene fragments were made;  
 
(1) MSP-2A with 5’ region of the MSP-1-hybrid as an overhang at the 3’ end, using MSP-
2A as a template, and  
forward primer MSP-2A (5' CATCCATGAATGAAAGCAAATACAGCAACACC 3’) and 
reverse primer MSP-2A-Hybrid (5’ AGATTCGTGGGTAACTTTGTTGATGCTCGC 3’).  
(2) The MSP-1 hybrid with MSP-2 A (5’) and B (3’) overhangs at each end, using  
forward primer  (5' GCGAGCATCAACAAAGTTACCCACGAATCTTAC 3’) and  
reverse primer  (5’ GCTATATTTGCTTTCATTGGAGCTATTATCGCTCGG 3’)  
(3) MSP-2B with a 3’ MSP-1 hybrid overhang on the 5’ end of the gene using the MSP-2B 
as a template, and  
forward primer (5’ AGCGATAATAGCTCCAATGAAAGCAAATATAGC 5’) and  
reverse primer  (5’ ctcgcggccgcttatttattaatgctggcaatattgctgc 3’) 
 
 These fragments were made using PCR cycling condition as follows: an initial 
denaturation at for 94C 2 minutes 50 seconds, followed by for 19 cycles of denaturation at 
94C for 30 seconds, annealing at 55C for 30 seconds and extension at 72C for 2 minutes 
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50 seconds, with a final extension at 72C for 5 minutes. PCR fragments were separated on 
agarose gels and PCR products of the correct size were purified. ------------------------------- 
 The original plan was to combine the MSP-2A and MSP-1 hybrid fragments by 
PCR, to fuse the gene fragments of these two genes. This product would then be further 
fused by PCR with MSP-2B, using the MSP-2A forward primer and the MSP-2B reverse 
primer. However, the recombinant genes that were achieved by this method were truncated, 
mostly missing part of the MSP-2 sequences. Some of the clones that contained sequences, 
of approximately the expected size, showed mutations within the repetitive region. 
Therefore, another method which relied on more conventional cloning and restriction 
enzyme digestion was used. ----……………………………………--------------------------- 
 To solve the mutation problem, the fusions of MSP-2A-MSP-1 hybrid and MSP-1 
hybrid-MSP-2B were made separately by PCR. The PCR products of MSP-2A and the MSP-
1 hybrid were used as a template to produce a gene fusion of MSP-2A and MSP-1 hybrid 
(M2a-H) using the forward primer of MSP-2A and reverse primer of MSP-1 hybrid, 
described earlier. Similarly, gene fusion between the MSP-1 hybrid and MSP-2B (H-M2b) 
was produced using the forward primer of MSP-1 hybrid and reverse primer of MSP-2B. 
Both PCR reactions were performed as follows: an initial denaturation at 94C for 5minutes, 
followed by 29 cycles of denaturation at 94C for 30 seconds, annealing for 55C for 2 
minutes and extension at 72C for 4 minutes, with a final extension at 72C for 5 minutes. 
Each fragment was then directly cloned into plasmid pCR4-TOPO using the TOPO TA 
cloning kit. TOPO plasmids were checked for cloned genes by restriction digest as suggested 
by the manufacturer’s protocol and checked for sequence integrity by Sanger sequencing. 
Plasmids which contained correct gene constructs were extracted and stored as stock DNA 
plasmids (Figure. 5.2) 




















Figure 5.2 (A) Schematic representation of the MSP-multihybrid protein construct. 
The construct encodes the MSP-2A, the MSP-1 hybrid, and the MSP-2B. (B) Amino 
acid sequence of the MSP-multihybrid. Sequences of MSP-2A and MSP-2B are 
presented in orange and pink respectively, while sequence of MSP-1 hybrid is 
presented in black.  
 
2.2.2 Restriction reaction 
 The two cloned DNA fragments (M2a-H and H-M2b) and the DNA expression 
vector pET28a were then cleaved by restriction enzymes to make compatible fragments for 
ligation cloning. The M2a-H and H-M2b genes were excised from the cloning plasmid 
sequentially by restriction enzyme NcoI (for M2a-H) or NotI (H-M2b) and then Bpu10I. All 
these restriction enzymes were used with Buffer 3 (NEB). DNA fragments were separated on 
agarose gels then purified and measured for concentration after each step. Ligation was 
 
MSP-1 hybrid 
MSP-2A      Block1     K1 BL2       RO33 BL2   MAD20 BL2      MSP-2B 
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performed overnight using purified stocks of both gene fragments and the linearised form of 
the pET28a plasmid (Novagen, UK), which had been cut sequentially with NcoI and NotI. 
2.2.3 Ligation reaction 
 Finally all gene fragments were all fused together by a ligation reaction. 
The ligation mix was transformed into E.coli XL-1 Blue using the protocol described in 
Chapter 2 (Materials and Methods, Section 4). Transformants with plasmids containing 
inserts of the correct size were checked for correct sequence and orientation. A clone which 
contained a full-length insert of the correct MSP-multihybrid sequence was selected, the 
plasmid DNA purified and then stored at -70C until use as described in Chapter 2, Section 
1. 
2.3 Protein production  
2.3.1 Protein expression  
 For each round of expression the recombinant multihybrid plasmid was freshly 
transformed into E. coli BLR (DE3) pLysS cells. Cultures were grown in LB broth, Terrific 
broth, or LBE 5052 using the same protocols as described in Chapter 2, Section 7). Cultures 
were induced with 1 mM IPTG at OD 600nm of 0.5-0.6 (log phase) and then sampled every 
hour until harvesting.  
 The fastest growth rate was observed when cells were grown in LB, providing 
around 4.5 gL
-1
 of wet cells at harvest 4 hours post induction (Figure 5.3). The highest total 
wet-cell weight was achieved from the culture in Terrific broth which gave 4.95 gL
-1
 of cell 
paste 4 hours post induction, and 8.08 gL
-1
 at 12 hours post induction.  
   
Figure 5.3: Growth curve of expression culture of MSP-multihybrid in different 
culture media; LB (circle), Terrific broth (square), LB5052 (triangle).   
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 Either after 4 hours or 12 hours (overnight), cell cultures was harvested by 
centrifugation. Cell pellets were stored at -70C until use. To extract soluble protein, cells 
were lysed by cycles of freeze-thawing. Cell culture samples and lysates were then examined 
by SDS-PAGE and Western blotting. No clear evidence could be seen of induction of 
expression of the multihybrid either by silver nitrate or Coomassie Blue staining of cell 
extracts (Figure 5.4).  
2.3.2 Heat treatment 
 Cell lysates were produced by the freezing-and-thawing method. As the first 
purification step for the MSP-multihybrid protein, heat treatment, as performed for MSP-1 
hybrid (Chapter 2, Section 9), was tested to see if it would be suitable. The heated product 
was investigated by SDS-PAGE and Western blotting using monoclonal and polyclonal 
antibodies to MSP-1 Block 2 and to MSP-2. ////////////////////////////////////////////////////////// 
 Heat treatment, which was successfully used as  a first purification step for the MSP-
1 hybrid and MSP-3.3C,  was similarly used for the  MSP-multihybrid. Using either 70C or 
90C treatments, host cell  proteins were denatured and then removed by centrifugation as 
before. However SDS-PAGE analysis of the resulting material showed very low 









Figure 5.4: SDS-PAGE of the E. coli cell pellets and lysates harbouring the MSP-
multihybrid plasmid at different production steps (M= marker, lane 1= culture before 
induction, lanes 2-5= culture 1, 2, 3 and 4 hours after incubation respectively, 6= cell 
lysate, 7= heated lysate) 
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2.3.3 Anion exchange chromatography 
 Partially purified soluble proteins from the heat treated lysate were dialysed 
extensively against 25mM Tris-Cl pH 8.0. Anion exchange chromatography was then used 
to further purify the MSP-multihybrid product. After loading a Q-sepharose FF column with 
the dialysed lysate, and washing with 25mM Tris pH8.0, a continuous gradient from 0 to 250 
mM NaCl in 25mM Tris pH 8.0 was applied to the column and fractions collected. Strongly 
bound proteins were then eluted from the column by washing with 1M NaCl.  
 Eluted samples were analysed by a rapid dot immunoblot. 2 µL of each protein 
sample was spotted on Schleicher and Schuell BA83 nitrocellulose membranes (Whatman). 
Once the spots were dried, the blot was blocked with Western blocking buffer (Chapter 2, 
Section 14). Blots were then probed using diluted pooled sera from 8 rabbits that were 
immunised with MSP-1 hybrid formulated with CoVaccine HT (Chapter 2, Section10). 
From these blots it was clear that fractions containing proteins reactive with MSP-1-hybrid 
antisera had eluted from the column at NaCl concentrations as low as 60mM, although 
antisera-reactive fractions continued up to 250mM NaCl and were also present in the 1M 
NaCl wash (Figure 5.5). Dot-blots probed with antibodies against MSP-2A and MSP-2B 








Figure 5.5: Fractions collected from the continuous 0-250mM NaCl gradient elution 
of Q-sepharose bound material were probed with rabbit sera against the MSP-1 
hybrid. The numbers on the blot indicate the percentage of elution buffer 
concentration (0.25M NaCl) at the point of elution.  
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 Each of eluted fractions was measured for protein concentration by BCA assay and 
analysed by SDS-PAGE. However, the protein concentrations were very low. Protein bands 
were not obviously visualised either by silver stained SDS-PAGE or byWestern blotting 
(data not shown). Based on these results, it was assumed that the concentration of the MSP-
multihybrid was very low. 
2.3.4 Antibody affinity chromatography  
 To purify the low levels of multiphbrid present in the lysates, an affinity 
chromatography column (HiTrap NHS activated HP, GE Healthcare, UK) was coupled with 
the 12.2 monoclonal antibody (gift of Dr. Graeme Cowan) and used to purify the MSP-
multihybrid. This purification method was expected to provide more a concentrated and pure 
MSP-1-multihybrid product, which then could be used for analysis. The lysate was applied 
to the column in 25mM Tris and the protein was eluted with 1M NaCl in 25mM Tris-pH 8.0. 
Samples that were collected from this step of purification were then further analysed on 
SDS-PAGE and Western blot. Monoclonal antibody 12.2, mouse sera to MSP-1 hybrid 
(from mice that were immunized with MSP-1 hybrid in conjugated with CoVaccine HT; 
Chapter 2 Section 10), 12.3 monoclonal antibody to MSP-2A and mouse sera to MSP-2B 
(both provided by Dr. David Cavanagh) were used to detect the product of the MSP-
multihybrid, for the Western blots and Dot blots. ………………………………………… 
 The purified product from the12.2 column was investigated on SDS-PAGE and 
Western Blot in parallel with MSP-2A, MSP-2B (provided by Dr. David Cavanagh) and 
MSP-1 hybrid proteins. The silver stained gel of this product showed five distinct bands, 
























        
Figure 5.6: Silver stained SDS-PAGE showing proteins in each purification step. M= 
molecular weight markers, 1) culture before induction, 2) culture 4 hours post 
induction, 3) cell lysate, 4) affinity purified protein, 5) MSP-2A protein, 6) MSP-2B 
protein, 7) MSP-1 hybrid protein. Protein bands of  ~200kDa, ~130kDa and 
~100kDa are indicated as A, B, and C respectively. 
  
 Using antibodies to the three MSP components of the multihybrid, different patterns 
of protein bands were detected. The 12.3 monoclonal antibody, which is specific to MSP-
2A, recognised two protein bands. The dominant band was ~200kDa, the same size as 
product A in SDS-PAGE (Figure 5.7). The second 12.3 reactive band of  ~130 kDa, is 
approximately the size of product B. MSP-2B antisera gave different patterns of reactivity 
with bamds of ~130kDa, ~100kDa, and ~70kDa observed. A band of ~200kDa was also very 
faintly detected. Using mAb 12.2, specific for an epitope in the K1 type of MSP-1 Block 2 , 
four bands of  ~200kDa, ~130kDa, ~100kDa and ~70kDa were detected (Figure 5.6).  
 Although the molecular weight of the full-length MSP-multihybrid was predicted to 
be 81.17 kDa, no protein band of that size was detected any antibody on Western Blots, but 
since IUPs migrate slowly in SDS-PAGE, bands corresponding to proteins of higher 
molecular weight were expected. The bands observed at ~200kD, ~130kDa and  ~100kDa 
were assumed to be products of the MSP-multihybrid. All three bands were sent to 
SIRCAMS for mass spectrometric identification.  However, due to the low concentrations of 
the purification products, they were out of detectable range by mass spectrometry and no 
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Figure 5.7: Western blot of purified MSP-multihybrid affinity-purified on the mAb 
12.2 column. Western blots were probed with mAb 12.3 (anti-MSP-2A, lanes 1 and 
2), sera against MSP-2B (lanes 3 and 4) and mAb12.2 (lanes 5 and 6). M= 
molecular weight markers; lanes 1,3 and 5; MSP-multihybrid; lane 2, MSP-2A; lane 
4, MSP-2B; lane 6, MSP-1 hybrid). 
 
2.4 Assays of antigenicity 
 The antigenicity of the MSP-multihybrid antigen was tested by ELISA for 
recognition by human sera from naturally exposed Africans, in parallel with recognition of 
MSP-1 Block 2 antigens and the MSP-1 hybrid. African sera reactive with at least one 
serotype of MSP-1 Block 2, MSP-2A or MSP-2B were used to probe the antigenic structure 
of the MSP-multihybrid. European sera from malaria naïve individuals were used as 
negative controls. Using our existing ELISA protocols, 50ng of the purified MSP-
multihybrid antigen was coated onto wells of 96 well plates and assays performed as 
described Chapter 2, Section 19.  
 The MSP-multihybrid was recognised on Western Blots and dot blots, by sera that 
from mice immunised with either the MSP-1 hybrid or MSP-2 antigens. A pool of sera from 
adults from Brefet, Gambia, known to recognise the MSP-1-hybrid, both types of MSP-2, 
and all five types of MSP-1 Block 2, reacted with the MSP-multihybrid in Western blots. A 
panel of sera, from Gabonese adults, known to react with both MSP-1 Block 2 antigens 
and/or MSP-2, were also tested against the MSP-multihybrid. As shown in Figure 5.8, the 
antibodies from these selected sera recognised the MSP-multihybrid. Positive correlations 
were observed between antibody reactivity to MSP-multihybrid and other antigens, 
including the MSP-1 hybrid, MSP-1 Block 2 antigens, and both serotypes of MSP-2. In 
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Figure 5.8: Reactivity of Gabonese adult sera with the MSP-multihybrid. ELISA 
reactivity to MSP-multihybrid, Block 2 antugens derived from MSP-1, the MSP-1 
hybrid and full-length MSP-2A and MSP-2B antigens were measured by ELISA. 
Reactivity of each serum sample against MSP-1 and MSP-2 antigens (Y axis) is 
plotted against reactivity with the MSP-multihybrid (X axis).  
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3. Discussion  
 The MSP-multihybrid was designed as a vaccine that would elicit antibody 
responses by immunization against multiple parasite antigens to overcome the problems 
associated with parasite antigenic diversity. This single polypeptide antigen incorporating 
most of the allelic and antigenic diversity of both MSP-1 and MSP-2 was designed to  
overcome the problems of administration of mono-allelic vaccines, which have been shown 
to be ineffective or incapable of inducing a protective response against heterologous parasite 
strains (Ogutu et al. 2009; Flück et al. 2004; Genton et al. 2002). Although the MSP-
multihybrid was expected to be relatively easy to produce, there were a number of problems 
and setbacks in producing, expressing and purifiying this protein. 
3.1 Difficulties in gene cloning and protein production 
 The PCR technique is inexpensive, easy to manipulate and rapid. However, some 
genes can be difficult to amplify. The MSP-multihybrid gene is about 2.5 kb long and 
sequences of this length may exhaust the PCR reaction. As a result, the PCR product may be 
truncated. In addition, the MSP-multihybrid contains domains within the two MSP-2 
components that are repeated. When two types of MSP-2 templates were present in the PCR 
reactions, they can potentially hamper the specificity of binding of the primers as they can 
both serve as alternative primer sites. Therefore, there is a chance that more than one product 
may be produced. This problem was overcome by separately joining each type of the MSP-2 
to the MSP-1 hybrid. Restriction enzymes were then used to cleave the relevant sites within 
MSP-1 hybrid and the two PCR fragments were sequentially joined by ligation reactions.  
 This expression system gave very low amounts of MSP-multihybrid protein, which 
was insufficient for intensive downstream studies. Many possible reasons have been 
proposed to account for the low production of this protein. The DNA sequence of the MSP-
multihybrid contains low-complexity regions and repetitive sequences. This kind of DNA 
sequence is more common in eukaryotes than in bacteria and the protein produced in E. coli 
may be particularly sensitive to proteolytic degradation. The more low-complexity regions 
there are in the gene, the less likelihood that the protein will be expressed well in a bacterial 
host (M. R. Dyson et al. 2004). Nevertheless, the MSP-1 hybrid, which contains similar 
repetitive sequences was expressed with much higher yields using similar expression and 
purification protocols. This suggested that the difficulty of MSP-multihybrid expression may 
be not only due to the structure of the protein but also its size. This protein is more than 
twice the size of the MSP-1 hybrid and to make the complete protein, E.coli needs to 
transcribe and translate a realtively long heterologous mRNA which has not been optimised 
for stability in bacterial systems. Experiments outlined in this chapter showed that extending 
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the expression period helped to improve total cell mass. However, the yield of MSP-
multihybrid was not significantly improved. Like most malaria genes, the MSP-multihybrid 
is a relatively AT rich gene, apart from the codon optimised MSP-1 hybrid component. The 
E.coli host may not have enough tRNA resources for the production of this foreign protein, 
thus resulting in low expression and/or truncated products. Expression media were also 
important for growth of E.coli, serving as an energy source, and therefore important for 
protein yields. Experiments reported in this chapter showed that in different media, E.coli 
grew at different rates. However, none of media used showed any significant capacity for 
improving the expression yield of this protein. 
 To improve protein expression, the DNA sequence of this protein may have to be 
codon-optimised to make it more compatible with the E.coli expression host. A codon 
adjustment strategy, known as codon harmonization, may be another interesting way of 
improving heterologous protein expression (Angov et al. 2008). Other kinds of bacterial host 
and expression media could be used to find the best conditions for MSP-multihybrid 
expression. Using a different expression host, such as yeast, could be an alternative method 
to improve expression efficiency of this synthetic parasite protein hybrid, although yeast 
expression systems are prone to hyperglycosylation and post-translational degradation of 
heterologously expressed proteins. Since this protein is expected to be used in 
immunological studies and further developed as a vaccine candidate, contaminants from 
yeast, or even bacterial products (such as LPS) can trigger the immune system (Medzhitov 
2001). These unintended immune responses may cause difficulty in the interpretation of the 
vaccine performance or could reduce the efficacy of any vaccine against malaria parasites. 
Purification methods have to be carefully designed to eliminate yeast or bacterial proteins 
from the protein product as much as possible. /////////////////////////////////////////////////////////////// 
 In the purification of the MSP-1 hybrid, heat treatment served as an efficient 
purification step that eliminated the majority of host bacterial protein contaminants. It was 
expected that this purification step could be used in a similar way for this protein 
purification, because the MSP-multihybrid was also predicted to be an IUP. Since the 
expression protocols used provided very low protein yield, this caused difficulty in 
measuring protein concentration and detecting the MSP-multihybrid protein. Thus, this 
purification step has been neither properly validated for efficiency nor has it been intensively 
tested. It would be interesting to re-test the heat treatment as a purification step if expression 
of the MSP-multihybrid could be improved. Further development of this purification method 
could be made, by adjusting the salt concentrations in the buffers and testing a range of 
heating temperatures to improve the yield of partially purified MSP-multihybrid. Further 
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purification steps, such as anion exchange chromatography should be re-investigated as more 
scalable methods than using antibody-affinity columns such as the 12.2 mAb column used 
here.  
 Assuming that this protein would perform in a similar way to the MSP-1 hybrid on 
SDS-PAGE, it was predicted that it would migrate more slowly than a globular protein of the 
same molecular weight. Based on the predicted size of the MSP-multihybrid of 81kDa, this 
protein is likely to migrate like a protein of twice its size (around 160kDa or higher). The 
evidence from SDS-PAGE and Western blotting indicates a variety of sizes that are 
potentially the MSP-multihybrid. Based on the bands visualised by silver stained SDS-
PAGE and the reactivity of the bands on Western Blots, the ~200 kDa band is likely to be 
the full-length product of the MSP-multihybrid gene, while the ~130kDa and  ~100 kDa 
bands are assumed to be degradation products which lack some part of the MSP-2A region, 
as reactivity with these bands was not visible with anti-MSP-2A sera.  
3.2 Properties  
 From the amino acid sequence, the MSP-multihybrid should have a molecular 
weight of 81 kDa and is likely to be an IUP. However, to show that the protein is 
intrinsically disordered, the protein should be characterised by circular dichroism and 
dynamic light scattering as the MSP-1 hybrid was, to obtain more conclusive data on the 
structure of this protein. ////////////////////////////////////////////////////////////////////////////////////////////////// 
 Antigenically the MSP-multihybrid contains epitopes recognised by antibodies in 
pooled and individual sera from two separate populations naturally exposed to malaria. 
Further analysis showed that all subunit antigens within this molecule are recognised by 
these selected sera, and by antibodies to all three MSP components raise by immunisation in 
mice. Positive correlations between serum recognition to this MSP-multihybrid and MSP-1 
Block 2 based antigens was shown. Similar trends were also observed when this antigen was 
tested against both MSP-2 serotype antigens. However, compared to the other antigens, these 
selected sera reacted weakly with the RO33 Block 2 and the MSP-2B antigen. This may be 
due to the low allele frequency of the RO33 Block 2 serotype in the studied population and, 
therefore, these individuals were infected with RO33serotype parasites less often. This may 
also be the same reason why these sera recognised MSP-2B antigen less frequently. Testing 
of more serum samples from different endemic regions might provide more conclusive data 
on the reactivity of the MSP-multihybrid with endemic sera. 
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3.3 Future plans 
To make a further progress with this vaccine antigen, MSP-multihybrid expression will need 
to be improved to allow further investigations of this protein. For the expression step, a 
combination of alternative E. coli strains, especially those that are designed for proteins with 
low complexity regions, for example protease-deficient strains or strains secreting the 
protein into the periplasm could be tested. By improving the expression media used, cell 
mass could be increased, which would increase protein yield. Heat treatment has proved to 
be a very efficient way to partially purify IUPs, such as the MSP-1 hybrid. This purification 
step should be re-tested on cell lysates of the MSP-multihybrid, once expression levels have 
been improved. If this is successful in partially purifying the antigen, further purification by 
anion exchange chromatography may be used as needed. //////////////////////////////////////////// 
 Immunogenicity testing of the MSP-multihybrid in mice and rabbits should provide 
important data to assess the potential of this protein as a vaccine candidate. Once (or perhaps 
if) sufficient purified antigen is available, testing of the antigen in combination with the 
more promising adjuvants used with the MSP-1 hybrid would be possible. Again, if more 
purified protein was available, it would be of benefit to test the antigen for its reactivity with 
a more extensive set of endemic sera, to confirm the antigenic integrity of the purified 
product. Sera raised by immunization of animals could also then be tested in functional 
antibody assays such as GIA, ADCI or the recently described antibody-dependent respiratory 
burst assay, which is reported to correlate with protective immunity (Joos et al. 2010) 
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Chapter 6: IUP identification methods 
1. Introduction 
 Developing novel vaccines for malaria is challenging because the malaria parasite 
has a complex life cycle and expresses many different proteins during its different life cycle 
stages. Although there are at least five thousand candidate malaria parasite proteins that 
could be or are being researched, not many antigens have proved successful as malaria 
vaccine candidates. This leads us to the question of whether the critical targets for producing 
a protective vaccine are still undiscovered. If that is the case, then what are these targets, and 
how can we identify them?  
 Despite the completion of the P. falciparum genome, most of the functions of the 
predicted proteins encoded and their interactions with other parasite or host proteins are still 
largely unknown. One of the reasons for this is the fact that the malaria parasite genome is 
enriched with many low complexity regions (Aravind et al. 2003; Pizzi & Frontali 2001; 
Brocchieri 2001). These regions cause difficulties in identifying homologues of plasmodium 
proteins (Feng et al. 2006). The genes encoding P. falciparum proteins are also hard to 
express in heterologous systems (Mehlin et al. 2006). One well-known feature of low 
complexity protein sequences is tandem repeat regions, and these are abundant in the surface 
antigens of malaria parasites (Pizzi & Frontali 2001). Low complexity regions are closely 
linked to IUPs (Mohan et al. 2008), which are abundant in pathogenic eukaryotes (Mohan et 
al. 2008; Feng et al. 2006; Vucetic et al. 2003). 
 IUPs are abundant in the malaria parasite. Up to 70% of P. falciparum proteins 
contain long disordered regions (Vucetic et al. 2003), and IUPs are predicted to take up a 
large proportion of the malaria parasite’s proteome (Feng et al. 2006). Our knowledge of 
these types of proteins, however, is still very limited and opinions as to their functions in 
malaria are very controversial. Some studies of the tandem repeats in proteins have 
hypothesized that they may function as a smoke-screen (Reeder & G. V. Brown 1996)  
possibly involved in an immune evasion strategies (Ferreira et al. 2003). Since IUPs 
generally contain arrays of short tandem repetitive sequences it has been suggested that IUPs 
may not be suitable as vaccine candidates (Pizzi & Frontali 2001).  
 However, many antigen candidates of the malaria parasite, such as MSP-1, MSP-2, 
MSP-3 CSP, AMA-1 and GLURP contain disordered regions or have been described as 
having IUP regions (Feng et al. 2006; Pizzi & Frontali 2001; Yang et al. 2007; Brocchieri 
2001; Nair et al. 2002; Burgess et al. 2005). Some of these repeats are very immunogenic 
  172 
and the antigens that contain them have shown potential as protective immunogens. It is 
therefore possible that not all malaria parasite IUPs are functionless and/or used in a 
immunological smoke-screen strategy, but may play important roles for parasite survival. 
IUPs are thought to have a role in binding to different protein partners (Feng et al. 2006; 
Turoverov et al. 2010), and may provide iconic plasticity for regions that require interaction 
to multiple partners (Mehlin et al. 2006; Singh et al. 2006a). For example, this plasticity may 
enable the surface antigens of the malaria parasite to interact with a broad variety of host 
ligands (Pizzi & Frontali 2001; Dunker et al. 2002). Alternatively, they may serve as linkers 
between two functional domains, controlling distance and timing of these interactions 
(Mohan et al. 2008; Dunker et al. 2002). Earlier in this thesis, other IUP vaccine candidates, 
which are derived from the surface proteins of malaria parasites, were able to elicit specific 
antibodies with functional anti-parasite activity in vitro. In addition, the evidence that 
naturally exposed African children with antibodies to the IUP regions of two of these 
antigens (MSP-1 Block 2 and MSP-2) are less likely to suffer from clinical malaria episodes 
argues that this type of protein target may be a promising source of new vaccine antigens. In 
the light of these data, it may be profitable to identify more IUPs from the blood-stages of 
malaria that may elicit protective immune responses, and that may potentially be made into 
useful anti-malaria vaccines.  
1.1 IUP identification 
 There are two main ways to identify IUPs. Firstly, the IUP can be identified using in 
silico prediction tools. The unique characteristics of IUPs, such as their low content of bulky 
hydrophobic amino acids, the presence of low complexity sequences, and a high proportion 
of polar and charged amino acids, are used as the basis of algorithms for prediction of IUP 
tendencies. However, for greater accuracy, combinations of the algorithms and 
computational programs available for IUP prediction are recommended (Mohan et al. 2008; 
Ferron et al. 2006).  
 IUPs can also be identified using experimental protein chemistry assays, based on 
their unique properties, such as lack of 3D structure and lower electron density compared to 
folded proteins. Biophysical techniques such as NMR, analytical ultracentrifugation, circular 
dichroism, dynamic light scattering or X-ray crystallography can be used to distinguish IUP 
profiles from the profiles of folded proteins (Feng et al. 2006; Dunker et al. 2001; Vucetic et 
al. 2003). These techniques, (once conditions are optimised), are very efficient, reliable and 
suitable for small samples. However, each of these techniques has different individual 
requirements and may not be suitable for use with every kind of protein. For example,  high 
protein concentrations are required for NMR and protein samples for circular dichroism need 
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to be in soluble form and in a limited range of buffer conditions (Vucetic et al. 2003; Kelly 
& Price 2000). IUPs of malaria parasites appear to be an important focus for further 
development as vaccine candidates or as drug targets. However, ways of identifying parasite 
IUPs are limited. Since the proteomic profile of the malaria parasite is yet to be completed, 
there is still a need for improvement of the IUP prediction algorithms. Also there are certain 
limitations in the available biophysical techniques for identification of IUPs from other 
structured proteins in the malaria cellular extracts. 
 A study by Csizmok in 2005 showed that IUPs can be distinguished from globular 
proteins by an uncoventional two-dimensional polyacrylamide gel electrophoresis (2D-
PAGE) technique (Feng et al. 2006; Csizmok et al. 2006). This technique is based on the 
differences in biochemical properties between IUPs and globular, structured proteins. Firstly, 
IUPs can be selectively isolated from total cell protein extracts by heating, because IUPs are 
generally heat-stable, whereas many globular proteins are irreversibly denatured by heat 
treatment. This step is optional, as some IUPs may be associated with globular proteins and 
could therefore be lost by heat treatment. Heat-treated protein extracts, including IUPs and 
the remaining heat-stable globular proteins, are then resolved by native gel electrophoresis, 
separating the products according to their charge/mass ratio. A second dimension 
electrophoretic process then separates these proteins further under denaturing conditions. To 
do this, lanes from the native gel are cut from the gel, stained briefly and then fixed sideways 
along the top of a denaturing gel containing 8M Urea. The rationale for this is that generally, 
the structure of IUPs in a chemical denaturing environment, such as 8M Urea, is the same as 
under native non-denaturing conditions. Therefore, IUPs should theoretically migrate in both 
dimensions at the same speed. This results in the deposition of the IUPs on a diagonal line 
when resolved in the 2
nd
 dimension, while globular proteins, which are unfolded in the 
denaturing environment of the second dimension, will run at a slower rate and accumulate in 
the area above the diagonal (Reeder & Brown 1996; Csizmok et al. 2006).  
 This novel method has been shown to be helpful in identifying new IUPs. It can be 
used to identify IUPs from a pool of unclassified proteins when run with known control 
samples of both globular proteins and IUPs. This separation of unstructured from structured 
proteins can be very effective when used in combination with mass spectrometric analysis. 
When compared with other predictors of unstructured protein such as PONDR (Xue et al. 
2010), and techniques such as CD analysis, and gel filtration chromatography, results from 
the 2D gel technique were generally in agreement with other applications (Feng et al. 2006) 
 In this part of the thesis the aim was to modify and develop a 2D gel IUP 
identification method as reported by Csizmok et al. (Csizmok et al. 2006). The protocol was 
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reported to work with protein extracts from several eukaryotic species (Pizzi & Frontali 
2001; Csizmok et al. 2006), but had not been used with protein extracts from malaria 
parasites. It was envisaged that a validated protocol from this study would be established as 
an alternative method for identification of the IUPs from malaria parasites, supporting other 
methods of characterisation and being introduced as a novel tool for vaccine antigen 
discovery. 
2. Materials and results 
2.1 Establishing a working protocol using E. coli protein extracts 
 To validate the pilot 2D gel protocol, protein extracts were prepared from a litre of 
the E.coli BL21 (DE3) pLysS culture. A single colony of cells was inoculated into a flask 
containing LB medium and grown overnight. The culture was harvested by centrifugation 
(Chapter 2, Section 8) and the pellet was washed several times in PBS. Cells were ruptured 
in 1/20 original volume of 25mM Tris pH8 by freeze-thawing. 1Units mL
-
DNAse 
(Benzonase; Novagen, UK) was added, incubated for 20 minutes, and then insoluble 
material removed by centrifugation (13,000 xg for 10 minutes) Cell lysates were either 
heated at 80 C for 10 minutes, and clarified by centrifugation (13,000 xg for 10 minutes) or 
left untreated. Soluble lysates were collected and stored at -20C until use. The protocol for 
the 2D acrylamide gel was derived from Csizmok et. al.  (Csizmok et al. 2006). Native 
polyacrylamide gels were made by the protocol given in Materials and Methods (Section 
13), but without SDS. In these experiments, two configurations of polyacrylamide gel 
concentrations were used; a) 3% acrylamide stacking gel and 8% resolving gel, or b) 4.5% 
and 12% respectively). Two resolving buffer conditions were also used; either 1.5M Tris 
pH8.8, or 0.5M CAPS pH10.5. The 1
st
 dimension sample was resolved on 0.7mm thickness 
gels in a small format (8x6 cm Mini Protean II from Bio-Rad). The 1
st
 dimension native gel 
was briefly stained with Coomassie blue dye, then soaked in 8M Urea solution (8M Urea in 
1M Tris pH6.6) for 45 minutes and lanes containing protein bands were cut into ~1cm wide 
strips. The 2
nd
 dimension 8M Urea gel, which formed the denaturing step of the protocol 
used only the resolving gel without a stacking gel. The gel strip from the first dimension was 
placed between 1-mm spacers to allow the 1
st
 dimension native gel strip, (which was swollen 
after incubation in 8M Urea buffer), to be fitted onto the second dimension gel. Both gel 
dimensions were run at the same voltage (90-120 V), using the same running buffer as 
described in Materials and Methods, Section 13, but without SDS, until the dye-front 
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reached around 5-10 mm from the bottom edge. Gels were then stained with silver nitrate 
stain and used for further analysis.  
 Both percentages of native gel (3% gel and 8% resolving gel, and 4.5% and 12% 
respectively) were successfully used in separating bacterial proteins. These ‘Diagonal gels’ 
showed different protein patterns between the heated protein extracts and the untreated 
protein samples. On both gels, some of proteins resolved on the diagonal between the two 
dimensions, indicative of IUPs, while other proteins ran above diagonal, as expected of 
globular, structured proteins (Figure 6.1).  
 
A)      B) 
 
Figure 6.1: Diagonal gels of bacterial protein extracts, with  either A) no heat 
treatment or B) lysates haet treated at 70 ˚C for 20 minutes. Proteins were resolved 
on both gels using 3% acrylamide stacking gel and 8% resolving gel for the 1st 
dimension and a homogeneous 8% acrylamide 8M Urea gel for the 2nd  dimension. 
Note that the protein marker on the left was used as a staining control and as an 
indicator that the protein sample had reached the bottom of the gel, but did not act 
as a reliable marker for molecular weight estimations.  
 
2.2 Parasite sample preparation 
 Parasite cultures for this experiment were prepared as described earlier in Materials 
and Methods (Section 21). Schizont rich cultures were harvested by centrifugation at 830 xg 
for 5 mintures and washed three times in PBS. Initially, a 0.15% saponin solution was used 
to lyse both uninfected and infected erythrocytes. Cell culture pellets were re-suspended in 
the saponin solution and incubated at room temperature for 5 minutes. An equal volume of 
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PBS was added to the mixture and parasites released from erythrocytes were pelleted by 
centrifugation at 830 xg for 5 minutes. The parasite pellet was washed several time in PBS 
and stored at -20C until use. Parasite pellets were re-suspended in 0.15% saponin solution 
and incubated on ice for 5 minutes. Insoluble material was then removed by centrifugation at 
at 13,000 xg for 5 minutes. at 4 ˚C. The supernatant was stored at -20C until use.  
 The saponin extracted parasite samples resolved on native PAGE gels were stained 
with silver nitrate stain, but resolution of individual protein bands was very poor, due to a 
strong gel background and smearing (Figure 6.3 lane 1). The saponin treated samples were 
then heated at 80C for 10 minutes, and clarified by centrifugation at 13,000 xg 5 minutes at 
4˚C. Heat-treated samples has lower levels of protein on the silver nitrate stained native gels 
and individual protein bands were readily visible, although smearing was still visible (Figure 
6.3 lane 2).  
 As problems were encountered with the first protein extraction method, an 
alternative method was tried. Erythrocyte membranes from parasite cultures were broken 
under mild conditions by freeze-thawing on ice. The parasite pellet was collected and 
washed with PBS and frozen until use. Using this parasite pellet, different methods were 
then used to extract parasite proteins. 
 Further freeze-thawing cycles were performed. Parasite pellets were re-suspended in 
PBS containing protease inhibitors (Roche). Cycles of freezing at -20C and thawing on ice 
were performed three times. Cell debris was separated from the soluble protein by 
centrifugation at 13,000 xg 5 minutes at 4˚C and stored at -20C until use.  
 Detergent or chemical treatments were used to disrupt parasite cell lysates. Parasite 
pellets were treated with either a) 1%NP40, b) 0.5% Triton X100, c) 0.5% NaCl in PBS or d) 
0.1M NaCo3 pH 11.0 and incubated for 10 minutes on ice. Soluble proteins were then 
harvested from the supernatant after clarification by centrifugation at 13,000 xg 5 minutes at 
4˚C. During all extractions protease inhibitors were used at the concentrations recommended 
by the manufacturer (cOmplete Tablets, Roche, UK) and, depending on the experiment, 
DNAse (1Units mL
-1
 Benzonase, Novagen, UK) was added. Clarified supernatants from 
DNAse treated lysates were collected and samples were resolved on native gels to assess 
quantities of proteins in each extraction, and the quality of resolution of these proteins on 
native PAGE gels. The most efficient extraction method was selected for sample preparation 
and further investigation by 2D gel electrophoresis.  
 Heat treatment was also used with some of the protein extract samples. Soluble 
protein lysates were heat-treated at 80C for 10 minutes. Samples were then chilled on ice 
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for a further 10 minutes and denatured proteins were removed by centrifugation at 13,000 xg 
for 5 minutes at 4˚C. 
 Using the freeze-thawing method, erythrocyte membranes are gently disrupted and 
the parasite pellets can be collected. Thereafter, several techniques can be used to produce a 
suitable parasite protein extract. The most successful treatment was freeze- thaw lysis which 
produced soluble proteins harvested from the parasite pellet that could be detected as 
discrete bands on silver stained native gels (Figure 6.3, lane 3). This sample provided clearer 
protein bands and lower background on the gel than samples prepared by saponin lysis 
(Figure 6.3, lane 1). Heat treatment was performed on this protein sample, but soluble 
proteins from the heating step were at very low concentrations and protein bands were barely 













Figure 6.2: Flow chart showing the protein extraction methods used to prepare 
parasite proteins from malaria parasite cultures.  
    Parasite Cultures 
   
Parasite pellets 
Parasite Saponin lysis 
Parasite proteins 
Freeze-thaw Saponin lysis Titron X NP40 NaCl/PBS Na2CO3 
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 Soluble proteins were also extracted from the parasite pellet using the detergent 
NP40. This detergent is not powerful enough to break nuclear membranes on mammalian 
cells, but can break their cytoplasmic membranes. As such, it can be used to obtain the 
cytoplasmic contents of a cellular culture. Using NP40, the length of incubation time period 
correlated with the amount of proteins extracted (Figure 6.3, lanes 5-6). However, other 
chemical extraction methods, including high salt treatment (0.5% NaCl in PBS) and high pH 
treatment (0.1M Sodium Carbonate pH11) gave very low concentrations of protein extract 
(data not shown).  
 Due to the limited time scale of this part of my project, the samples from NP40 
extraction were not further treated by the heating method. Only the protein samples from the 
freeze-thawing method were further tested on 2 dimension gels (Figure 6.4). 
. 
    
 
Figure 6.3: Parasite protein samples from different extraction methods resolved on 
native PAGE. Proteins from parasite pellets were prepared either by saponin lysis 
(lane 1) or by freeze-thawing method (lane 3). These two samples were heated and 
the clarified solutions are shown in lane 2 (saponin) and lane 4 (freeze-thawing). 
Subsequently, parasite pellets prepared by freeze-thawing were incubated with 1% 
NP40 for 10 minutes (lane 5) or 20 minutes (lane 6). (M= molecular weight markers 
in kDa) 
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2.3 Native/denaturing 2D gels of parasite protein extracts 
 Unlike the bacterial protein samples, protein extracts from malaria cultures 
contained some contaminants from red blood cells, which appeared to interfere with the gel 
staining dyes and give background on the 2D gels. It was also noticed that these protein 
samples migrated realtively slowly on the 1
st
 dimension native gel. Because of this slow 
migration, lower percentages of native gel (3% stacking gel and 8% resolving gel) and the 
2
nd
 dimension 8M Urea gel (8% acrylamide ) were used in order to allow proteins to migrate 
further. To test whether higher pH in the gel might improve this migration by increasing the 
negative charge on the proteins, a running buffer of 0.5M CAPS pH10.5 was used as an 
alternative to the 1.5M Tris pH8.8 in the standard protocol. However, it did not improve 
resolution of the protein dots on the 2D gel (data not shown). The velocity of protein 
migration, which is directly proportional to the voltage across the terminals in the PAGE 
tank, was another factor that affected the resolution of these diagonal gels. I was able to 
show that using a lower voltage could improve the resolution of the 2D gel.   








Figure 6.4: Representative native/denaturing 2D gel of parasite proteins extracted 
by the freeze-thawing method, and then A) heat treated or B) without heat treatment 
afterward. A small number of proteins were observed to migrate at equal velocities 
in both dimensions, and thus migrate close to the diagonal. One prominent spot was 
observed close to the diagonal in the lower right hand part of the gel (arrowed).  
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3. Discussion  
3.1 Protein sample preparation 
 These experiments confirmed that the 2D native/denaturing gel technique could be 
performed in the laboratory, using soluble proteins from bacteria. However, this protocol is 
not yet optimised for malaria IUP identification. The main problems encountered were that 
1) protein samples from parasite cultures were not sufficiently concentrated to detect IUPs, 
especially in heat-treated samples and 2) samples contained some red blood cell 
contaminants, which interfered with the migration of proteins in both the native and 
denaturing dimensions. The protein extract that was prepared for this experiment turned out 
to be too dilute to visualize proteins well on the 2D gel. As a consequence, it was hard to 
compare the proteins from each extraction process qualitatively and quantitatively. By 
examining earlier studies by others, using conventional 2D gels (isoelectric focusing/SDS-
PAGE gels) for P. falciparum protein identification, approximately 30 mL of parasite culture 
at 8% parasitaemia, 5% haematocrit was used to reliably detect parasite proteins in that 
system (Smit et al. 2010). Therefore, it seems that this technique requires larger amounts of 
soluble protein that I expected, and that a much greater amount of starting material was 
needed in my experiments than I initially estimated. 
 The optimisation of lysis buffers and protein extraction methods is however equally 
important. Optimised protocols should not only maximise solubility of parasite proteins and 
therefore allow more proteins to be detected, but may also play an important role in 
eliminating the contaminants that interfere with protein migration, cause non-specific 
background staining, and allow further assays on gels such as mass spectrometry. Ideally, the 
protein lysate used should to give high-resolution spots and have low streaking effects on the 
2D gel. In this study, different detergents were tested for their ability to extract different 
cohorts of proteins. The freeze-thawing method appeared to be the gentlest technique for 
disrupting the erythrocyte membrane and the parasite membrane. Saponin treatment was also 
able to disrupt these two membranes as well as the parasitophorus vacuolar membrane and 
should therefore release more proteins from the parasite. However, saponin seems to 
interfere with protein migration on PAGE and cause smearing effects. NP40 was also used 
for protein extraction, producing a soluble protein extract that could be visualised on native 
PAGE. Other extraction methods (high salt, high pH) seemed to give protein samples of very 
low concentration.  
 Haemoglobin from red blood cells has been shown in other studies to interfere with 
assays such as conventional 2D PAGE, as well as mass spectrometry (Alvarez Llamas et al. 
2009). It is likely that haemoglobin carried over from the cell lysis step may have affected 
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the resolution of these 2D gels. This suggests that future protein preparation steps should be 
designed to exclude haemoglobin as much as possible. This should improve the clarity and 
reduce background staining of the gel and ensure that any IUPs identified can be further 
analysed by mass spectrometry. Other purification steps, such as anion exchange 
chromatography, can remove haemoglobin (Sun & Palmer 2008), and may be used to 
eliminate haemoglobin from the sample, while allowing collection of other proteins from the 
parasite extract. Nevertheless, this protocol has to be tested with the malaria infected red 
blood cell sample to be validated before it can be used. The work by Smit, et. al in 2010 
suggests that using the lysis buffer of Nirmalan et al (Nirmalan et al. 2004) yielded parasite 
protein extracts suitable for use with conventional 2D isoelectric focusing/SDS-PAGE. In 
that study, it was reported that a lower percentage of saponin, shorter sonication time, and an 
increase in washing steps reduced haemoglobin contaminants significantly and improved 
resolution on 2D gels (Smit et al. 2010). This protocol could be tested for preparation of 
samples to be run on these native/denaturing diagonal gels. 
 The protein extraction methods used in this study should be repeated using more 
parasite material, to establish which method(s) are most suitable for malaria parasite 
proteins. These different methods may extract different groups of proteins, which may 
localize at different parts of either the erythrocyte or parasite structures. Sequential protein 
extraction, using different combinations of these methods may also useful. Each protein 
sample from each step of the extraction procedure could be tested separately on different 
gels. By separating whole cell proteins extracts into subsets by these fractionation methods, 
gel resolution may be improved by decreasing the number of individual spots on each gel. 
This should greatly facilitate downstream analysis such as mass spectrometry for final 
identification of IUPs in the parasite proteome.  
 Heat treatment was expected to remove most heat-sensitive globular proteins, 
precipitate DNA/protein complexes and to leave the sample with a higher proportion of 
IUPs. Heating certainly improved the resolution of the 1
st
 dimension native gel step, giving 
more defined protein bands. However, in the samples used with their low concentration of 
protein it was difficult to detect protein spots on the 2D PAGE gels. Again, more 
concentrated samples would be needed to validate this technique in future experiments. 
Although IUPs are heat stable, they may be very sensitive to proteases (Dunker et al. 2001; 
Wright & Dyson 1999). Protease inhibitors should therefore be used through the extraction 
process.  
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3.2 Limitations of the diagonal gel assay 
 The native gel PAGE method used for the 1
st
 dimension of this diagonal gel method 
has poor resolving power. This was reported by Csizmok et al, who stated that the resolution 
of the native/denatured 2D system is not as high as of that of conventional isoelectric 
focusing/SDS-PAGE 2D gels. However, they also suggested that this can be overcome by 
using non-charged, mild detergents in protein extraction steps (Csizmok et al. 2006). The 
same paper by Csizmok et al also concluded that the buffer system also affected the outcome 
of the assay. Since roughly half of IUPs would have a net positive charge in the buffers used 
in this system, i.e. that they have a basic isoelectric point, they would not resolve on these 
gels when standard conditions are used (Csizmok et al. 2006). In our experiments an 
alternative buffer with a higher pH was used. However, it did not seem to improve the 
detection of IUP spots, but since these gels were tested with low concentration samples, 
these experiments should be repeated.  
 The limitations and sensitivity of the gel staining methods used are also to be 
considered. Ideally, a sensitive, reproducible, and easy staining method is required and 
crucially, it should not interfere with further analysis, such as mass spectrometry. Coomassie 
Blue, which is used in the original paper by Csizmok et al., is based on direct or indirect 
binding of aromatic and/or basic amino acids and cysteine. It has been shown that this 
method underestimates the concentration of IUPs, which have low levels of these types of 
amino acid residues (Szollosi et al. 2007). Thus, the less abundant IUPs may not be able to 
be visualized by this method. Using a more sensitive staining dye, such as silver nitrate 
staining, was suggested. However, since different proteins stain differently according to their 
unique physical and chemical properties, several different staining methods should be tested 
and the results should be compared.   
3.3 Future plans 
 This 2D gel technique was proposed as an alternative method for identifying and 
confirming proteins as intrinsically unstructured (IUPs). Uniquely, it can be used with 
proteins from whole cell extracts, which will allow novel IUPs to be discovered from a 
protein mixture (Csizmok et al. 2006). Although these experiments did not prove to be 
currently suitable for malaria protein extracts, there still a large amount of room for 
improvement of the protocols of protein extraction and detection. Once these methods are 
validated for malaria parasite extracts, many novel proteins may be discovered. Newly 
discovered IUPs can then be identified by mass spectrometry, and investigated for their 
localization in the parasite, functions and their potential to be developed as vaccine 
candidates.  
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Chapter 7: Discussion 
 Many malaria antigens under development as vaccine candidates were selected by 
means of their reactivity with human immune sera. However, due to the nature of the 
parasite antigens selected (i.e. their relative abundance, immunogenicity, polymorphism, 
etc.) and our limited knowledge of the mechanisms of acquisition of immunity to malaria, 
these selection methods are of limited value and empirical. This causes difficulty in 
comparative studies (Holder & Holder 2009) and there is always the risk that the good 
vaccines are dropped while poor vaccines are taken into further development stages (Richie 
& Saul 2002). 
 Malaria vaccine research has not been focused in any way on IUPs until recently, 
when many of the existing vaccine candidates were reported to contain unstructured regions 
(Cowan et al. 2011; Yang et al. 2007; Burgess et al. 2005; Pizarro et al. 2005). With this 
knowledge, two sides of opinion were formed concerning the roles of malaria parasite IUPs 
and their relationship with host immunity. The first view proposed that IUPs are functionally 
important for parasite survival, and therefore may be good targets for protective immune 
responses. This has been supported by the fact that several of the potential vaccine 
candidates which are IUPs are targets of antibody responses which appear to be associated 
with protective immunity or at least reduced incidence of clinically significant malaria 
infections (Polley et al. 2006; Cavanagh et al. 2004; Roussilhon et al. 2007; Metzger et al. 
2003; Conway et al. 2000). In contrast, in the past, others have suggested that IUPs are used 
as part of the parasite’s immune evasion strategies, by eliciting non-protective, cross-reactive 
antibodies that act as an immunological ‘smoke screen’ (Kemp et al. 1987). This idea is 
supported by the fact that IUPs have the ability to take up a variety of conformations, which 
may hamper the efficiency of antibody recognition and therefore immune responses (Feng et 
al. 2006).  
 In this PhD project I have shown that the two studied IUPs, the MSP-1 hybrid and 
MSP-3.3C were immunogenic when formulated with adjuvants. Antibodies in malaria 
exposed children specific for the MSP-1 hybrid were associated with protection from clinical 
malaria episodes in a cohort of Ghanaian children. Antibodies raised to MSP3.3C by 
immunization in rabbits showed very strong parasite growth inhibitory effects in vitro. This 
encouraging data suggests that these IUPs (and possibly others) are an interesting repertoire 
of antigens that have the potential to be developed as vaccine candidates. This alternative 
rationale for antigen selection is supported by the fact that several of the leading vaccine 
candidates have been shown to possess IUP domains or to be wholly IUP themselves. 
 IUPS can be distinguished from globular, structured proteins by their unique 
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biochemical properties. Using the native/denaturing diagonal gel method, I attempted to 
identify IUPs from parasite protein extracts. Unfortunately, due to problems with the 
efficiency of the protein extraction procedures, and some underestimation of the volumes of 
parasite material needed, I was not successful in identifying novel IUPs in parasite extracts. 
Once this technique has been further developed, this protocol may serve as a simple, novel 
strategy for proteome-wide IUP screening. Identified protein sequences could then be 
analysed by bioinformatics, the products expressed in recombinant systems and tested in pre-
clinical immunological assays to establish whether these antigens are vaccine candidates.  
 This PhD project showed that IUPs such as MSP-3.3C, the MSP-1 hybrid and the 
MSP-multihybrid can be produced either as single recombinant proteins based on one gene 
or as multi-component vaccine antigens. By designing constructs with synthetic sequences or 
multiple gene components fused togthere, this can overcome the problem of antigenic 
polymorphism, as well as provide multiple targets for immune recognition. Protocols for the 
production and purification of the MSP-1 hybrid and for MSP-3.3C were easily developed 
and are both scalable methods amenable to process-scale vaccine production. For larger 
antigens such as the MSP-multihybrid, further codon optimization of the MSP-2 components 
may be necessary for optimum yields.   
The unique properties of IUPs make these proteins easy to express, handle and purify. The 
heat stability of the proteins makes production steps simple, and simplifies the purification 
process. Unlike many proteins expressed in bacteria refolding steps are not required for 
IUPS, as they lack rigid structure in their native form. Once these IUP antigens have been 
characterised, Good Laboratory Practice (GLP) procedures should be established in order to 
guarantee the quality of any vaccine before it can be further tested in non-human primates. 
The results from these pre-clinical studies will surely be good guidelines for further trials, 
which require the higher exigencies standard such as Good Manufacturing Practice (GMP).  
Unlike other vaccines, which can rapidly lose potency due to temperature sensitivity, IUPs 
such as the MSP-1 hybrid are stable. This unique heat-stable property of IUPs has practical 
benefits for vaccine delivery, especially for the distribution of malaria vaccines to locations 
where they are needed without cold chain supply. Older studies of the silk protein fibroin, 
which has a similar circular dichroism profile to the IUPs in this study (Iizuka & Yang 
1966), reported  that it was a good stabilizer for labile vaccines, by enhancing 
thermostability and prolonging the shelf life of the vaccines (Zhang et al. 2012).  
 This project has shown that surface IUP antigens from malaria parasites are 
promising malaria vaccine candidates. But how are these IUP antigens processed and 
presented by the immune system? What could be the molecular activities of antibodies to 
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IUPs? Why it do antibodies to MSP-3.3 seem to be very effective in parasite killing in vitro? 
These questions remain to be resolved and will need to be further investigated by 
experimentation. However, based on current knowledge, it may be that IUPs adopt stable 
conformations only for short periods of time when they interact with their partner ligands 
(Tompa 2002). This ‘just in time regulation’ of protein structure may benefit parasite 
survival by narrowing the chance for immune cells or antibodies to recognise discontinuous 
epitopes within IUPs, which are part of transient conformationally active sites. However, 
specific antibodies that bind to continuous epitopes on these proteins may also disrupt the 3D 
structure formation process and impair IUP protein function. 
 It was believed until recent years that only properly folded proteins could perform 
physiologically relevant functions; those that failed to develop rigid structures were regarded 
as a the cause of pathology or doomed to be destroyed by internal cellular structures such as 
the proteosome. Studies of IUPs have reshaped our understanding toward these fundamental 
aspects of protein functions. Research on IUPs will not only let us understand more about 
their roles, but will also benefit immunological studies and vaccine development research, 
especially for pathogens such as malaria parasites, in which IUPs are abundant.  
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